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ABSTRACT 
The desired healing response to electrospun scaffolds in tissue engineering is often 
limited by poor ingrowth due to insufficient porosity, thrombogenicity, lack of 
vascularisation and/or excessive inflammation. This study aimed at increasing 
structural porosity and incorporating/delivering anti-thrombotic/angiogenic (heparin) 
and anti-inflammatory (dexamethasone) agents. 
Porosity enhancement techniques were explored using two different approaches i) 
electrospinning of biostable polymer (Pellethane®, Pel) with concomitant 
electrospraying of soluble microparticles, which were subsequently removed to increase 
scaffold interconnectivity and ii) electrospinning of biodegradable polymer (DegraPol®, 
DP) at low collecting temperatures. Dexamethasone (Dex) was incorporated by simple 
admixture, while heparin (Hep) required chemical modification (heparin tributyl-
ammonium, HepTBA) to achieve solubility. Release rates were determined in vitro, 
followed by thrombogenicity (thromboelastography) and cytotoxicity (cell viability) 
assessments of modified/unmodified heparin prior to incorporation and after elution. 
Finally, in vivo responses were evaluated in a subcutaneous model (24 rats) for up to 
12 weeks. 
Porosity was enhanced (P<0.001) for both Pel (79 to 90%) and DP (50 to 83%) 
scaffolds. Incorporated drugs showed a burst release (Dex 36%, HepTBA 47%, 7 days) 
followed by a sustained delivery (78%, 48%, 90 days). Heparin, post modification, 
retained its anti-thrombotic properties and showed no difference in cytotoxicity 
(P>0.1). At 12 weeks of implantation, high-porosity Pel scaffolds allowed for full tissue 
ingrowth (>98%) while conventional scaffolds were limited (<42%). The localised 
delivery of HepTBA resulted in additional blood vessel formation (P<0.01), while Dex 
did not significantly suppress scaffold inflammation (P>0.3). 
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High-porosity scaffolds produced by combined electrospinning/spraying have the 
potential to enhance healing. Dex or HepTBA can be incorporated and eluted from 
degradable electrospun scaffolds, and localised delivery of HepTBA improves implant 
vascularisation. This study may contribute towards tissue engineered vascular graft 
development where anti-thrombogenicity and increased vascularisation are desired. 
  
University of Cape Town  WJ van den Bergh 
 






University of Cape Town  WJ van den Bergh 
 
 Drug Eluting Electrospun Scaffolds for Tissue Regeneration vii 
 
ACKNOWLEDGEMENTS 
I would like to thank my supervisor, Assoc. Prof Deon Bezuidenhout, for his hands-on 
contributions, continuous mentorship and enthusiasm throughout the course of this 
project. He s a valuable asset towards the health science community and I m grateful 
for his generous investment in my development.  
The completion of this project would not have been possible without the help from a 
group of incredible individuals. Whether their inputs were in the form of assistance, 
mentorship, consultations or merely emotional support - I thank you all from the 
bottom of my heart: Aliza Janse van Rensburg (mentorship), Anel Oosthuysen (heparin 
and experimental consultations), Carla Gustafsson (biology consultations), Claudia de 
Sousa (lab assistance), Damita Zireva (lab assistance), David Conradie (polymer 
consultations), Emma Doubell (project support), Helen Ilsley (histological 
preparations), Jandre de Villiers (polymer consultations), Janet McCallum (animal 
welfare), Jason Voorneveld (mentorship), Joel Du Toit (technical lab support), Johan 
Coetzee (polymer consultations), Kim Tutt (surgical procedures), Kyle Goetsch 
(biology consultations), Lizel Loo (blood analysis), Miranda Waldron (SEM 
preparations), Nikolaus Thierfelder (clinical/biology consultations), Pete Roberts 
(NMR analysis), Rodney Lucas (technical animal support), Rudy Cozett (chemistry 
consultations) and Waled Hadasha (polymer consultations).  
A deep appreciation for the financial support is expressed to the following organisations: 
University of Cape Town (UCT) and the postgraduate funding office, Medical Research 
Council (MRC), National Research Foundation (NRF) of South Africa and the 
International Centre for Mechanical Sciences (CISM) in Italy.  
I would also like to thank ab medica s.p.a. (exclusive licensee) for providing the 
DegraPol® biomaterial (owners: ETH Zürich and the University of Zürich) and 
University of Cape Town  WJ van den Bergh 
 
 Drug Eluting Electrospun Scaffolds for Tissue Regeneration viii 
Integrated Engineering software (Dr Prasad) for the evaluation and assistance of their 
simulation environment: Coulomb3D.  
A great deal of appreciation is given to my family and friends, and especially to my 
parents, Jaco and Anet, for their encouragement over the years. To my beloved Caren, 
thank you for your love and support - you have inspired me in more ways than you 
realise. Finally, I praise the Creator for leading me down this blessed journey. 
  
University of Cape Town  WJ van den Bergh 
 




List of conference appearances 
 W. van den Bergh, A. Oosthuysen, T. Franz, P. Zilla, D. Bezuidenhout. Improved 
healing of electrospun tissue engineered scaffolds by increased porosity and drug delivery.  
5th International Conference on Electrospinning, 16-18 January 2018, Stellenbosch, SA. 
 ORAL PRESENTATION 
฀ W. van den Bergh, A. Oosthuysen, T. Franz, P. Zilla, D. Bezuidenhout. In vivo response 
to tissue engineered electrospun scaffolds with drug delivery and enhanced porosity . 14th 
annual UNESCO/IUPAC workshop & conference on Macromolecules & Materials, 11-13 April 
2017, Stellenbosch, SA.  ORAL PRESENTATION 
฀ W. van den Bergh, A. Oosthuysen, T. Franz, P. Zilla, D. Bezuidenhout. Drug eluting 
electrospun scaffolds for tissue regeneration . 10th Leiden International (bio)-Medical Student 
Conference (LIMSC), 15-19th March 2017, Leiden, NL.  POSTER PRESENTATION 
฀ W. van den Bergh, A. Oosthuysen, T. Franz, P. Zilla, D. Bezuidenhout. Combined 
electrospinning/spraying for high porosity tissue regenerative scaffolds with concurrent 
drug delivery . 2nd South African Biomedical Engineering Conference, 22-24 March 2016, 
Stellenbosch, SA. ORAL PRESENTATION 
Publication in progress (2018) 
Preliminary title (article): Improved healing of electrospun tissue engineered scaffolds by 
increased porosity and drug delivery.  
  
University of Cape Town  WJ van den Bergh 
 
 Drug Eluting Electrospun Scaffolds for Tissue Regeneration x 
 
CONTENTS 
Abstract ...................................................................................................................... iv 
Graphical Abstract ..................................................................................................... vi 
List of Tables ............................................................................................................ xiv 
List of Figures ............................................................................................................ xv 
List of Appendices .................................................................................................. xviii 
List of Abbreviations ................................................................................................ xix 
List of Symbols ........................................................................................................ xxii 
Glossary .................................................................................................................. xxiii 
1 Introduction ................................................................................. 1  
1.1 Background ........................................................................................................ 1 
1.1.1 The burden of cardiovascular diseases ........................................................ 1 
1.1.2 Medical devices for cardiovascular therapies .............................................. 2 
1.1.3 The challenges of implantable devices ........................................................ 4 
1.1.4 The tissue engineering concept ................................................................... 5 
1.1.5 Design parameters for tissue engineered scaffolds ....................................... 6 
1.2 Applied electrohydrodynamics for tissue engineering ........................................ 9 
1.2.1 Introduction to electrohydrodynamics ........................................................ 9 
1.2.2 Electrospinning of polymeric fibres ............................................................ 10 
1.2.3 Electrospraying of polymeric particles ....................................................... 21 
1.2.4 Challenges with electrospun scaffolds ........................................................ 22 
1.2.5 Porosity enhancement techniques .............................................................. 22 
1.2.6 Drug incorporation techniques ................................................................... 26 
1.3 Synthetic biomaterials and bioactive agents ..................................................... 28 
1.3.1 Pellethane® ................................................................................................ 28 
University of Cape Town  WJ van den Bergh 
 
 Drug Eluting Electrospun Scaffolds for Tissue Regeneration xi 
1.3.2 DegraPol® .................................................................................................. 29 
1.3.3 Heparin ....................................................................................................... 31 
1.3.4 Dexamethasone .......................................................................................... 38 
1.3.5 Drug release kinetics .................................................................................. 39 
1.4 Research proposal ............................................................................................. 40 
1.4.1 Problem statement ..................................................................................... 40 
1.4.2 Objectives ................................................................................................... 41 
2 Materials and Methods ............................................................... 43  
2.1 Materials ........................................................................................................... 43 
2.2 Preparation of polymer films ............................................................................ 43 
2.3 Polymer degradation in aqueous solutions ........................................................ 44 
2.4 Measuring solvent evaporation rates ................................................................ 44 
2.5 Solution viscosity determination ....................................................................... 45 
2.6 Scanning electron microscopy ........................................................................... 45 
2.7 Nuclear magnetic resonance spectroscopy......................................................... 45 
2.8 Heparin surface immobilisation ......................................................................... 45 
2.9 Heparin confirmational staining ........................................................................ 46 
2.10 Surface heparin quantification ....................................................................... 47 
2.11 Heparin modifications .................................................................................... 48 
2.12 Cell viability assay......................................................................................... 49 
2.13 Thromboelastography .................................................................................... 50 
2.14 Scaffold drug release characterisation ............................................................ 51 
2.15 Polymer solution preparations ....................................................................... 53 
2.16 Experimental setup for electrospinning/electrospraying ............................... 53 
2.17 Electric field simulations ............................................................................... 56 
2.18 Electrospraying parametric studies ............................................................... 58 
2.19 Electrospinning parametric studies ................................................................ 59 
2.20 Porosity enhancement by electrospinning and spraying ................................ 60 
2.21 Mechanical characterisation .......................................................................... 62 
2.22 Scaffold architectural characterisation .......................................................... 63 
University of Cape Town  WJ van den Bergh 
 
 Drug Eluting Electrospun Scaffolds for Tissue Regeneration xii 
2.22.1 Electrosprayed microparticles .................................................................... 63 
2.22.2 Electrospun fibres ....................................................................................... 64 
2.23 Healing evaluation of electrospun scaffolds ................................................... 67 
2.23.1 Implant manufacturing and study overview .............................................. 68 
2.23.2 Subcutaneous implant and explant procedures .......................................... 70 
2.23.3 Histology of explants .................................................................................. 72 
2.23.4 Image processing for scaffold healing evaluation ........................................ 73 
2.24 Statistical analysis ......................................................................................... 77 
3 Results and Discussion ............................................................... 78  
3.1 Material studies of polymer films ...................................................................... 78 
3.1.1 Mechanical properties ................................................................................ 78 
3.1.2 Degradation in aqueous solutions ............................................................... 79 
3.2 Biostable scaffold development ......................................................................... 81 
3.2.1 Electrospinning of biostable fibres ............................................................. 81 
3.2.2 Electrospraying of soluble microparticles ................................................... 84 
3.2.3 Combined electrospinning and spraying .................................................... 92 
3.2.4 Biostable implant production ..................................................................... 96 
3.2.5 Healing assessment of biostable implants ................................................ 100 
3.3 Biodegradable scaffold development ............................................................... 112 
3.3.1 Solvent evaporation rates ......................................................................... 112 
3.3.2 Scaffold drug incorporation ...................................................................... 113 
3.3.3 Electrospinning of degradable fibres ........................................................ 124 
3.3.4 Biodegradable implant production ........................................................... 137 
3.3.5 Healing assessment of biodegradable implants ......................................... 144 
4 Conclusion ............................................................................... 153  
University of Cape Town  WJ van den Bergh 
 
 Drug Eluting Electrospun Scaffolds for Tissue Regeneration xiii 
5 Recommendations ..................................................................... 157  
6 References ................................................................................ 161  
7 Appendices ............................................................................... 174  
 
  
University of Cape Town  WJ van den Bergh 
 
 Drug Eluting Electrospun Scaffolds for Tissue Regeneration xiv 
 
LIST OF TABLES 
Table 1.1: The global need for principle CVD medical devices. ...................................... 3 
Table 1.2: A comparison of tissue engineering approaches. ............................................ 5 
Table 1.3: Controllable electrospinning parameters ....................................................... 12 
Table 1.4: Parametric control of electrospun scaffold morphology. ............................... 20 
Table 1.5: Processing parameters for electrospinning of Pellethane® ............................ 29 
Table 1.6: Summary of DegraPol® electrospun TE applications ................................... 30 
Table 1.7: Processing parameters for electrospinning of DegraPol® .............................. 31 
Table 1.8: Examples of electrospun scaffolds with heparin incorporation ...................... 37 
Table 1.9: Examples of electrospun scaffolds with dexamethasone incorporation. ........ 38 
Table 1.10: Models used to describe drug dissolution .................................................... 39 
Table 1.11: Interpretation values for diffusion release kinetics ...................................... 40 
Table 2.1: Reagent concentrations for Heparin-TBA ion-exchange processes ................ 49 
Table 2.2: Heparin treatments for whole blood thromboelastographic analyses ............ 51 
Table 2.3: Selected time points for in vitro drug elution studies. .................................. 52 
Table 2.4: Curve fitting models used to describe in vitro drug release kinetics. ............ 53 
Table 2.5: Material properties of parts used for electric field simulations. .................... 58 
Table 2.6: Parametric investigations for developing electrosprayed porogens. .............. 58 
Table 2.7: Parametric investigations for developing biostable scaffolds ......................... 59 
Table 2.8: Parametric investigations for developing degradable scaffolds. ..................... 60 
Table 2.9: Summary of specimens tested for mechanical properties. ............................. 63 
Table 2.10: Scaffold groups selected for subcutaneous implantation ............................. 68 
Table 2.11: Electrospinning parameters used for implant production. ........................... 69 
Table 3.1: Solubility of drug selection in DegraPol® electrospinning solvents. ........... 116 
Table 3.2: Theoretical models for LTE release kinetics of HepTBA and Dex ............. 142 
 
  
University of Cape Town  WJ van den Bergh 
 
 Drug Eluting Electrospun Scaffolds for Tissue Regeneration xv 
 
LIST OF FIGURES 
Figure 1.1: Examples of implantable medical devices for the heart. 2 
Figure 1.2: Graphical representation of tissue engineering approaches. 6 
Figure 1.3: The fibrous network of natural extracellular matrices. 7 
Figure 1.4: Tissue engineered electrospun scaffolds for implantable medical devices. 8 
Figure 1.5: A brief history of electrohydrodynamics. 9 
Figure 1.6: Fibre formation during electrospinning. 11 
Figure 1.7: Chain entanglement as a function of concentration and molecular weight. 13 
Figure 1.8: Organic solvent properties: a selection for experimental electrospinning. 16 
Figure 1.9: The difference between electrospinning and electrospraying 21 
Figure 1.10: The influence of electrospraying parameters on particle size. 21 
Figure 1.11: Host response towards thick compared to thin-fibrous scaffolds. 24 
Figure 1.12: Techniques to enhance electrospun scaffold porosity. 25 
Figure 1.13: Drug incorporation techniques for electrospun fibres. 27 
Figure 1.14: Chemical structure of Pellethane® 28 
Figure 1.15: Chemical structure of DegraPol®. 29 
Figure 1.16: Chemical composition of heparin. 32 
Figure 1.17: Improved vascularisation of heparinised polyurethane foam discs. 33 
Figure 1.18: Illustrative diagram of heparin incorporated electrospun fibres. 34 
Figure 1.19: Heparin surface modified Pellethane fibres. 35 
Figure 1.20: Heparin-TBA incorporated PLCL electrospun scaffolds. 37 
Figure 2.1: Typical absorbance curves for heparin concentration determination. 47 
Figure 2.2: Ion-exchanges during the heparin-TBA modification process. 48 
Figure 2.3: A typical experimental setup for electrospinning/spraying. 54 
Figure 2.4: Hollow collectors used for rotational collecting. 55 
Figure 2.5: Needle and base electrode configuration for electrospraying. 55 
Figure 2.6: Model of an annual disc as a base electrode for electrospinning. 56 
Figure 2.7: Base electrode and collector model used for 3D simulations. 57 
Figure 2.8: An illustration of scaffold volume determination. 61 
Figure 2.9: Tensile testing of polymer specimens. 62 
Figure 2.10: Image processing of electrosprayed microparticles. 64 
Figure 2.11: Manual measurements of fibre diameters from SEM images. 65 
Figure 2.12: A demonstration of fibre orientation characterisation. 65 
Figure 2.13: Image processing of electrospun scaffolds for pore size determination. 66 
Figure 2.14: An overview of the in vivo assessment of electrospun scaffolds. 70 
Figure 2.15: Summary of subcutaneous implant and explantation procedures. 72 
Figure 2.16: Image processing for quantification of scaffold tissue ingrowth. 73 
Figure 2.17: Image processing for quantification of scaffold collagen deposition. 74 
University of Cape Town  WJ van den Bergh 
 
 Drug Eluting Electrospun Scaffolds for Tissue Regeneration xvi 
Figure 2.18: Image processing for quantification of cellular densities 75 
Figure 2.19: Image processing for quantification of scaffold vascularisation. 76 
Figure 3.1: Mechanical properties of polymer films. 78 
Figure 3.2: Accelerated degradation of polymer films in different media. 80 
Figure 3.3: Fibre orientation for Pel scaffolds at different collecting speeds. 81 
Figure 3.4: The influence of fibre orientation on mechanical properties. 82 
Figure 3.5: The influence of flow rate on electrospun Pel fibre diameter. 84 
Figure 3.6: Electrosprayed PEG particles from different solvents. 85 
Figure 3.7: The influence of dielectric constant on electrosprayed particles. 85 
Figure 3.8: Particle morphology of electrosprayed PEG particles over a distance. 87 
Figure 3.9: The influence of collecting distance on electrosprayed particles 88 
Figure 3.10: The influence of needle diameter on electrosprayed particle size. 89 
Figure 3.11: Electrosprayed polyethylene glycol microparticles. 90 
Figure 3.12: Particle distribution of a triple needle electrospray configuration 91 
Figure 3.13: Composite materials created by combined electrospinning and spraying. 92 
Figure 3.14: Porosity-enhanced scaffolds after sacrificial bead removal. 93 
Figure 3.15: Combined electrospinning and spraying results. 94 
Figure 3.16: Architectural comparison of conventional and high-porosity scaffolds. 95 
Figure 3.17: Biostable scaffold selection for subcutaneous implantation. 96 
Figure 3.18: Fibre morphology of heparinised Pellethane® fibres. 97 
Figure 3.19: Characteristics of biostable implant groups. 98 
Figure 3.20: Mechanical properties of biostable implant groups. 99 
Figure 3.21: Representative H&E micrographs of biostable implant groups. 101 
Figure 3.22: Tissue ingrowth of biostable implant groups. 102 
Figure 3.23: Representative PSR micrographs of biostable implant groups. 103 
Figure 3.24: Collagen deposition of biostable implant groups. 104 
Figure 3.25: Representative ED1 micrographs of biostable implant groups. 105 
Figure 3.26: Cellular density of biostable implant groups. 106 
Figure 3.27: Macrophages per tissue area of biostable implant groups. 108 
Figure 3.28: Representative CD31 micrographs for no-degradable implant groups. 109 
Figure 3.29: Blood vessels per tissue area of biostable implant groups. 110 
Figure 3.30: DP solvent evaporation rate comparison. 112 
Figure 3.31: Chemical structures used for degradable scaffolds development. 113 
Figure 3.32: The ion-exchange of heparin sodium to heparin-tributylammonium. 114 
Figure 3.33: 1H NMR spectra of heparin-tributylammonium variations. 115 
Figure 3.34: Drug elution study from RT electrospun scaffolds. 117 
Figure 3.35: Mass loss of DP electrospun scaffolds in vitro. 118 
Figure 3.36: Reaction times of human blood treated with heparin variations. 119 
Figure 3.37: Anti-thrombotic properties of heparin before and after electrospinning. 120 
Figure 3.38: Rat SMC prior to and after heparin treatments. 122 
Figure 3.39: Rat SMC viability assay of heparin variations. 122 
Figure 3.40: Fibre orientation for DP scaffolds at different collecting speeds. 124 
University of Cape Town  WJ van den Bergh 
 
 Drug Eluting Electrospun Scaffolds for Tissue Regeneration xvii 
Figure 3.41: Fibre fusion at different solvent systems of DP scaffolds. 126 
Figure 3.42: Scaffold morphology and distribution observed DP concentrations. 127 
Figure 3.43: Scaffold architectural changes due to shifts in DP concentration. 129 
Figure 3.44: Electric field curves of annular disc shaped base electrodes. 129 
Figure 3.45: Electric field visualisations of a simple base electrode configuration. 130 
Figure 3.46: The influence of base electrode size on DP scaffold morphology. 131 
Figure 3.47: Influence of base electrode size on fibre diameter and pore size 132 
Figure 3.48: Morphology of DP spun scaffolds using a small base electrode. 132 
Figure 3.49: Combined electrospinning and spraying with DP and PEG. 133 
Figure 3.50: The influence of collecting temperature on DP electrospun fibres. 133 
Figure 3.51: Electrospun fibre fusion correction by low temperature collecting. 134 
Figure 3.52: LTE with a dry ice and the large collector. 135 
Figure 3.53: SEM images of LTE fibre morphology. 135 
Figure 3.54: Degradable scaffold selection for subcutaneous implantation. 137 
Figure 3.55: Characteristics of degradable implant groups. 138 
Figure 3.56: Mechanical properties of degradable implant groups. 140 
Figure 3.57: HepTBA in vitro release profiles from degradable implants. 141 
Figure 3.58: Dexamethasone in vitro release profiles from degradable implants. 141 
Figure 3.59: Representative H&E micrographs of degradable implant groups. 144 
Figure 3.60: Internal ridges found in the cross section of LTE scaffolds. 145 
Figure 3.61: Tissue ingrowth of degradable implant groups. 146 
Figure 3.62: Representative PSR micrographs of degradable implant groups. 147 
Figure 3.63: Collagen deposition of degradable implant groups. 148 
Figure 3.64: Representative ED1 micrographs of degradable implant groups. 148 
Figure 3.65: Cellular density of degradable implant groups. 149 
Figure 3.66: Macrophages per tissue area of degradable implant groups. 150 
Figure 3.67: Representative CD31 micrographs of degradable implant groups. 151 
Figure 3.68: Blood vessels per tissue area of degradable implant groups. 152 
 
  
University of Cape Town  WJ van den Bergh 
 
 Drug Eluting Electrospun Scaffolds for Tissue Regeneration xviii 
  
LIST OF APPENDICES 
A1: Properties of organic solvents. 174 
A2: Additional DegraPol® review summaries. 175 
A3: Supporting thromboelastography results. 183 
A4: Output of a typical mechanical tensile testing report. 184 
A5: Output of a typical statistical report. 184 
A6: Comparison of tissue ingrowth from different fixation media. 185 
A7: Solvents tested for DegraPol® solubility at room temperature. 185 
A8: Supporting NMR spectra of heparin ion-exchange process. 186 
A9: Supporting numerical results of electric field simulations. 187 
A10: Coaxial drug encapsulation attempt. 188 
 
  
University of Cape Town  WJ van den Bergh 
 
 Drug Eluting Electrospun Scaffolds for Tissue Regeneration xix 
 
LIST OF ABBREVIATIONS 
Ac Acetyl 




BE Blend electrospinning 
bFGF Basic fibroblast growth factor 
BP Boiling point 
C Circumferential 
CAD Coronary artery disease 
CD31 Cluster of differentiation 31 
CD68 Cluster of differentiation 68 
CDCl3 Deuterated chloroform 
CF Coulombic fission 
CHCl3 Chloroform 
CRU Cardiovascular research unit 
CVD Cardiovascular disease 
Da Dalton 




DI Deionised water 
DMAC Dimethylacetamide 
DMF Dimethylformamide 
DMSO Dimethyl sulfoxide 
DP DegraPol® 
EC Endothelial cell 
ECM Extracellular matrix 
EDA Ethylene diamine 
EDC Ethyl dimethyl aminopopyl carbodiimide 
EHD Electrohydrodynamics 
ePTFE Expanded polytetrafluoroethylene 
ESRD End stage renal disease 
FBR Foreign body response 
FDA Food and drug administration 
FGF-2 Fibroblast growth factor 
GaGs Glycosaminoglycans 
GF Growth factor 
GlcA Glucuronic acid 
GlcNAc Acetyl-glucosamine 
University of Cape Town  WJ van den Bergh 
 
 Drug Eluting Electrospun Scaffolds for Tissue Regeneration xx 
GlcNS Sulfo-glucosamine 
H&E Hematoxylin and Eosin 
HCl Hydrochloric acid 
Hep Heparin 
HepH Heparin acid 
HepNa Heparin sodium 
HepTBA Heparin-tributylammonium 
HF Heart failure 
HFIP Hexafluoro-iso-propanol 
HP High-porosity 
IdoA Iduronic acid 
KCl Potassium chloride 
L Longitudinal 
LBe Large base electrode 
LMWH Low molecular weight heparin 
LP Low-porosity 
LTE Low temperature electrospinning 
M1 Macrophage phenotype 1 
M2 Macrophage phenotype 2 
MA Maximum amplitude 
MBe Medium base electrode 
MBTH Methyl benzothiazolinehydrazone hydrochloride 
MCP Monocyte chemoattractant protein 
MDI Methylene-di-phenyldiisocyanate 
MeOH Methanol 
MES Morpholino ethanesulfonic acid 
MS Microsoft 
NaCl Sodium chloride 
NaOH Sodium hydroxide 
NMP Methyl pyrrolidone 
NMR Nuclear magnetic resonance 
OI Orientation index 
PAD Peripheral artery disease 
PAN Polyacrylonitrile 
PBS Phosphate-buffered saline 
PCL Polycaprolactone 
PDGF Platelet-derived growth factor 
PEG Polyethylene glycol 
Pel Pellethane® 
PEO Polyethylene oxide 
PGA Polyglycolic acid 
PGS Polyglycerol sebacate 
PHB Polyhydroxybuterate 
PLA Polylactic acid 
PLCL Poly(lactide-co-caprolactone) 
PLGA Poly(lactic-co-glycolic acid) 
University of Cape Town  WJ van den Bergh 
 
 Drug Eluting Electrospun Scaffolds for Tissue Regeneration xxi 
PLLA Poly-L-lactic acid 
PS Polystyrene 
PSR Picroserius Red 
PSU Polysulfone 
PTMO Polytetramethylene oxide 
PU Polyurethane 
RGB Red, green and blue 
RH Relative humidity 
RHD Rheumatic heart disease 
ROI Region of interest 
RSA Republic of South Africa 
RT Room temperature 
RTE Room temperature electrospinning 
SANS South African national standard 
SAVC South African veterinary council 
SBe Small base electrode 
SEM Scanning electron microscope 
SM Surface modification 
SMC Smooth muscle cell 
TA Transanastomotic 
TB Toluidine blue 
TBA Tributylamine 
TE Tissue engineering 
TEG Thromboelastography 
TFA Trifluoro acetic acid 
TFE Trifluoroethanol 
TGF-b Transforming growth factor-b 
THF Tetrahydrofuran 
TM Transmural endothelialisation 
UCT University of Cape Town 
UTS Ultimate tensile strength 
VAD Ventricular assist device 
VEGF Vascular endothelial growth factor 
VG Vascular graft 
VHD Valvular heart disease 
wt% Weight percentage 
  
University of Cape Town  WJ van den Bergh 
 
 Drug Eluting Electrospun Scaffolds for Tissue Regeneration xxii 
 
LIST OF SYMBOLS 
 Area 
 Bulk volume � Clot strength � Conductivity 
 Correlation coefficient square 
 Density 
 Diameter of fibre/particle/pore � Dielectric constant 
 Drug release constant � Drug release exponent 
Em Electric field intensity 
 Entanglement number 
 Flow rate 
 Length 
 Mass �  Maximum elongation � NMR proton signal 
 Number � Orientation index 
 Particle aspect ratio 
 Particle circularity � Polymer concentration �  Polymer molecular weight 
 Porosity 
 Quantity of drug released 
 Radius 
n Sample size �  Solution entanglement molecular weight 
P Statistical P value 
 Surface charge density  � Surface tension 
 Tangential collector velocity � TEG clot formation time �  TEG maximum amplitude 





 Young s modulus 
  
University of Cape Town  WJ van den Bergh 
 
 Drug Eluting Electrospun Scaffolds for Tissue Regeneration xxiii 
 
GLOSSARY 
ablumen Outside surface 
adhesion A process by which a cell attaches to a surface/device/other cells 
adverse effects Device or drug inducing undesirable/cytotoxic side effects 
amphiphilic Polymer or salt with both hydrophobic and hydrophilic properties 
angiogenesis The formation of new blood vessels from pre-existing vessels 
arrhythmia Abnormal cardiac rhythms 
arteriosclerosis Thickening of the arterial wall due to cholesterol build-up 
atomisation  The formation of small particles by electrospraying 
avascularised A scaffold without a vasculature 
binary Image containing only two pixel intensity values - black and white 
calcification Abnormal calcium depositions causing the tissue/surface to harden 
cellularisation The formation/infiltration of cells within a scaffold 
circumferential Direction going around the circumference of a rotating collector 
coherency Image processing measurement of fibre alignment from SEM images  
compliance Mechanical responsiveness of vessel to an internal pulsating force 
decellularised A scaffold made from tissue that were striped from all cells 
differentiation A process by which a cell develops into a more complex type 
electrohydrodynamics Interdisciplinary study of fluid dynamics and electrostatics 
explant Implant retrieved from animal model at a selected time point 
femoral Refers to the main artery that supplies blood to the leg 
haemodialysis Artificial blood purification for poorly functioning kidneys 
hydrophilic A polymer or salt soluble in water/polar solvents 
hydrophobic A polymer or salt not soluble in water/polar solvents 
hypertension High blood pressure  
in situ Investigations performed in its natural/original context 
in vitro Investigations performed outside of its biological context 
in vivo Investigations performed on living organisms 
longitudinal Direction going along the length of a rotating collector 
lumen Inside surface 
off-the-shelf Medical devices that are readily available 
popliteal  Refers to the artery found in the fossa behind the knee 
porogen A particle acting as a space holder to create additional pores 
proliferation The process by which cells are growing in numbers  
restenosis The narrowing of a blood vessel 
semi-dilute Polymer solutions with a certain degree of macromolecular overlap 
Taylor cone Cone-shaped droplet at a critical charge during electrospinning  
thrombogenicity Tendency of a material in contact with blood to form a clot 
thrombosis Blood clot formation that is blocking the device from the inside 
vascular graft Device to replace or repair arteries/veins - vascular prostheses 
vascularisation The formation of new blood vessels within a scaffold 
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1 INTRODUCTION 
This chapter provides background information on the need for medical devices aimed 
at cardiovascular disease treatment. The subsections to follow covers a literature review 
on topics related to the development of tissue regenerative scaffolds using synthetic 
biomaterials and bioactive molecules. Thereafter, a research proposal is framed in the 
form of a problem statement and project objectives. 
1.1 Background 
1.1.1 The burden of cardiovascular diseases 
Cardiovascular disease (CVD) is the number one killer of humankind since the 1990 s. 
Globally, one out of every three deaths (~16 million human lives per annum) is caused 
by heart related diseases [1]. The mortality rate of CVD among developing economies 
(which accounts for 80-85% of the global population) is on the rise [1, 2]. Estimates 
show that Sub-Saharan African countries, such as South Africa, could see a 41% 
increase in the number of deaths (ages 35-65 years) due to CVD within the period of 
2000 to 2030 [3]. It is believed that the cumulative adoption of a western life style 
(smoking, physical inactivity, poor nutrition and obesity) that lead to hypertension, 
high blood cholesterol, diabetes mellitus, metabolic syndrome and chronic kidney 
disease could be at the root of the expected incline of CVD fatalities [4]. Nevertheless, 
these trends are likely to result in higher patient numbers and may set fragile economies 
under immense pressure. An urgent need for next generation cardiovascular treatments 
and devices are therefore highlighted. New solutions should be focused on therapies 
that would reduce hospitalisation and recovery times, minimise re-admissions, lower 
cost and improve the patient s overall quality of life [5]. 
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1.1.2 Medical devices for cardiovascular therapies 
Clinicians turn to implantable medical devices when conventional, lower risk therapies 
(like corrective surgery) have failed or is insufficient to treat end-stage CVD patients 
[6]. Arteriovenous (AV) access shunts, bypass grafts, heart valves, pacemakers, stents 
and ventricular assist devices are principle medical devices for invasive CVD treatments 
(two examples of such devices shown in Figure 1.1).  
 
Figure 1.1: Examples of implantable medical devices for the heart. On the left, a vascular graft (great 
saphenous vein) and on the right, a mechanical heart valve (Starr-Edwards caged ball valve). 
Illustrations were adapted from [7]. 
Prosthetic heart valves (mechanical or bioprosthetic) are used to replace diseased valves 
of patients that have valvular heart disease (VHD). Severe stenosis (narrowing of the 
valve orifice and stiffening of the leaflets) in high pressure sites like the mitral or aortic 
valve, or less often tricuspid/pulmonary valves, of patients with VHD disorders may 
require valve replacements. Rheumatic heart disease (RHD) is a VHD that mainly 
occurs in developing countries, with numbers on the rise, and may lead to the need for 
mitral/aortic valve replacement [8, 9]. A ventricular assist device (VAD) is an 
electromechanical pump designed to aid poor performing chamber(s) of the heart with 
blood circulation to the rest of the body. Patients that experienced heart failure (HF) 
may require the implantation of a VAD (commonly aiding the main pumping chamber 
of the heart, i.e. the left ventricle) to accommodate for weak cardiac outputs [10]. 
Implantable pacemakers provide external electrical stimuli to strategically excite heart 
tissues of patients with cardiac arrhythmia-related symptoms (abnormal heart beats). 
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Patients with arrhythmia could have insufficient blood supply to heart muscles due to 
arteriosclerosis (thickening of the arterial wall), called coronary artery disease (CAD) 
[11]. Besides the narrowing of arteries around the heart, arteriosclerosis can also occur 
in lower limb regions (e.g. femoral/popliteal arteries) which is referred to as peripheral 
artery disease (PAD). Vascular stents (cylindrical wire-framed structures) are catheter 
deployable implants that forcefully open, and retain, the lumen of constricted arteries 
of CAD/PAD patients [12]. Individuals suffering from end stage renal disease (ESRD) 
undergo regular haemodialysis (external blood purification) due to kidney failure. 
Dialysis is often performed through vascular access provided by an arteriovenous (AV) 
access shunt. AV shunts are implantable tubes that connects arterial and venous blood 
flow, sutured to deep veins and arteries in the fore/upper arm, to generate a higher 
flow rate required by the artificial kidney machine (i.e. the dialyser) [13]. Bypass grafts, 
also tubular devices, are used to replace or re-direct blood flow (bypass) of 
restricted/occluded blood vessels in CAD/PAD patients [14]. Although, bypass surgery 
could be considered as a last resort procedure after lower risk therapies (such as vascular 
stenting) have reached its threshold of repetition or were unable to allow sufficient 
blood flow. The related CVD, estimated annual need and therapy cost for each of these 
devices are summarised in Table 1.1. 
Table 1.1: The global need for principle CVD medical devices. End stage renal disease (ESRD), 
coronary artery disease (CAD), peripheral artery disease (PAD), valvular heart disease (VHD), 
rheumatic heart disease (RHD) and heart failure (HF). Adapted from [15, 16]. 
Implantable device  Related CVD Annual need  Cost (bil.USD/yr.) 
Arteriovenous shunts  ESRD 1 028 000 59.4 
Bypass grafts CAD/PAD 750 000 24.0 
Heart valves VHD/RHD 244 000 14.6 
Pacemakers CAD 669 000 16.7 
Stents  CAD/PAD 1 750 000 36.8 
Ventricular assist devices  HF 250 000 49.3 
Total  4 691 000 200 
    
Accounting for 40% of the total annual need and therapy costs (1.8 million and 85 
billion US dollars respectively), vascular prostheses (AV shunts plus bypass grafts) 
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have the highest demand and financial burden of the principle devices listed in Table 
1.1. Medical advances on vascular grafts (VG) could play a significant role in the fight 
against CVD. Therefore, it is important to investigate technologies that have the 
potential to improve VG in ways that would align with the challenges set out in section 
1.1.1.  
1.1.3 The challenges of implantable devices 
Despite the overall success of implantable medical devices, there are a vast number of 
reports submitted to regulatory affairs of complications or adverse outcomes each year. 
More than 900 000 of such cases were reported to the United States Food and Drug 
Administration (FDA) in 2015 alone [17]. Although many other factors could lead to 
device failure (such as inadequate sterilisation [18, 19], compliance mismatch [20, 21], 
mechanical fatigue [22], restenosis [23, 24] or thrombosis and calcification [9, 25, 26] in 
cases of VG), many of the complications can be attributed to poor healing due to 
fibrotic encapsulation (associated with the human s foreign body response -FBR) [27–
32]. The underlying complication involves an avascularised fibrous layer that isolates 
the implant from the surrounding tissue. After merely 2 weeks of implantation, fibrous 
encapsulation may wall off biosensors/pacemakers leads, shut down drug delivery 
systems, occlude and inhibit endothelialisation of vascular grafts or cause an acute 
inflammatory response. This is troubling due to complicated revision surgeries that may 
follow which could compromise the patient s life. It is of even greater concern that 
biocompatible materials (FDA approved biomaterials) were used in the construction of 
these failed medical devices. However, it is known that one biomaterial could be 
compatible in a particular application and may present adverse effects in another [33]. 
Therefore, leading experts (DF.Williams [34], R.Langer [35], P.Zilla [29, 36] and 
B.Ratner [37]) have suggested that healthy biological integration between a medical 
device and its host is achievable when significant emphasis is carried out on biomaterial 
microarchitecture and its surface chemistry at the implant/tissue interface. Tissue 
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engineering is a discipline dedicated to provide solutions to overcome biocompatibility 
issues and eventually improve the long-term performances of the already millions of 
implantable CVD devices.  
1.1.4 The tissue engineering concept 
Tissue engineering (TE), as defined by DF.William [34], is the creation of new tissue 
for the therapeutic reconstruction of the human body, by the deliberate and controlled 
stimulation of selected target cells through a systematic combination of molecular and 
mechanical signals. Or, as explained by R.Langer [35], newly functional living tissue 
fabricated using living cells, which usually associated, in one way or another, with a 
matrix or scaffolding to guide tissue development. Regardless of the official definition, 
current day TE can conveniently be subdivided into two main approaches: i) classic in 
vitro TE or ii) in situ TE [38, 39]. The main differences are summarised in Table 1.2. 
Table 1.2: A comparison of tissue engineering approaches. Adopted from [39] 
 In vitro TE In situ TE 
Off-the-shelf availability Possible More likely 
Scalability Difficult Easier 
Clinical translation Complex More likely 
Biomaterials Extensively used Extensively used 
Bioreactors Yes Not commonly used 
Chemical factors Yes Yes 
Cells (pre-seeding) Yes Not commonly used 
Cost High More affordable 
   
Classic in vitro tissue engineering entails a 3D biomaterial (with or without bioactive 
molecules) that is seeded with targeted cells, usually harvested from the eventual host, 
and cultured in a bioreactor until a desired bulk of living tissue is developed before 
implantation. On the other hand, in situ tissue engineering typically involves a cell-free 
3D biomaterial (with or without bioactive molecules) that is immediately implanted 
into the host (as is) and uses its own body as the cell source and natural bioreactor to 
populate the structure and grow into functional native-like organ tissue (the latter 
approach may also be considered as a form of regenerative medicine [32, 40, 41]). This 
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idea is more practical in a clinical setting, especially in developing countries, as it would 
require less time and resources (skills, equipment and funds) to generate an implant-
ready device compared to in vitro TE. A graphical representation of the two TE 
strategies are displayed in Figure 1.2 (blue and red arrows are for in vitro and in situ 
TE respectively).  
 
Figure 1.2: Graphical representation of tissue engineering approaches. Blue arrows indicate in vitro TE 
and the red arrow in situ TE respectively. Altered from the original sketch [39].  
Although simplified in vitro TE approaches have already gained some clinical success 
(e.g. heart valve [42–45] and vascular prostheses [46, 47]), it will be advantageous to 
develop off-the-shelf  products that can be implanted with immediate effect along with 
the embedded signals (mechanical and chemical) that would allow for complete in vivo 
tissue regeneration over time. 
1.1.5 Design parameters for tissue engineered scaffolds 
Despite the different approaches towards TE, the reconstruction, repair or replacement 
of tissue constructs (e.g., nerve, tendon, cartilage, bone or cardiac/smooth/skeletal 
muscle) require a porous three-dimensional structure that would ultimately house the 
cells either permanently (non-degradable) or preferably, only temporarily allow cells 
and then disappears (degradable biomaterials). Researchers have widely reported [29, 
34, 36, 37, 48–50] that the microenvironment of these scaffolds plays a substantial role 
in stimulating the desired cellular response for the intended tissue remodelling. Ideally, 
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scaffold microarchitecture should be designed to closely match that of the natural 
extracellular matrix (ECM) of the targeted tissue. The ECM act as a media that 
accommodates intercellular communication. It is enriched with cell surface receptors 
(e.g., integrins, laminin, and syndecans) and structural proteins (e.g., collagens, 
laminins, fibronectin, vitronectin, and elastin) which allow cellular adhesion, migration, 
proliferation and differentiation [51]. The natural ECM can be observed and studied 
when tissue constructs are decelullarised. A porous network of fibres (wave-like strings 
made up of collagen/elastin) can be seen in Figure 1.3 for a decellularised a) canine 
aorta and b) the leaflet of a porcine aortic valve. 
 
Figure 1.3: The fibrous network of natural extracellular matrices. Decellularised tissue: a) longitudinal 
fibres (canine aorta [52]); b) wave-like fibres of a heart valve leaflet (porcine aortic valve [53]). 
While mimicking the architecture of the targeted tissue s ECM, tissue engineers should 
also consider the following parameters for developing a TE scaffold [54]: 
 Biocompatibility - appropriate biomaterial selection (either natural or synthetic 
origins, but should be non-toxic with minimal induced immunogenic responses). 
 Porosity and pore size - sufficient interconnectivity and void spaces to allow for 
the desired cells to infiltrate/migrate with additional spaces to also 
accommodate waste/nutrient transportation.  
 Surface area - a high surface area to volume ratio is desirable for optimising 
cellular attachment sites and has the additive advantage of optimising drug 
delivery. 
 Surface properties - suitable surface chemistry and morphology that would 
promote protein absorption and cellular adhesion, growth and proliferation. 
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 Bioactivity - ideally, the scaffold should provide bioactive cues to residing cells 
with beneficial effects towards tissue generation.  
 Mechanical properties - the structure should be able to support the cells and have 
a mechanical performance that matches that of the native tissue. 
 Biodegradability - preferably, the scaffold should be completely resorbed after it 
has full fill its mechanical responsibilities. 
 Cost - the manufacturing process should have a viable translatable cost involved. 
Among the techniques developed to manufacture porous TE scaffolds (e.g., phase 
inversion/porogen extraction [55], phase separation [56], self-assembly [57], gas foaming 
[58], salt leaching [59], freeze drying [60] and 3D printing [61]), electrospinning is a 
versatile process that produces fibrous scaffolds and has the potential to accommodate 
most of the design parameters set out in the above list. An electrospun vascular graft 
[62] and heart valve [63] along with representative images of their respective nano-and-
micro-fibrous networks are on displayed in Figure 1.4. 
 
Figure 1.4: Tissue engineered electrospun scaffolds for implantable medical devices. a) small diameter 
vascular graft [62] and b) pulmonary prosthetic heart valve [63]. SEM scale bars are 5 and 50 µm. 
Although significant advances have been made in the field of TE scaffolds as medical 
devices (using electrospinning and other methods), the following are key scientific 
challenges that remain unsolved [64]: 
 Minimise immune response, 
 Control inflammatory reaction, 
 Reduce thrombogenicity, and ultimately, 
 Favour cellular infiltration, remodelling and growth.  
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1.2 Applied electrohydrodynamics for tissue engineering 
This section introduces electrohydrodynamics and how it can be applied as an additive 
manufacturing process for producing micro to nano-scaled particles and fibres towards 
the development of 3D tissue engineered scaffolds. Furthermore, the challenges and 
latest advances of electrospun TE scaffolds are reviewed.  
1.2.1 Introduction to electrohydrodynamics 
In the year 1600, William Gilbert (Figure 1.5.a) published a book on his observations 
of static drops of water deforming into cone shapes when approached by a rubbed 
(charged) piece of amber [65, 66]. Lord Rayleigh, in 1882, was the first to describe the 
relationship between the surface tension of a droplet and the electrostatic forces acting 
on it within an electric field [67]. He referred to the cone shaped droplet as being in a 
critical  state when the electrostatic forces attempt to overcome the surface tension of 
the liquid at a certain charge. More than three centuries after Gilbert s observation, 
John Zeleny [68] and Sir Geoffrey Taylor [69, 70] re-investigated the critical sate of 
water/glycerine droplets fed through a small capillary and subjected to an electric field 
(Figure 1.5.b). Taylor in particular [69] derived theoretical models and experimentally 
confirmed that the critical cone shape of a water droplet was angled at 49.3 (now 
known as the Taylor cone). Furthermore, they found that a high enough potential 
created an above critical charge that caused a thin jet of fluid to shoot from the apex 
of the Taylor cone towards the counter electrode (Figure 1.5.c) [70].  
Figure 1.5: A brief history of electrohydrodynamics. The English medical doctor a) William Gilbert 
(1544-1603)[66]; b) a typical electrospinning setup used by Sir G. Taylor and c) a Taylor cone 
published by Taylor himself in 1969 [71]. 
a) b) c) 
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During flight, the authors observed that the straight jet rapidly became unstable (in a 
fashion that resembles pushing instead of pulling on a piece of string) and eventually, 
dissipated into a cascade of droplets. These early discoveries laid the foundations of 
electrohydrodynamics (EHD), the study of electrically charged fluids in motion [72]. 
Following the work of Taylor and peers, researchers such as L. Larrondo et al.[73–75], 
D.H. Reneker et al.[76–82], A.L. Yarin et al.[78, 79, 81–84] published influential studies 
that started in 1980, 1990 and 2000 (respectively) which brought a new light to EHD. 
Their focus was on exploiting a process that applied EHD to semi-dilute polymer 
solutions with a sufficient degree of macromolecular entanglement that would resist jet 
break-up during the instability phase. Under the right conditions, such experiments 
produced continuous polymeric nanofibers - a phenomenon we now refer to as 
electrospinning. Soon, electrospinning became widely adopted in research areas such as 
microfiltration for air [85] or water systems [86], composite materials for structural 
reinforcement [87], sound attenuation [88], energy generation from solar [89] or 
mechanical sources [90], energy storage [71], high intensity heat exchangers [91], 
biosensors [92] and tissue engineering [93]. Electrospinning is attractive to these 
applications due to its relatively low manufacturing cost, upscaling potential and in 
particular, its ability to produce structures with a high surface area to mass ratio [82]. 
1.2.2 Electrospinning of polymeric fibres 
Current electrospinning systems are fundamentally unchanged since their discovery 
(e.g. Figure 1.5.b). A basic experimental setup for producing polymeric fibres include a 
semi-dilute solution that is supplied (e.g. 0.1-10 ml/h) through a highly charged (e.g. 
30-500 kV/m) capillary with a grounded collector situated at some distance away (e.g. 
50-350 cm) [94, 95]. Applying enough voltage causes solution from the tip of the 
capillary to form an above critical Taylor cone. An initial jet accelerates from the cone 
and follows a unidirectional path while becoming narrower as it travels towards the 
counter electrode. Consequently, surface charge density escalates and induces 
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axisymmetrical instabilities (wave formed) to occur down the length of the jet [78, 96, 
97]. Statistical variance of surface charge modulation causes same charges to repel one 
another, thereby inducing radial forces. The lateral movements amplify the repelling 
effect which evolves into a spiral with an increasing radius, while jet radius continuous 
to decrease, towards the counter electrode (a flat, rotating or custom-made collector 
[98]). This process could repeat itself by developing secondary, tertiary [82] or even a 
fourth series [78] of coils (depending on solution properties) before the solvent 
evaporates and the jet solidifies into polymeric fibres. It was estimated that the initial 
jet could experience velocities and strain rates in the range of 1-15 m/s [99–101] and 
105/s [82] respectively, resulting in solid fibres after ~25 ms that are less than 500 nm 
in diameter [82, 102, 103]. The fibre formation processes is summarised in Figure 1.6.  
 
Figure 1.6: Fibre formation during electrospinning. a) Taylor cone, b) straight jet region; and unstable 
region of c) primary d) secondary coil formation. 
In contrast to the simplistic experimental design, controlling the outcome of the 
electrospinning process is complex. Numerous factors could affect the fibre formation 
process. Thus, it is important to identify and understand the existing control 
parameters for the development of application specific electrospun structures (e.g. 
control over porosity, inter-fibre pore sizes, average fibre diameter and/or fibre 
alignment). Due to polymer-solvent specific properties and complex inter parametric 
relationships, theoretical models are not yet capable of predicting the outcome of the 
electrospinning process [102]. Therefore, the following subsections explored a few 
parameters from literature to provide an empirical overview of their influences. Table 
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1.3 is a list of parameters identified according to the following sub-categories: solution, 
climate or processing parameters. 
Table 1.3: Controllable electrospinning parameters 
Solution Climate Processing 
Viscosity 
Polymer concentration 





Solvent surface tension 
Solvent dielectric constant 
Solvent vapour pressure 
Ambient temperature 







   
1.2.2.1 Electrospinning solution 
Solution viscosity is one of the main controllable parameters for influencing the 
resultant electrospun fibre diameter [93, 94, 98, 102, 104, 105]. In general terms, a 
higher viscosity is known for producing thicker fibres. Polymer concentration and 
molecular weight are two common properties used for solution viscosity adjustment, 
and thereby controlling fibre diameter. Several studies have reported that fibres with 
larger diameters were produced at higher polymer concentrations [106–109]. For 
example, Yang et al. showed that fibre diameters increased from 0.7 µm to 3.5 µm 
when the concentration of PLLA (300kDa), dissolved in DCM:DMF at 70:30, was 
increased from 2 to 5wt% [109]. At a constant concentration, changing the molecular 
weight of the polymer is known for inducing/reducing the degree of beading and altering 
the diameter of electrospun fibres due to its strong influence on solution viscosity [110–
113]. Tao et al. doubled the thickness of electrospun fibres (200 to 400 nm) when the 
molecular weight was increased from 10 to 18 kDa at 30wt% concentration of PVA in 
distilled water [112]. This effect was also confirmed by others [111, 114]. Despite the 
ease of controlling fibre diameter by varying solution viscosity (a power-law relationship 
[107]), it should be noted that such effects only exist within a certain range. Viscosities 
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that are too high (e.g. >4000 cPoise) might resist the formation of a Taylor cone and 
are physically unspinnable. On the other hand, a viscosity below a certain point (e.g. 
<800 cPoise) might not have sufficient polymer chain entanglements (due to 
concentration and/or the molecular weight being too low) to resist jet break-up after 
Taylor cone formation [98]. In such a case, beads or beaded fibre are formed instead of 
smooth cylindrical fibres. An ideal concentration (� ) at which smooth fibres are 
formed is unique to each electrospinning solution.  
 
Figure 1.7: Chain entanglement as a function of concentration and molecular weight. Critical 
concentrations for a) PS/THF and b) PLA(DMF:DCM) [115]. The lines represent different molecular 
weights and fibre formation is indicated by the dashed line at = 3.5 and higher. c) SEM 
images of PS(19 kDa) electrospun at different concentration (40-53%) from DMF [116]. 
Molecular weight and polymer-solvent interactions (e.g. solubility) are the main factors 
determining �  [115]. An entanglement number,  : equation (1-1) from 
[117], is often used to describe the concentration region for fibre formation � > �  
of a particular electrospinning solution; where �  is the molecular weight of the 
polymer and �  the solution entanglement molecular weight:  
= ���  (1-1) 
Shenoy et al. [115] and later Eda et al. [116], investigated the morphological influence 
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of chain entanglement on electrospun PS and PLA of different molecular weights at 
various concentrations (examples shown in Figure 1.7). Their semi-empirical model 
predicted that smooth fibres are formed when  > 3.5 [115], unless � <100 
kDa and/or �  >30wt% [116]. Although molecular weight does influence fibre 
morphology and governs at which point �  would be, concentration is a more 
practical parameter for fine tuning fibre diameter.  
A solution with a higher conductivity (�) has a greater charge carrying capacity and 
would experience more elongation during the fibre formation process resulting in 
thinner fibres [93, 95, 98, 107, 118]. Solution conductivity can be controlled by strategic 
selection of solvent(s) and/or by salt additives. Solvents with a higher dielectric 
constant (ε) are associated with a higher conductivity � ∝  , (also known as the 
Nernst-Thomson rule) [119]. Young et al. showed that the inclusion of 2wt% salt 
(benzyl triethylammonium chloride) reduced the average fibre diameter of electrospun 
PLGA/chloroform from 760 to 450 nm [120]. Moreover, the authors showed that fibres 
electrospun from PLGA/HFIP (ε = 17.8) produced thinner fibres (270nm) compared 
to the fibres spun from chloroform (ε = 4.8). Increasing solution conductivity shifts the 
minimum concentration for producing smooth fibres (�  to a lower point, as 
shown by Young et al. [120]. This explains why many observed reduced beading when 
fibres were spun from more conducting solutions [121–124]. Solution conductivity could 
also be used to control the fibre orientation of electrospun fibres on a rotating collector. 
Sun et al. demonstrated that a high degree of fibre orientation was obtainable by 
electrospinning PEO from a poorly conductive solution (prepared by solvent selection, 
chloroform, ε = 4.8) when compared to the collecting patterns of a more conductive 
PEO solution (water, ε = 79.7) [125].  
The surface tension of an electrospinning solution can be altered by strategic solvent 
selection and/or adding surfactants [104, 111, 116, 126–128]. After the Taylor cone is 
formed, a solution with a higher surface tension (an elastic force attempting to 
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shapeshift the jet back into a droplet) dominates the electrostatic forces that are trying 
to elongate the solution, resulting in spherical/elongated beads or beaded fibres 
(depending on polymer entanglement) [123, 129, 130]. Heating the electrospinning 
solution reduces its viscosity and increases the electrical conductivity (assuming semi-
conductor behaviour). As expected, several authors have observed thinner fibres when 
electrospinning solutions at higher temperatures compared to those processed as room 
temperature [107, 131–133]. Wang et al. controlled the solution temperature by 
circulating heated silicon oil through a custom-made double walled syringe [132]. The 
average diameter of the fibres they captured while electrospinning a solution of PDLLA 
(20wt%, DMF) at 45C were nearly 60% reduced (503 to 318 nm) compared to those 
spun from a room temperature (25C) solution. 
Solvent selection can be a powerful tool in electrospinning control. Ideally, all available 
solvents should be identified that dissolves the selected polymer at room temperature. 
Thereafter, properties such as viscosity, surface tension, dielectric constant, boiling 
point/vapour pressure etc. should be taken into consideration before making the final 
selection. For comparison, properties of twenty-four common organic solvents are 
summarised in Figure 1.8 (ranked according to an increasing dielectric constant). A 
solvent with a higher viscosity will automatically increase the overall solution viscosity 
and therefore, would produce thicker fibres when compared to a same concentration 
solution prepared using a less viscous solvent [106, 123]. In the same fashion, a solvent 
with a lower dielectric constant will result in a less conductive spinning solution and 
thereby produce thicker fibres [125]. A solvent s surface tension may influence the 
overall surface tension of the solution and, as mentioned before, could result in fibre 
beading [123]. The volatility (in terms of boiling point/vapour pressure) of the 
electrospinning solvent system could induce significant morphological alterations. 
Solvents with a higher boiling point (lower vapour pressure) have a greater difficulty 
to evaporate during the instability phases compared to a more volatile solvent system. 
If the boiling point is too high, insufficient evaporation may result in wet  or fused 
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fibres instead of smooth cylindrical fibres [107, 134–136]. Matsuda [135] and Kidaoki et 
al. [134] showed that increasing the content of DMF of a DMF:THF co-solvent system 
(with boiling points of 153 and 66C for DMF and THF respectively), resulted in more 
fusion of segmented polyurethane electrospun fibres due to an overall increase in solvent 
boiling point.  
 
Figure 1.8: Organic solvent properties: a selection for experimental electrospinning. Abbreviations: 
tetrahydrofuran (THF), trifluoro acetic acid (TFA), trifluoroethanol (TFE), dichloromethane (DCM), 
dichloroethane (DCE), hexafluoro isopropanol (HFIP), methyl pyrrolidone (NMP), dimethylformamide 
(DMF), dimethylacetamide (DMAC) and dimethyl sulfoxide (DMSO). Numerical data [137] can be 
found in Appendix A1.  
Considering the multitude of solvent specific effects, and their mutual dependencies, 
solvent selection is vital for achieving a desired outcome. The fluorinated alcohol 
1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP) is known for being one of the most popular 
electrospinning solvents [93, 94, 138, 139], and was used for many synthetic (e.g. 
Pellethane® [140], PHB [141], PLCL [142], PGA [120], PLA [143], PLGA [144], PGS 
[145] and PCL [104]) and natural (e.g. collagen [146], fibrinogen [147], silk fibroin [148] 
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popularity as a fibre producing solvent may include: its ability to dissolve a wide array 
of polymers/drugs, mid-range dielectric constant (ideal for producing nanofibers), 
relatively low boiling point (a fast evaporation rate), low surface tension (less likely to 
form beads) and being versatile as a co-solvent with almost any other organic solvent 
(miscible with polar-opposites, e.g. water and chloroform). It is therefore not surprising 
to use co-solvent systems made up of those from different ends of the spectra to balance 
each other s short comings. For example, combining low and high dielectric constant 
or boiling point solvents such as DMF:CHCl3 [150], MeOH:CHCl3  [151, 152] or 
DMF:THF [134, 142, 153]. 
1.2.2.2 Electrospinning climate 
The ambient conditions (temperature and humidity) are known to affect solvent 
evaporation rates and filament flow dynamics [104]. Electrospinning in a warmer 
environment decreases solution viscosity and enhances solvent evaporation rate, 
thereby producing thinner fibres. Zhang et al. produced fibres with 50% reduced 
diameters by increasing the ambient temperature from 35 to 50C while electrospinning 
aqueous gelatin solutions [154]. Thinner fibres due to higher ambient temperatures were 
also reported by others [155, 156]. Conversely, increasing the relative humidity (RH) 
of the electrospinning environment has been observed to produce thicker fibres [157–
159]. Huang et al. showed that increasing the RH of 0 to 50/60% while electrospinning 
polyacrylonitrile (PAN) or polysulfone (PSU) dissolved in DMF resulted in thicker 
fibres [158]. The average diameter was increased from 150 to 630 nm and 1.15 to 3.58 
µm for PAN and PSU fibres respectively. Such an effect could be explained by less 
whipping of the filaments before solidification. The higher moisture content (available 
water molecules at a high RH) between the needle and the collector caused more 
electrostatic discharge to occur on the surfaces of incoming filaments [159], thereby 
reducing the degree of stretching (whipping) when compared to observations at a lower 
RH. Moreover, it was found that electrospinning at higher RH may also alter fibre 
surface roughness [157–159]. Casper et al. found that electrospinning of polystyrene 
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(PS) at >30% RH induced surface nanopores that increased in size and frequency as 
RH was further increased [157]. It should be noted that RH s influence on the outcome 
of electrospun structures strongly depends on polymer hydrophobicity and solvent 
properties (vapour pressure and its miscibility with water) [105]. Therefore, an 
appropriate solvent system and constant awareness/control of ambient conditions 
should be considered when designing and reproducing eletrospinning experiments. 
1.2.2.3 Processing parameters 
Processing parameters for electrospinning control can be categorised into pre-processing 
(constant during the process) and real-time adjustable parameters. Depending on the 
experimental setup, pre-processing parameters could include collecting distance and 
needle diameter while examples of real-time control parameters are the applied voltage, 
flow rate and colleting speed. The air gap between the needle and the collector has a 
direct influence on the time for solvent to evaporate and the strength of the electric 
field. At short distances, solvent might not have sufficient time to evaporate completely 
and could result in wet  or fused fibres [160]. Moreover, fibre beading has also been 
associated with a collecting distance being too close to the collector [161]. Increasing 
the working distance creates space for additional instabilities to occur and therefore 
could produce thinner fibres [106, 162]. Although, many have observed an increase in 
the average fibre diameter attributed to significant less fibre stretching/whipping due 
to a weaker electric field at distances further as appose to closer from the Taylor cone 
[160, 163–165]. Needle diameter is yet another control parameter with contradicting 
observations. Predominantly, fibre diameter was found to be directly proportional to 
the needle diameter [166–169] while a minority suggested an inverse relationship [170] 
or that no correlation exist [171]. According to the electrospinning model developed by 
Thompson et al., a needle with a larger diameter will produce a Taylor cone with a 
larger initial jet radius and, essentially, would produce thicker fibres compared to those 
spun from a smaller orifice [169]. This assumption was experimentally confirmed [166–
168]. The applied voltage has multiple influences on the electrospinning process, and 
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again, not without associated contradictions. In general, it was found that a higher 
applied voltage reduced electrospun fibre diameters [106, 111, 160, 172]. This trend is 
expected as greater electrostatic forces, caused by a higher electric field, would promote 
more solution stretching and thus, produce thinner fibres. Increasing the electric field 
could also induce fibre beading [114, 130, 173]. Ki et al. observed beaded fibres and an 
increase in their frequency when gelatin-formic acid was electrospun at >20 kV while 
smooth fibres were found at a lower voltage (7.5 kV) [173]. In such cases, fibre beading 
is said to be the result of an unstable Taylor cone [114], which usually forms on the 
edges of the needle and not in the centre as it would for a stable cone. It is therefore 
necessary to find the optimal voltage (specific to each electrospinning solution) for 
producing smooth cylindrical fibres. A minimum flow rate exist that would sufficiently 
replace the volume of solution that gets drawn from the needle at a set of constant 
electrospinning conditions (e.g. working distance, voltage, needle diameter etc.) [174]. 
Such a flow rate is required to maintain a stable Taylor cone and therefore, for the 
production of uniform (bead free) fibres [175]. Although small adjustments to the flow 
rate may not have a significant effect on the outcome (e.g. electrospinning PCL at 0.6-
1.5 ml/h [176]), increasing the solution feed rate has been observed to increase the 
average fibre diameter [132, 169, 177, 178]. Milleret et al. showed that DegraPol® fibres 
of 4 µm could be produced at a flow rate of 4 ml/h while thicker fibres (10 µm) were 
obtainable at 12 ml/h [178]. This is mainly due to a larger initial jet radius caused by 
an increase of solution volume at the tip of the needle which lead to a thicker fibre 
formation [169]. A further increase in flow rate might result in ribbon like or fused 
fibres due to insufficient solvent evaporation [105, 179]. In the case of a rotating 
collector, collecting speed can be used to alter the orientation of deposited fibres and 
thus, tailor the mechanical/architectural properties of electrospun scaffolds. Fibre 
alignment is directly proportional to collector face velocity [178, 180–183]. Moreover, 
collecting speed was also shown to influence the average fibre diameter (higher speeds 
resulted in thinner fibres) [125, 178]. Sun et al. found that the average diameter of 
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electrospun fibres (PEO/CHCl3) decreased with increasing collector face velocity (0.6-
16 m/s) until it reached a point where diameter remained constant despite a faster 
speed (1.6 µm and reaching a plateau of 658 nm at 12 m/s) [125]. Considering all 
mentioned factors, Table 1.4 is a summary for electrospinning parametric control.  
Table 1.4: Parametric control of electrospun scaffold morphology. 
Desired outcome Parameter(s) to upregulate References 








[93, 95, 98, 107, 118] 
[107, 131–133] 
[154–156] 
[106, 111, 160, 172] 
[125, 178] 
[106, 162] 










[132, 169, 177, 178] 
[106–109] 




Reduce fibre fusion 
 
Collecting distance 
Solvent vapour pressure 
[160, 179] 
[107, 134–136] 
Induce fibre fusion 
 
Flow rate 
Solvent boiling point 
[105, 179] 
[107, 134–136] 










[104, 116, 126–128] 
[160, 161] 
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1.2.3 Electrospraying of polymeric particles 
Electrospraying is fundamentally the same process as electrospinning. While 
electrospinning produces polymeric fibres, electrosraying is a process for creating nano 
or micro particles. The main distinguishing variable between electrospraying and 
electrospinning is the molecular entanglement number of the processing solution. At a 
constant molecular weight, reducing the polymer concentration below a certain point 
would produce beads (� <  � )  instead of fibres (Figure 1.9) [184]. 
 
 
Figure 1.9: The difference between electrospinning and electrospraying 
The same processing parameters that govern the electrospinning process also control 
the outcome of electrosprayed particles. Therefore, principal parameters such as flow 
rate, solution conductivity and polymer concentration can be used to manipulate the 
size of the particles. Several authors have developed empirical scaling laws to describe 
the relationship between the principal parameters and the resulting particle diameter 
[184–191]. Analogous to the electrospinning relationships (Table 1.4), the diameter of 
electrosprayed particles can be expected to increase with increasing flow rate ( ) and 
polymer concentration (�) while smaller beads would be produced when sprayed from 
a more conductive solution (�). These relationships are demonstrated in Figure 1.10.  
 
Scaling laws for electrospraying: 
 Flow rate ( � ∝ /  
 Concentration ( � ∝ � / ) 
 Conductivity ( � ∝ /� / ) 
Figure 1.10: The influence of electrospraying parameters on particle size. a) Non-dimensional influence 
of processing parameters according to b) empirical scaling laws from literature. 
� > �  � < �  
b) a) 
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1.2.4 Challenges with electrospun scaffolds 
Over the past two decades, electrospinning was explored using more than fifty different 
(natural/synthetic) polymers and has gained wide spread interest as a potential 
technique to develop tissue regenerative scaffolds [192, 193]. Tissue specific applications 
included: skin, nerves, muscle, bone, cartilage, ligament and vasculature [194–196]. 
Apart from the many advantages that electrospinning could offer as a scaffold 
production technique (e.g. ease of manufacturing, ECM morphological resemblance, 
high surface area, cost, scalability etc. [93, 138, 139, 194–197]), there are limitations 
that are hindering the healing performance of such implants [139, 175, 179, 198, 199]. 
Functional tissue restoration using conventional electrospun scaffolds is often limited 
by poor ingrowth due to insufficient structural porosity and interconnectivity, blood 
clot formation, a lack of proper vascularisation and/or excessive inflammation. Several 
strategies have therefore been investigated to enhance both i) architectural and ii) 
biochemical cues that would promote scaffold healing [139, 179, 198, 199]. The sections 
to follow will reflect on the current scaffold porosity enhancement and drug 
incorporation techniques to address the underlying structural and chemical challenges. 
1.2.5 Porosity enhancement techniques 
Poor cellular infiltration is a critical concern for the in vivo usage of electrospun 
structures as TE scaffolds [139, 179, 199, 200]. Scaffold architecture (pore size, porosity, 
fibre diameter and fibre alignment) is known to have a direct influence on how cells 
behave (attach, migrate and proliferate) and therefore, the device s overall healing 
performance [198, 201]. Although conventional electrospun scaffolds are considered to 
be porous, they have inherently small pores, a tight packing density and are layered 
(2D) rather than interconnected, 3D structures [139, 179, 198, 199]. Consequently, 
tissue ingrowth and vascularisation of such scaffolds have been found to be only 
superficial (in vivo)  - leaving the rest of the scaffold hypoxic and without waste removal 
or nutrient supply systems [139]. 
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There is an ongoing dispute on the ideal pore size and porosity for TE scaffolds [139, 
197, 202]. Despite some suggesting that a desirable pore size is 20-40 µm [201–204], the 
general consensus is that the pores should be adjustable for wider range of 5-500 µm 
[200, 205]. Moreover, the average pore size and its morphology should be optimised to 
accommodate tissue specific cell types, since cells differ in size (round cells usually range 
between 5-20 µm [198, 206, 207]) and behaviour (attach, migrate and proliferate) [205]. 
In terms of scaffold porosity, a higher porosity is desirable as it promotes tissue 
ingrowth and diffusion of nutrients/waste. However, the enhancement of both porosity 
and pore sizes are associated with mechanical losses. It is therefore suggested that 
scaffold pore size and porosity should be balanced with the required mechanical 
properties [200]. 
Addressing these challenges, several techniques have been considered to enhance 
electrospun scaffold porosity and pore sizes. The different approaches can be categorised 
as parametric optimisation, collector modification, post-processing and the inclusion 
and removal of sacrificial components. As an initial attempt, scaffold porosity/pore size 
can be improved by optimising fibre orientation, fibre fusion or fibre diameter by 
controlling the electrospinning parameters as summarised in Table 1.4. The average 
pore size and total porosity of scaffolds with aligned fibres are known to be 
smaller/lower than those formed by random orientated fibres [182]. Reducing the degree 
at which fibres are fusing with adjacent ones has shown to increase both the average 
pore size and porosity compared to scaffolds with more fibre fusion [208]. The average 
fibre diameter is probably the most common architectural property of electrospun 
scaffolds to control (considering Table 1.4). Moreover, it is known that fibre diameter 
has a positive relationship with fibre diameter and pore size [209, 210]. Tomadakis et 
al. developed a model to describe the characteristic pore size ( ) as a function of 
fibre diameter ( ) and porosity ( ). This relationship, =  −  , correlated 
well with experimental data when porosity was  = 80-88% [211], and was also 
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confirmed by others [151, 210, 212]. 
 
Figure 1.11: Host response towards thick compared to thin-fibrous scaffolds. Diagram acquired from 
[210]. 
By parametric control over fibre diameter, Wang et al. produced PCL scaffolds with 
enhanced porosity (84%) and pore sizes (40 µm) when microfibres (6 µm) were spun 
instead of nanofibres (66%, 6 µm and 700 nm) [213]. The authors showed an improved 
healing performance (cellular ingrowth, collagen secretion and vascularisation) of the 
microfibrous scaffolds relative to that of the nanofibrous scaffolds. Such findings were 
explained by a higher density of M2 polarised macrophages (tissue remodelling 
phenotype) found inside the microfibrous scaffolds (larger pores), while M1 
macrophages (pro-inflammatory phenotypes) were in abundance within the nanofibrous 
scaffolds (small pores) - illustrated in Figure 1.11. Unfortunately, controlling scaffold 
pore size/porosity by parametric optimisation is not independent of fibre morphological 
changes. Increasing fibre diameter facilitates cellular infiltration, however, it could also 
reduce cellular attachment when fibres are too thick [142, 214]. It is therefore advisable 
to obtain a balance between scaffold fibre diameter and pore size that would allow for 
functional tissue restoration [139]. Scaffold porosity/pore sizes can be enhanced 
independently of fibre diameter by post electrospinning techniques such as 
ultrasonication [149, 215, 216], gas foaming [217–220] or laser ablation [212, 221, 222]. 
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Specialised collectors have also been investigated to increase/control inter-fibre spaces 
during the electrospinning process. Over the last few years, such designs included 
patterned surfaces [223–225] (charged geometries), perforated cylinders [201, 203, 226] 
(tubes with pressurised airflow) or even the use of a liquid bath as the collector [227, 
228]. All the above-mentioned techniques have the potential to produce highly porous 
scaffolds (  >90%) and exhibit some control over pore size (ranging from 2 to 500 µm). 
However, their applications are limited due to associated disadvantages such as 
restricted scaffold thickness, heterogenous distribution of enlarged pores, inability to 
retain the original scaffold shape/dimensions or complicated translation to a geometric 
specific application such as a small calibre (2-4 mm) vascular graft [139, 199].  
Alternatively, removable materials can be included while electrospinning structural 
fibres, to act as temporary space holders (porogens) and selectively extract them 
afterwards to create additional voids in the resulting scaffold. Porogens for selective 
removal from electrospun scaffolds have already taken the form of water-soluble fibres 
[153, 178, 209, 229–232] and microparticles [148, 233] or salt [234, 235] and ice [205, 
208, 236, 237] crystals. Some of the porosity enhancement strategies mentioned in this 
section are on display in Figure 1.12. 
 
Figure 1.12: Techniques to enhance electrospun scaffold porosity. Porosity enhancement by a) 
ultrasonication b) low temperature collecting and c) sacrificial fibre removal as demonstrated by [199]. 
Nano-CT scans of PCL and PLA scaffolds (d-e) and their LTE porosity-enhanced versions (f-g) [205].  
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Wang et al. showed that tissue ingrowth of silk fibroin scaffolds could be enhanced (in 
vitro and in vivo) by the removal of water-soluble (polyethylene glycol - PEG) 
microparticles that were electrosprayed while simultaneously electrospinning of the 
structural fibres [148]. Simonet et al. developed the low temperature electrospinning 
(LTE) technique [205, 208]. Briefly, scaffold porosity and pore sizes are enhanced by 
evaporating/melting ice crystals that were simultaneously embedded between the 
deposited fibres due to condensed moisture from the air near a cold collector (filled 
with dry ice, -70C). Leong et al. have shown that LTE produced scaffolds allowed for 
a higher degree cellular infiltration and vascularisation (in vivo) compared to those 
prepared by conventional electrospinning [237]. The LTE process is separated from the 
rest of the techniques by having the added ability to homogenously increase 3D void 
spaces [205]. At the time of writing, such homogeneity has not yet been achieved for 
the selective removal of electrosrpayed microparticles. However, fine control over the 
electrospraying process should allow for the production of smaller porogens at larger 
quantities (e.g. 30µm particles sprayed from multiple sources) and potentially, enhance 
the porosity with a more homogeneous distribution of pores compared to the current 
approach (50µm particle from a single source [148, 233]). Nevertheless, both the LTE 
and selective removal of electrosprayed particles approaches have been acknowledged 
as translatable techniques towards vascular graft and/or heart valve applications [205, 
238]. 
1.2.6 Drug incorporation techniques 
In addition to the architectural advantages of electrospun scaffolds, bioactive agents 
can be incorporated into fibres to be delivered in a localised, controlled manner over a 
strategic period of time that would assist in functional tissue restoration [198]. A 
localised delivery also has the advantage of eliminating the side effects associated with 
systemic delivery [239]. In the past, molecules such as antibiotics [240], DNA [241], 
growth factors [242], anti-thrombotic (e.g. heparin) [243] and anti-inflammatory (e.g. 
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dexamethasone) [244] drugs have been incorporated and delivered from electrospun 
scaffolds. Current electrospun scaffold drug incorporation techniques can be categorised 
as either a one-step or post processing methodology. Emulsion, co-axial and blend 
electrospinning are examples of one step drug encapsulation techniques while physical 
absorption and surface modification are post processing approaches (Figure 1.13 
illustrates the differences between these techniques). 
  
Figure 1.13: Drug incorporation techniques for electrospun fibres. a) blend/emulsion electrospinning, b) 
co-axial encapsulation, c) physical absorption and d) surface modification. Adopted from [54]. 
Drug incorporation by blend [98, 198] or emulsion [198, 245] electrospinning simply 
requires the polymer solution to be doped with the selected agent before processing 
(either solubilised or in an emulsion state). At optimal conditions, the drug can be 
encapsulated during the fibre formation phase either uniformly (blend) or in 
concentrated pockets (emulsion). Although, a uniform drug distribution by blend 
electrospinning is usually achievable only when the solution of polymer-drug is either 
hydrophobic-hydrophobic or hydrophilic- hydrophilic [54]. Co-axial electrospinning 
requires the use of a co-axial needle where two solutions are individually supplied to 
construct a core-shell configured fibre [246–249]. For such a fibre, multiple combinations 
of drug and its associated carrier material may be loaded in the core, shell or 
encapsulated into both. Furthermore, fibres can be coated with bioactive molecules by 
physically absorbing the agent from a solution or surface modification by chemical 
immobilisation post electrospinning [104]. The latter usually requires functionalisation 
of the polymer properties by plasma treatment, chemical treatment or surface graft 
polymerisation [250]. Nevertheless, both blend electrospinning and the surface 
modification drug incorporation techniques will be investigated during this project as 
an attempt to further enhance scaffold healing responses. 
a) b) c) d) 
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1.3 Synthetic biomaterials and bioactive agents 
The section to follow introduces the synthetic biomaterials selected for this project, 
namely, Pellethane® (Pel) and DegraPol® (DP). Moreover, experimental conditions to 
produce fibrous scaffolds from both materials using the electrospinning process are 
summarised from literature. Next, the bioactive molecules selected for this project gets 
introduced: heparin and dexamethasone, followed by summaries of previous attempts 
of incorporating them into electrospun scaffolds. Finally, a short section on drug release 
kinetics and their associated models are provided. 
1.3.1 Pellethane® 
Pel is a segmented polyetherurethane composing of poly(tetramethylene oxide) 
(PTMO) as the soft-segment and a hard-segment made up of an aromatic junction unit 
4,4 methylene-di-phenyldiisocyanate (MDI) and chain extender 1,4-butanediol (BDO) 
[251], as shown in Figure 1.14. This biomaterial holds a good balance between 
physicochemical and biological properties as well as ease of processing. Although Pel 
may undergo oxidative degradation, it is generally considered to be hydrolytically stable 
[251]. Over many years, the in vivo applications of Pel included, artificial ventricles, 
pacemaker leads, heart valves or cardiovascular tubing and catheters [252].  
 
Figure 1.14: Chemical structure of Pellethane®. Poly(tetramethylene oxide) (PTMO) as the soft-
segment and a hard-segment made up of an aromatic junction unit 4,4 methylene-di-
phenyldiisocyanate (MDI) and chain extender 1,4-butanediol (BDO) [251] and shown by [253].  
Moreover, Pel has been a material selection in previous studies towards the 
development of an electrospun small diameter vascular graft [140, 153, 254–256]. Table 
1.5 is a summary of the electrospinning parameters used for processing Pel. A typical 
vascular graft scaffold is produced from a Pel solution of 5-20wt% in THF/DMF that 
is supplied at a flow rate of 0.6-5 ml/h using a charged (10-20kV) needle of 0.3-1.4 mm 
(inside diameter) situated at a distance 90-200 mm away from a rotating collector. 
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Such parameters produced scaffolds with average fibre diameters of 0.5-8 µm and 
porosities 63-76%. These conditions can be used as a starting point for producing the 
biostable (Pellethane®) implants for this project. 





























7 DMF 2.4 
n/a 
n/a 

















5 HFIP 0.6 
2.1 
200 
































DegraPol® (DP) is a biodegradable polyester urethane block copolymer (chemical 
structure shown in Figure 1.15). The degradation products of both the hard and soft 
segments are considered non-toxic [94, 257]. The mechanical properties can be altered 
to meet specific TE applications by adjusting the hard to soft segment ratio [258–260]. 
Moreover, hydrolytic degradation of DP is controllable, independent of mechanical 
properties, by varying the glycolide content at the soft segment side of the co-polymer, 
normally 0, 15, 30 or 40%. Thus, DP with a higher glycolide content has a faster 
degradation rate (e.g DP30 degrades faster compared to DP0). 
Figure 1.15: Chemical structure of DegraPol®. Poly((R)-3-hydroxybutyric acid)-diol (hard-segment) 
linked with 2,2,4-trimethylhexamethylene diisocyanate (junction unit) to an amorphous segment of 
poly(e-caprolactone-co-glycolide)-diol (soft-segment), [261, 262].  
Although this polymer has gained some traction in the field of TE, there are a lot of 
unexplored opportunities with regards to its use in electrospun scaffold development. 
Therefore, studies using DP over the last two decades have been collected (an extended 
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summary of all studies as well as the chemical composition of the copolymer used in 
each investigation can be found in Appendix A2). Applications where DP was 
investigated specifically as an electrospun TE scaffold (summarised in Table 1.6) 
included: skeletal muscle, cartilage, tendon, smooth muscle and cardiovascular designs. 
In these studies, DP has shown positive results for a wide array of cell types (in vitro) 
and has been evaluated for up to 12 weeks in vivo. At the time of writing, no 
investigations were found that conducted a long-term evaluation (12 weeks) of the fast 
degrading DP30. Additionally, no in vivo evaluation of a bioactive DP electrospun 
scaffold, of any kind, was found.  
Table 1.6: Summary of DegraPol® electrospun TE applications 
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Tenocytes n/a [262] 
A typical DP electrospun scaffold was produced using the following conditions: a 
polymer solution of 8-30wt% in chloroform (or combinations of chloroform and HFIP) 
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supplied at a flow rate of 0.1-12 ml/h using a charged (5-20 kV) needle of 1.0 mm 
(inside diameter) situated at a distance 100-300 mm away from a rotating collector. 
Parameters within this range produced scaffolds (excluding the porosity enhancement 
techniques) with average fibre diameters of 1.0-25 µm and porosities 60-83%. These 
conditions (summarised in Table 1.7) can be used as a starting point for developing the 
biodegradable scaffolds for this project. 
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Heparin is a natural therapeutic agent that was discovered at John Hopkins University 
over a century ago. Isolated from either porcine intestine or bovine lung, heparin is 
clinically used since 1935 as a potent anticoagulant for the treatment/prevention of 
University of Cape Town  WJ van den Bergh 
 
 Chapter: Introduction 32 
thrombosis (blood clotting) [274]. Found on cellular surfaces and in the natural ECM, 
this compound is a highly sulphated and heterogenous polysaccharide (molecular weight 
of about 15 kDa) that is part of the glycosaminoglycans (GaGs) family [275]. Its 
molecular structure, the most complex among the GaGs, may comprise of six different 
uronic acid and glucosamine linked disaccharides formed from the ten monosaccharides 
identified in Figure 1.16.a. The repeating sequence of heparin mainly consist (70 or 90% 
for porcine or bovine origins respectively) of IdoA(2S)-(1→4)-GlcNS(6S) while the 
remainder is made up of uronic acid and glucosamine linked disaccharides with various 




Figure 1.16: Chemical composition of heparin. a) monosaccharides; b) major and minor repeating 
disaccharides. Adopted from [276] 
Heparin predominantly interacts with neighbouring proteins via electrostatic 
mechanisms, but hydrophobic effects, hydrogen bonding and the formation of secondary 
structures may also occur [278]. This diverse interactivity makes heparin a potential 
binding partner for numerous proteins, e.g.: antithrombin [279], lysozyme [280] and 
specific growth factors (GFs). Moreover, heparin is considered to guard its captured 
molecules from fluctuations in pH, heat as well as enzymatic degradation [281]. Basic 
fibroblast growth factor (bFGF) [282], fibroblast growth factor (FGF-2) [283], 
transforming growth factor-b (TGF-b) [284], platelet-derived growth factor-BB 
a) 
b) 
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(PDGF-BB) [285] and vascular endothelial growth factor (VEGF) [286, 287] are all 
GFs known to have affinity with heparin. Consequently, this agent does not only 
possess useful antithrombotic properties, it has also been shown to moderate 
inflammation, promote cell adhesion, inhibit smooth muscle cell proliferation [288, 289] 
and stimulate angiogenesis [290–293] (although it is also studied for its potential anti-
angiogenicity [294]). It is therefore no surprise that heparin has been used to coat 
biomaterials since the 1960 s and, more recently, gained significant interest in the field 
of tissue engineered scaffold development [295].  
 
Figure 1.17: Improved vascularisation of heparinised polyurethane foam discs. a) macropores without; 
and b) with heparin surface coatings. Adopted from [292]. 
Vascularisation of tissue engineered scaffolds is essential for in vivo survival, but 
remains an elusive challenge [296]. In the absence of new blood vessel formation, tissue 
ingrowth is restricted to 100-200 µm (cells would die beyond this) due to the diffusion 
limit of oxygen from native capillaries [297]. Angiogenesis is the formation of new 
vasculature from pre-existing blood vessels through proliferation, migration and 
remodelling of endothelial cells (EC s) [298]. Strategies to encourage angiogenesis of TE 
structures include optimisation of scaffold architecture, biomechanics and/or the 
incorporation of bioactive molecules that would attract proangiogenic GFs [55, 299, 
300]. Cabric et al. demonstrated heparin s ability to bind to proangiogenic growth 
factor, VEGF, with the aim of attracting endothelial cells (ECs) and thereby induce 
angiogenesis and revascularisation. After two days of in vitro culture, the authors 
University of Cape Town  WJ van den Bergh 
 
 Chapter: Introduction 34 
showed that human isolated pancreatic islets with surface immobilised heparin were 
surrounded with positively stained VEGF and attracted 150% more ECs (and favoured 
cellular adhesion) when compared to the un-heparinised controls [301]. Bezuidenhout 
et al. showed that polyurethane (PU) discs (which had well-defined, interconnected 150 
µm pores) with surface immobilised heparin (38 mg/g) enhanced vascular density of 
newly ingrown tissue by 62% compared to the untreated controls in a rat 
subcutaneously after 28 days of implantation (Figure 1.17). Furthermore, Janse van 
Rensburg et al. filled similar microporous PU discs with degradable/nondegradable 
polyethylene glycol (PEG) hydrogels incorporated with/without heparin (0.6 mg/g). 
The slow release of heparin (zero order kinetics), when covalently bound to degradable 
PEG gels, enhanced vascularisation of the local tissue by 50% when compared to the 
controls (without heparin) after 28 days of implantation in a subcutaneous rat model 
[302]. These studies, and many other [303–306], recognized heparin s potential not only 
to create antithrombotic surfaces (for cardiovascular application such as vascular grafts 
and heart valves) but its effectiveness to promote angiogenesis when either surface 
immobilised or slowly eluted from TE scaffolds. Aiming to achieve similar results with 
electrospun scaffolds, several studies were identified where heparin was either surface 
modified or eluted from heparin blended electrospun fibres (see Figure 1.18 for an 
illustration of the two different types of heparin incorporation). 
 
Figure 1.18: Illustrative diagram of heparin incorporated electrospun fibres. 
A few groups have attempted to attach heparin to the surfaces of electrospun fibres. 
Voorneveld et al. studied tissue ingrowth of porosity-enhanced Pellethane scaffolds 
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(using a sacrificial fibre technique) with and without covalently attached heparin 
(8mg/g, as shown in Figure 1.19). Heparinised groups had little to no influence on 
tissue ingrowth, inflammation or vascularisation after 28 days in a rat subcutaneous 
model [153]. 
 
Figure 1.19: Heparin surface modified Pellethane fibres.As shown by [153]. 
In terms of blend electrospinning heparin, Luong-Van et al. incorporated unmodified 
heparin in PCL fibres using a cascaded co-solvent system of water, methanol and 
dichloromethane (heparin is soluble in water, and not DCM nor methanol). The authors 
only incorporated heparin at relatively low concentrations 0.05-0.5wt%. The system 
precipitated when concentrations reached 1wt%. Release rate of 20-25% in first 24 hours 
and 55-60% after 14 days for concentrations 0.05-0.5wt% (both had a followed a Fickian 
diffusion model). Vascular smooth muscle cells were treated with and without heparin 
(before and after electrospinning). Heparin, before and after electrospinning, 
successfully inhibit VSMC proliferation (40% reduction in net growth) when compared 
to the untreated groups. Confirming, to some extent, that the bioactivity of heparin 
was unaffected by the harsh conditions (hazardous solvents and high electrostatic 
fields) associated with the electrospinning process [243]. In a different blend 
electrospinning study, low molecular weight heparin (3 kDa) was by itself or covalently 
bonded to four-arm star PEG to form PEG-LMWH compound and blended with either 
PEO/H2O or PLGA/DMF carrier polymers to form electrospun fibres at concentrations 
that ranged from 3.5-85 mg/g. Incorporation of LMWH or LMWH-PEG in PLGA at a 
concentration of 0.2wt% enhanced the scaffold s ability to bind to BFGF when 
compared to the untreated control fibres. Interestingly, LMWH-PEG was more effective 
than LMWH to bind to the growth factors due to LMWH being more imbedded in the 
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scaffold and LMWH (being a smaller molecule) was more susceptible to diffusion 
despite them having the same concentration at inception [307]. Centola et al. seeded 
heparin releasing PLLA/PCL electrospun scaffolds (incorporated at 0.8 mg/g) with 
human mesenchymal stem cells and analysed them in terms of morphology, mechanical 
tensile strength, cell viability and differentiation. Methanol was used as a co-solvent to 
add the unfractioned heparin to a PLLA/DCM spinning solution prior to processing. 
Kurpinski et al. investigated cellular infiltration of biodegradable PLLA electrospun 
scaffolds with and without surface modified heparin in vitro and in vivo. The infiltration 
of bovine aortic endothelial cells seeded on heparinised PLLA scaffolds was similar 
when compared to the control groups (in vitro). On the contrary, a higher density of 
positively stained endothelial cells (CD31+) and macrophages (CD68+) were observed 
in vivo (7 days in a dermal rat model) for the scaffolds with surface immobilised heparin 
compared to the unheparinised controls [308]. The different outcomes were attributed 
to the complex multi-cell signalling environment that exist in an in vivo model and are, 
not yet, fully replicated in vitro. Nevertheless, a higher density of both endothelial cells 
and macrophages (specifically M2 phenotypes which orchestrates the healing process in 
ways that promote angiogenesis and tissue remodelling [204] and [309]) are indications 
of an improved healing response. 
Blend electrospinning of heparin (hydrophilic) with common biodegradable polymers 
(hydrophobic) is challenging. Kwon et al. modified heparin to a tri-n-butylammonium 
salt of heparin (HepTBA, amphiphilic) before dissolving it into the electrospinning 
solution of PLCL/HFIP [310]. Although the authors showed successful incorporation, 
the only in vitro studies that were performed were an elution study (1, 5 and 10wt%) 
to show the release profiles of HepTBA in a phosphate buffered saline (PBS) media. 
Results showed a burst release (7, 16 27%) followed by sustained release of (31, 36 and 
53%) over 4 weeks (as seen in Figure 1.20). This is a promising heparin incorporation 
especially towards a vascular graft application. However, more in vitro research (e.g. 
bioactivity and/or cytotoxicity) is needed before moving towards in vivo studies.  
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Figure 1.20: Heparin-TBA incorporated PLCL electrospun scaffolds.a) release profile for HepTBA at 1, 
5 and 10wt%; b) SEM of 5wt% HepTBA fibres at 4 weeks of incubation. Adopted from [310]. 
Table 1.8 is a summary of electrospun scaffolds with either surface modified (SM) or 
heparin blended (BE) into the fibres. It should be noted that an electrospun scaffold 
eluting the HepTBA compound has not yet been evaluate in vivo. Such an investigation 
may provide useful information to the TE community, especially if HepTBA could 
promote scaffold vascularisation. 
Table 1.8: Examples of electrospun scaffolds with heparin incorporation Drug incorporation techniques: 
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1.3.4 Dexamethasone 
A major concern for implantable scaffolds made from synthetic biomaterials is their 
potential to induce a non-specific host response [239, 314]. Therefore, scientists have 
suggested the incorporation of controllable delivery systems of anti-inflammatory 
agents to moderate foreign body response, and thereby, improve the long-term 
performance of medical devices [31, 314, 315]. Dexamethasone (Dex) is an anti-
inflammatory steroid that has been shown to reduce scaffold inflammatory response 
when delivered locally [239, 316, 317]. Dex was found to effectively reduce inflammation 
in rats (250-350 g) when delivered twice at a daily dosage of 1 mg/kg days post-
operatively [318–321]. Considering an electrospun scaffold with a typical mass of 10-
15mg, an effective dose of Dex would translate to an incorporation load 3-7wt%. Dex 
has been incorporated into electrospun scaffolds before (see Table 1.9) at dosages 
varying 0.3-20wt%. Although, the only study that showed effective in vivo results used 
a load of 5.7wt%, which is also in agreement with the above translation dosage. 
Solvent(s) used for blend electrospinning of this drug included: HFIP, CHCl3, DMF, 
DCM and ethanol. This information could be useful to consider when designing a Dex 
eluting electrospun scaffold. 
Table 1.9: Examples of electrospun scaffolds with dexamethasone incorporation. Drug incorporation by 
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1.3.5 Drug release kinetics 
Diffusion is considered to be the main mechanism behind the release kinetics of 
bioactive molecules from electropsun scaffolds [241–244, 324–326]. Many factors may 
influence their diffusion profiles, such as fibre/scaffold architecture, polymer 
degradation, solubility of both drug and polymer or the physiological conditions. 
Besides the architecture and material selection of the delivery device (mean diffusion 
distance and polymer degradation rate [198]), the drug type and its polymorphic form, 
crystallinity, molecular size, the total load in the polymer matrix and the drug s 
solubility in the release medium are known factors that influences the release kinetics 
of a drug from the same polymer matrix [327, 328]. A sustained delivery, zero-order 
release kinetics, is considered an ideal release mechanism for many drug delivery 
applications [329, 330]. For such a mechanism, the release of the agent is constant over 
time regardless of its concentration.  
Table 1.10: Models used to describe drug dissolution. The amount of drug dissolved (U), release 
constant (k), release exponent (�) and time (T). Adopted from [327] 
Model Equation 
Zero order = +  
First order  =  +  
Second order / −  
Hixson-Crowell / − / =  
Weibull  [− ln − / ]  =  ∗  −  
Higuchi = √  
Baker-Lonsdale /  [ − − / / ] − / =   
Korsmeyer-Peppas / =   
Quadratic = +  
Logistic = /[ + ] 
Gompertz =  
Hopfenberg / = − [ − / ]  
  
Mathematical models are useful to engineers/scientists to describe the release of 
delivery devices. Such formulations can be used to predict dosages at certain timepoints 
and provide important parameters for further optimisation of delivery effectiveness 
[331]. Therefore, numerous models have been developed to describe drug dissolution 
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from a polymer matrix (as summarised in Table 1.10). Among these, zero-order, 
Higuchi and Korsmeyer-Peppas are generally consider to best describe the drug release 
phenomena from polymer matrices [327]. Interpretation values given in Table 1.11 are 
used to distinguish between diffusion transport mechanisms: Fickian diffusion, Non-
Fickian transport, case II transport or super case II transport. 
Table 1.11: Interpretation values for diffusion release kinetics. Adopted from [331] 
Release exponent (�) Drug transport mechanism Rate as a function of time 
0.5 Fickian diffusion − .  
0.45< � = 0.89 Non-Fickian transport �−  
0.89 Case II transport Zero order release 
Higher than 0.89 Super case II transport �−  
1.4 Research proposal 
1.4.1 Problem statement 
Small diameter vascular grafts made from expanded polytetrafluoroethylene (ePTFE) 
show full endothelialisation after relatively short periods of implantation in animals. 
Unfortunately, such grafts are almost completely without endothelium when used in 
humans, even after 10 years of implantation [22]. The small efforts of endothelialisation 
that does occur in human, is due to the outgrowth of endothelial cells at the 
anastomoses (graft ends sutured to the native vessel) and is limited to approximately 
10-20mm (referred to as transanastomotic (TA) endothelialisation) [332]. This limited 
TA endothelialisation and overall poor healing responses are known reasons why half 
of the ePTFE grafts occlude within the first five years after implantation in medium 
sized applications [333, 334]. It is believed that the emphasis should be on transmural 
endothelialisation (through the graft s wall - TM) instead of TA endothelialisation. 
Studies performed by UCT s Cardiovascular Research Unit (CRU) indicated that a 
healthy endothelial lining is limited due to insufficient porosity, pore sizes and 
interconnectivity through the graft s wall [29, 335]. The scaffold of an ideal vascular 
graft should not only facilitate tissue ingrowth but also provide routing for cellular 
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waste, nutrient and oxygen supply [336]. At the time of writing, a synthetic vascular 
graft with the embedded biological signals that would allow function tissue regeneration 
(in situ tissue engineered - off-the-shelf) has not yet been clinically realised for small 
diameter applications (<6 mm) [64, 138, 337]. Such a device (with an annual need of 
1.8million prostheses) would have a substantial impact in the fight against CVD.  
1.4.2 Objectives 
The microenvironment of an ideal scaffold should provide the i) architectural and/or 
ii) biochemical cues that are attractive to cells, and ultimately, facilitate functional 
tissue restoration. Considering these challenges for electrospun TE scaffolds and 
keeping a vascular graft application in mind, the following objectives were formulated 
for this project: 
Development of biostable TE electrospun scaffolds (Pellethane®): 
 Establishment of optimal conditions to electrospin and electrospray biostable 
fibres and water-soluble microparticles respectively. 
 Enhancement of scaffold porosity and pore sizes by simultaneous inclusion and 
subsequent removal of 30 µm porogens electrosprayed from multiple sources. 
 Immobilisation of heparin to the surfaces of porosity-enhanced scaffolds to create 
an anti-thrombotic and pro-angiogenic scaffold. 
 Investigation of the influence of porosity enhancement and heparin surface 
modification on scaffold architecture and mechanical properties. 
 Evaluation of the healing response towards biostable electrospun scaffolds in a rat 
subcutaneous implantation model for up to 3 months: show improvement of i) 
tissue ingrowth for high-porosity scaffolds and ii) vascularisation for heparinised 
scaffolds.  
Development of biodegradable TE electrospun scaffolds (DegraPol®): 
 Establishment of optimal conditions to electrospin biodegradable fibres. 
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 Simulation of the electric field as a function of base electrode surface area and 
investigation of its effect(s) on the electrospinning process. 
 Enhancement of scaffold porosity and pore sizes by low temperature 
electrospinning. 
 Incorporation of dexamethasone into electrospun fibres via blend 
electrospinning to moderate the inflammatory response by localised delivery. 
 Modification of heparin to an amphiphilic salt that would allow drug 
incorporation into the scaffold via blend electrospinning to provide anti-
thrombotic and pro-angiogenic properties by localised delivery. 
 Assessment of the bioactivity and cytotoxicity of the modified heparin. 
 Investigation of the different in vitro release mechanisms associated with 
dexamethasone and heparin. 
 Investigation of the influence of scaffold drug incorporation on architectural 
and mechanical properties.  
 Evaluation of the healing response towards degradable electrospun scaffolds in 
a rat subcutaneous implantation model for up to 3 months: show i) moderation 
of inflammation for dexamethasone incorporated scaffolds and ii) improvement 
of vascularisation for heparin incorporated scaffolds. 
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2 MATERIALS AND METHODS 
This chapter provides information on the selected materials and summaries of the 
standardised methods used during the development of non- and -degradable electrospun 
scaffolds. Optimal conditions for producing a selection of scaffolds for in vivo 
evaluations are provided. Finally, on overview of the animal study, implant/explant 
procedures, histological and associated quantifications are described. 
2.1 Materials 
The reagents used for this project were purchased from Sigma-Aldrich (Pty) Ltd. 
(RSA), Fluka (Buchs, Switzerland), Merck Millipore (RSA), Saarchem Holpro Analytic 
(RSA) and Oakwood Chemicals (USA), unless specified otherwise. Dexamethasone and 
heparin sodium were obtained from Pharmacia & Upjohn Company LLC (i.e. Pfizer 
Inc, USA) and Celsus Laboratories (USA) respectively. The two biomaterials chosen 
for scaffold development were, a thermoplastic elastomer called Pellethane® (2363-
80AE, 1.12 g/cm3, Lubrizol, USA) and a biodegradable polyester urethane block 
copolymer called DegraPol® (DP0 and DP30, 1.15 g/cm3, ab medica, Lainate, Italy). 
Polyethylene glycol (PEG, 10 and 20 kDa) was used for developing water-soluble 
microparticles as scaffold porogens. 
2.2 Preparation of polymer films 
Polymer films of DP and Pel for bulk material characterisation (mechanical properties 
and in vitro degradation studies) were prepared using a heat-press. Methods on heat-
pressing DP and Pel films have been described before [254, 260]. In similar fashion, 
dried polymer powder/pellets were placed, at a mass of 3g, between two temperature 
controlled plates covered with Mylar sheets (held at either 120C for DP0/DP30 or 
180C for Pel). The material was compressed for 5 min at 20 MPa. The carefully 
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removed films (n = 2 per material) were transparent, free from defects and had a 
thickness of 200-300 µm.  
2.3 Polymer degradation in aqueous solutions 
The rate of hydrolytic degradation in aqueous solutions of polymer films/electrospun 
scaffolds was characterised by mass loss (%) over time. The initial mass ( ) of each 
sample (10x10 mm square, n = 3 of each group) was recorded before being placed inside 
a glass tube along with 1 ml of aqueous solutions - physiological (PBS at pH = 7.4), 
acidic (1.0M HCl at pH = 0.8) or basic (1.0M NaOH at pH = 13.0). Each tube top was 
sealed with Parafilm® (to prevent evaporation) and placed inside an incubator at 37C. 
The mass was again recorded at each selected time point ( ) after the fluid was 
drained and the material was dried (1 hour in a vacuum oven at 50C followed by 
another 24 hours at room temperature in a fume hood). Sample mass was determined 
with a five-decimal balance (XS105, Mettler-Toledo AG, Greifensee, Switzerland). The 
mass loss percentage at each time point was expressed as: 
�   % =  −  (2-1) 
2.4 Measuring solvent evaporation rates 
The rate at which 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) or chloroform (CHCl3) 
evaporated, either in pure form or in a DP30 solution (� = 18wt%), was characterised 
by mass loss over time (2, 3, 4, 5 and 24hours, n = 3 per group). Approximately 650mg 
of solvent or solution (the exact mass ( ) was determined using a five-decimal 
balance) was transferred to an empty polypropylene cap of known mass ( ). The 
samples from all four groups (having a combined solvent volume <5 ml) were placed 
inside a sealed glass desiccator (5 L) filled with argon gas to prevent mass changes due 
to hygroscopic effects. The combined mass of each solution/solvent filled cap ( ) was 
recorded at the selected time points followed by refilling the desiccator. Solvent 
evaporation was determined using equation (2-2) where = − �  and � 
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= 18wt% or �  = 0wt% for samples containing DP solutions or pure solvents 
respectively. 
 �  % =  + −  (2-2) 
2.5 Solution viscosity determination 
Solution viscosities were determined using a viscometer (Brookfield DVI Prime with a 
small sample adapter - spindle no.21). Both the DP (24wt%DP30 in 50:50% 
HFIP:CHCl3) and Pel (16wt%Pel in 50:50% THF:DMF) solutions were rotated (21-
22C and 60-64% RH) at a speed of 6rpm until  a stable measurement (converging at 
8 cPoise) was obtainable. 
2.6 Scanning electron microscopy 
Dry specimens were placed on metal stubs and sputter coated with gold (120 ms at 35 
mA and 1.4kV, Polaron SC7640, Quorum Technologies, England) before imaging with 
a Zeiss (LEO) 1450 Scanning Electron Microscope (SEM) operating at 15-20 keV. 
Images of electrospun or electrosprayed fibres or particles were captured at suitable 
magnifications for their respective image analyses. 
2.7 Nuclear magnetic resonance spectroscopy 
All compounds were prepared by dissolution (4 mg/ml) and microfiltration (0.45 µm) 
in either deuterated chloroform (CDCl3) or heavy water (D2O). Nuclear Magnetic 
Resonance (NMR) spectra were recorded at room temperature (RT) using a Bruker 
DRX-400 spectrometer at standard operating conditions (10 s recycle delay, 128 scans). 
The resulting signals were processed (MestReNova, v11.0, Spain) for phase correction, 
baseline subtraction and numerical integration. 
2.8 Heparin surface immobilisation 
Heparin was attached to the surfaces of Pel electrospun scaffolds by a covalent bonding 
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technique [153, 286, 292, 338]. Briefly, the porosity-enhanced groups were removed from 
their porogen extraction solutions of deionised water (DI):ethanol (90:10) and rinsed 
thrice in DI water only. Next, the scaffolds were grafted with acrylic acid/acrylamide 
co-polymer by immersing them in a solution of acrylic acid (4.0 M), acrylamide (1.0 
M) and coper nitrate (0.1 M). Cerium ammonium nitrate (0.006 M, (NH4)2[Ce(NO3)6]) 
was added after oxygen removal by argon gas bubbling. Scaffolds were sonicated in this 
solution for 40 min at RT (Integral Systems Ultrasonic UMC5, 100 Watts, RSA). Then, 
the scaffolds were aminated during a 2 hour reaction (sonicated at RT) with ethylene 
diamine (EDA, 0.5 M) in 2-(N-morpholino)-ethanesulfonic acid (MES, 0.5 M) buffer 
solution (pH = 5.0) also containing 1-ethyl-3(3-dimethyl-aminopopyl) carbodiimide 
(EDC, 0.05M). Finally, heparin was covalently attached to Pel fibre surfaces through 
reductive amination. Aminated scaffolds were treated with a solution of nitrous acid 
de-aminated heparin (2 mg/ml) in acetate buffer (0.2 M sodium acetate, 0.2 M acetic 
acid, pH = 4.6) with addition of sodium cyanoborohydride (NaCNBH3, 0.016 M). 
Afterwards, the heparinised samples were rinsed trice with DI water and washed 
overnight on a platform shaker (New Brunswick Scientific C1, USA). Following the 
final wash, scaffolds were freeze-dried for 48hours (VirTis manifold dryer, United 
Scientific, RSA).  
2.9 Heparin confirmational staining 
The presence of heparin on electrospun scaffold surfaces was confirmed by positive 
staining (purple) with a Toluidine Blue (TB) solution (0.025wt% toluidine blue in 0.025 
M tris base, 0.025 M tris acid). This heparin staining technique has been used before 
[280, 286]. Briefly, each heparinised or control sample (10x10 mm) was placed in a 24 
well plate (Sigma Aldrich, RSA) followed by 1 ml of TB solution and stirred for 5 min 
on a platform shaker. Afterwards, the TB solution was removed from each well using 
a plastic pipette and the samples were rinsed thrice with 1ml of DI water. During the 
heparin surface modification process, each step was visually confirmed with a positive 
University of Cape Town  WJ van den Bergh 
 
 Chapter: Materials and Methods 47 
stain of TB (blue|white for positive|negative grafting), Ponceau S (red|white for 
positive|negative amination) and again with TB (purple|dark blue for positive|negative 
heparinisation). 
2.10 Surface heparin quantification 
The amount of heparin on the surface of heparinised Pel scaffolds was quantified by an 
adapted calorimetric method, known as the 3-methyl-2-benzothiazolinehydrazone-
hydrochloride (MBTH) assay [339]. Dry scaffolds with and without surface heparin (n 
= 5 per group) were submerged in DI water (250 µl). Afterwards, 500 µl of nitrous acid 
solution (0.025 M HNO2 in 0.9 M HCl) was added and sonicated at RT for 30 min. The 
degradation reaction was stopped by the addition of an ammonium sulfamate solution 
(1 M, 250 µl), mixed with a vortex mixer and then transferred into a clean test tube. 
Each scaffold was rinsed with a NaCl solution (1 M, 500 µl) which was added to the 
degradation solution. Next, 500 µl of MBTH solution (0.011 M) was added to the 
degraded heparin (15 min at 50C). The MBTH molecule was complexed by the 
addition of a FeCl3 solution (9.031 M, 500 µl, 20 min at 50C).  
 
Figure 2.1: Typical absorbance curves for heparin concentration determination. 
The resulting solution was transferred to a disposable cuvette and its absorbance was 
measured at a wave length of 660 nm (Shimadzu UV-1601PC spectrometer, Canada). 
y HepNa = 4,18x + 0,12
r² = 0,99




















Concentration (mg/ml in 250µl)
HepNa⁺ HepTBA500
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Finally, scaffold heparin content (mg/g) was determined using a standard curve 
(generated using the same MBTH-assay methodology) from known concentrations (0–
0.2 mg/ml, 8 data points). Typical MBTH-assay absorbances curves can be seen in 
Figure 2.1. 
2.11 Heparin modifications 
Sodium salt of heparin (HepNa+, porcine derived, 12 kDa, 196 U/mg) was modified to 
HepTBA by ion-exchange [310] in which the sodium ions of HepNa+ were exchanged 
for H+ and subsequently replaced by tributylamine (TBA), as shown in Figure 2.2. The 
current project not only produced fully substituted HepTBA (complete TBA 
complexation), but also investigated heparin products with controllable TBA content.  
 
Figure 2.2: Ion-exchanges during the heparin-TBA modification process. a) numbering reference for the 
methyl groups of TBA; b) sites where ion-exchanges are expected to occur on the heparin molecule. 
Briefly, 1 g of HepNa+ was dissolved in 100ml of DI water (pH = 6.5). Assisted with 
compressed air, the solution was passed through a glass column (Di = 10.8 mm) packed 
with resin (7.5 g, 50Wx8 [H+], 200-400 mesh, Dowex®, Sigma Aldrich) at a flow rate of 
5 ml/min (11 s/cm). Another 100 ml of DI water was passed through the same column 
to yield a 200 ml stock solution of heparin acid (HepH+/DI water, 5 mg/ml, pH = 2.0). 
Next, heparin with various degrees of TBA substitutions were produced by reacting 
different concentrations (as indicated in Table 2.1) of tributylamine/methanol solutions 
(TBA/MeOH, 10 ml) with 40ml of the HepH+ stock solution (stirring for 2 hours). The 
MeOH was subsequently evaporated (RII Rotavapor Buchi, at 122 mbar and 40C for 
1 hour) until a volume of approximately 40 ml remained. Thereafter, the unreacted 
TBA was removed by liquid-liquid extractions with hexane (3x100 ml). All 
a) b) 
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HepTBA/DI solutions were freeze-dried for 48 hours to obtain white powdery products. 






HepH+ 0 N/a 
HepTBA25 4 5 
HepTBA50 8 5 
HepTBA75 12 5 
HepTBA100 16 5 
HepTBA500  80 5 
   
The relative peak intensities (1H NMR spectra in D2O) between the average 
methyl/methylene protons of TBA and the acetyl protons of heparin were used to 
describe and compare the degree of TBA complexation for each of the HepTBA 
products. For quantification purposes, a ratio between the integrated proton signals 
(�) were calculated using the following equation (the functional groups of TBA were 
numbered according to the sequence shown in Figure 2.2.a): 
 =
∫ � + ∫ � + ∫ � + ∫ � ∫ �  (2-3) 
2.12 Cell viability assay 
The XTT viability assay has been used to characterise the biocompatibility of seeded 
TE scaffolds (natural and synthetic) by measuring the number of metabolically active 
cells over time [340, 341]. XTT is a tetrazolium derivative that is reduced to the highly 
coloured formazan dye by mitochondrial dehydrogenase enzymes. Thus, an increase or 
decrease of formazan dye indicate cellular proliferation or death respectively. The 
current study was designed to evaluate the in vitro effects on rat smooth muscle cell 
(rSMC) proliferation when treated with/without heparin at a dosage that would 
simulate an extreme case of instantaneous resorption of a 5wt% loaded electrospun DP 
scaffold (a typical sample of 10 mg and 100 mm2). Briefly, sterile heparin/PBS stock 
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solutions were prepared to contain 2,5 mg/ml of HepNa+, HepTBA25, HepTBA75, 
HepTBA500 or no heparin (to serve as the control treatment). All solutions were 
filtered, 0.2 µm GVS filter unit and DB20 syringe, and transferred to 5 ml self-standing 
screw cap tubes. Approximately 5000 rSMC were seeded (at -24 hours) for five groups 
(n = 4 per group) in a 96-well plate (Sigma-Aldrich). Treatments (a total volume of 
100 µl at a pH of 7.4) were given at 0 hours to the pre-seeded cells in the form of 80 µl 
MCDB medium (M8537, Sigma-Aldrich) plus 20 µl of a blinded treatment solution. 
Therefore, the final concentration of a heparin treated well was 500 µg/ml (equivalent 
to the total dose delivered by a typical 10 mg scaffold loaded at 5wt%). At 72 hours of 
incubation, the media was removed and each well was washed twice with 100 µl of 
sterile PBS. Thereafter, fresh media (100 µl of MCDB) and the XTT detection fluid 
(50 µl, containing an electron coupling solution at a ratio of 1:50) was added to each 
well containing cells, and three empty ones to serve as background readings. The cells 
were returned to the incubator for 2 hours, after which absorbance readings (light 
scattering) of each well were taken at 450 nm and subtracted by that measured at 655 
nm using a Bio-Rad microplate reader (170–6800; BioRad, RSA). The cells were 
photographed for morphological changes before (-24 and 0 hours) and after (24, 48 and 
72 hours) treatments. All procedures were performed under sterile conditions. 
2.13 Thromboelastography 
The anti-thrombotic activity of modified/unmodified heparin was analysed using a non-
invasive diagnostic instrument, TEG®5000 thromboelastograph hemostasis analyser 
(Haemonetics Corporation, USA). Firstly, all sample channels (n = 8, four analysers 
with two channels each) were tested and approved for their accuracy against the 
provided Level I biological control fluid (see Appendix A3 for the calibration results). 
Heparin treatments, HepNa+ or any form of HepTBA were prepared at 0.01 mg/ml in 
PBS, were added (110 µl) to 1 ml of citrated whole human blood extracted from 
Vacuette collection tubes (coagulation sodium citrate 3.2%, 9NC, BD Medical, RSA). 
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A sample (1 ml) of this blood plus treatment mixture was transferred to a Kaolin-
coated vial (BD Medical, RSA) and gently inverted five times. Next, 340 µl of the 
mixture was placed inside a disposable, pre-warmed (37C) TEG® analyser cup 
(Haemonetics) that contained 20 µl of calcium chloride (CaCl2 at 0.2 M, Haemonetics). 
Finally, the oscillating blood clotting process was recorded with the provided TEG®5000 
software. The following parameters were recorded: reaction time ( , time from 
inception until the waveform breaches 2 mm above the baseline), clot formation time 
(�, time from 2 to 20 mm above the baseline), rate of clot strength build-up (�) and 
the maximum amplitude (� , i.e. clot strength). Following the same operating 
procedure, the activity of HepTBA500 was also evaluated as an eluate from electrospun 
scaffolds after 48 hours of in vitro incubation (PBS at 37C). The eluates (110 µl) were 
normalised (HepTBA500/PBS at 0.018 mg/ml) and compared to equimolar heparin 
concentrations of the un-modified version (HepNa+/PBS at 0.01 mg.ml). Table 2.2 
summarises the selected blood treatments and their sample sizes for TEG analysis.  
Table 2.2: Heparin treatments for whole blood thromboelastographic analyses 
Treatment (110µl PBS) Concentration (mg/ml) Sample size 
HepH+ 0.01 1 
HepNa+ 0.01 2 & 3 
HepTBA25 0.01 2 
HepTBA50 0.01 2 
HepTBA75 0.01 2 
HepTBA100 0.01 2 
HepTBA500 (before electrospinning) 0.01 & 0.018 2 & 3 
HepTBA500 (after electrospinnning) 0.01 & 0.018 2 & 3 
Control (PBS only) N/a 2 & 3 
   
2.14 Scaffold drug release characterisation 
Drug loaded electrospun scaffolds were prepared in sealed glass tubes (15x20 mm strips 
immersed in 1 ml PBS) and incubated under static conditions (37C). The elution fluid 
of each sample was collected for drug content measurement, and replaced with new 
PBS (1 ml) at selected time points (see Table 2.3). The eluates (200 µl) of Dex 
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incorporated scaffolds (1, 2 or 5wt%) were analysed for content release by UV 
spectroscopy (rectangular quartz cuvettes at a wave length of 241 nm). The 
concentration of eluted Dex (mg/ml) was calculated from a standard absorbance curve 
generated using known Dex/PBS data points. Eluates (250 µl) of scaffolds that 
contained HepTBA500 (at 1, 2 or 5wt%) were analysed for heparin content using a 
modified MBTH-assay (in a similar fashion as mentioned in section 2.10). Briefly, each 
eluate was reacted (sonicated at RT) with 500 µl nitrous acid solution (0.025 M HNO2, 
1 M HCl) for 30 min followed by the addition of 250 µl ammonium sulfamate solution 
(1 M). This mixture was diluted with 300 µl NaCl solution (1 M), reacted with 500 µl 
MBTH solution (0.011 M) for 15 min (sonicated at 50C) followed by 500 µl of FeCl3 
solution (0.031 M) reacted for 20 min (sonicated at 50C). Finally, the resulting 
colorimetric solutions were transferred to disposable cuvettes and their absorbances 
were measured by UV spectroscopy (wave length of 660 nm). A standard absorbance 
curve for HepTBA500 was generated, at known concentrations, and was used to 
calculate the concentration (mg/ml) of released HepTBA500 from each sample (a new 
curve was re-created for each batch of measurements, e.g. in Figure 2.1). The theoretical 
drug content (Dex or HepTBA500 to scaffold, mg/g) was determined by normalising 
the released concentrations with the initial scaffold masses. Release curves were 
expressed as instantaneous and/or cumulative delivery rates. 
Table 2.3: Selected time points for in vitro drug elution studies. *Scaffolds produced for in vivo 
evaluations. 
Sample Time points (days) Sample size 
DP30 (control) 1, 2, 3, 4, 5, 6, 14, 22, 30 & 44 3 
DP30 + 1 or 2wt% Dex 1, 2, 3, 4, 5, 6, 14, 22, 30 & 44 3 
DP30 + 1 or 2wt% HepTBA500 1, 2, 3, 4, 5, 6, 14, 22, 30 & 44 3 
*DP30 (control) 1, 2, 3, 5, 7, 10, 15, 21, 30 & 90 3 
*DP30 + 5wt% Dex 1, 2, 3, 5, 7, 10, 15, 21, 30 & 90 3 
*DP30 + 5wt% HepTBA500 1, 2, 3, 5, 7, 10, 15, 21, 30 & 90 3 
   
Furthermore, the elution curves of the scaffolds selected for in vivo evaluations, those 
loaded at 5wt%, were correlated with each of the drug release models listed in Table 
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2.4. Model variables (k and/or n), and their correlation with the experimental data, 
were determined using a nonlinear least squares optimisation approach (Levenberg-
Marquardt algorithm, Matlab). Finally, the best fit model (i.e. the function that 
produced the highest r2 value) were used to describe the release kinetics of each drug. 
Table 2.4: Curve fitting models used to describe in vitro drug release kinetics. The amount of drug 
dissolved (U), release constant (k), release exponent (�) and time (T). 
Zero-order First-order Higuchi Korsmeyer-Peppas = +  = +  = √  =  
    
2.15 Polymer solution preparations 
All electrospinning/electrospraying solutions were prepared by 24 hour magnetic 
stirring at RT, depending on volume, using glass test tubes or bottles (Pyrex®). After 
mixing, solutions were left to rest for 1hour to equalise the minimal heat generated by 
stirring and to remove bubbles before transferring to a syringe for processing. 
Concentrations were expressed as weight-by-weight percentage (wt%) for polymer to 
solvent, unless stated otherwise (i.e. weight-by-volume, w/v). 
2.16 Experimental setup for electrospinning/electrospraying 
The experimental setup for TE scaffold production consisted of a custom-built rotating-
translating mechanism with adjustable speed settings (only 0-5000 rpm and 1.4 mm/s 
were investigated during this project). Three high voltage power supplies were available 
(two ES30P-5W and one ES30N-5W power unit, Gamma High Voltage Research, 
USA). The negative power supply was used to charge the rotating collector (kept at -
1 kV) while the two identical positive power supplies were for electrospinning (primary 
source, 0-30 kV) and electrospraying (secondary source, 0-30 kV) respectively. Two 
dual-syringe pumps (SE400B, Fresenius, Bad Homburg, Germany) were used to feed 
polymer solutions to needle-base electrode configurations on opposite sides of the 
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collector (blunt hypodermic needles connected to charged aluminium plates). The 
Taylor cone was visualised for real-time control on an LCD display via a CCD camera 
(Techgear Eaglescope, China) connected to a laboratory computer. The collecting 
rotational speed and ambient conditions (temperature and humidity) were recorded 
with a non-contact tachometer and a thermo-hygrometer (Lasec, South Africa). A 
typical experimental setup used during this project can be seen in Figure 2.3 (this 
configuration was snugly fitted inside a fume hood for the extraction of built-up solvent 
fumes through the top and side chamber holes). 
 
Figure 2.3: A typical experimental setup for electrospinning/spraying. [A] Rotary speed controller; [B] 
Digital timer; [C] Collector DC motor; [D] Background light source; [E] CCD camera; [F] Humidity 
and temperature sensor; [G] Taylor cone display; [H] Translational speed controller; [I] Secondary 
syringe pump; [J] Handheld tachometer; [K] Primary positive power supply; [L] Negative power 
supply; [M] Translation stepper motor; [N] Secondary positive power supply; [O] Primary syringe 
pump; [P] and [Q] indicate the sides for electrospraying and electrospinning respectively. 
Hollow cylindrical collectors (outside diameters of 25 and 75 mm, Figure 2.4.a-b) with 
one-side removable lids were used for collecting at room and low temperatures (when 
filled with dry ice). Both collector types were mounted on 6mm diameter shafts. Small 
holes were drilled (1 mm) on one side of the collector to allow for internal gas expansion 
caused by the release of CO2 from the dry ice. 
P Q 
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Figure 2.4: Hollow collectors used for rotational collecting. a) small and b) large collectors with 
respective outside diameters (D). Models were created in SolidWorks. 
An auxiliary electrospraying station was purposely designed for upscaled microparticle 
production while simultaneous electrospinning was allowed on the opposite site of the 
collector. Briefly, a base electrode with the same dimensions to the one at the 
electrospinning side (60x60 mm aluminium plate) was attached to a mobile foot piece 
as indicated in Figure 2.5.a. Furthermore, blunt cut needles protruded 10 mm from the 
base electrode at a pitch of 12 mm (a maximum of three needles were used as indicated 
in Figure 2.5.b). 
 
Figure 2.5: Needle and base electrode configuration for electrospraying. a) full view of the auxiliary 
electrospraying station with b) close-up on a multiple needle configuration (triple G22 needles). All 
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2.17 Electric field simulations 
The potential influence of base electrode size (variable surface areas) on the 
electrohydrodynamics during a typical electrospinning process was investigated. Firstly, 
the electric field intensity produced by a positively charged base electrode was 
mathematically modelled as a thin annular disc (previously derived by [342]) of inner 
radius ( ) and outer radius ( ) which carried a uniform charge density ( ). The 
charge enclosed by a differential surface element ( ′) was represented by � , 
as shown in Figure 2.6.  
Figure 2.6: Model of an annual disc as a base electrode for electrospinning. a) a simple needle and base 
electrode configuration charged by a positive high voltage direct current (+HVDC) power supply, b) 
the electrical field intensity at P due to a uniform charge distribution (adapted from [342]). 
Applying charge symmetry with respect to a point observation, the electric field 
intensity (�⃗) at any point ( ) along the x-axis ( > , i.e. away from the base electrode 
towards the collector) was expressed by equation (2-4): 
�⃗ =  �[ + ] ��⃗ (2-4) 
, and simplified as: 
�⃗ =  + − + ��⃗ (2-5) 
 
The changes that base electrode size may have on the electric field was simulated by 
a) b) 
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solving equation (2-5) for three different annual disc dimensions (  = 1.5 mm and  
= 8, 16 and 32 mm) while all other variables were assigned with constant values (  = 
8.854×10-12 F/m, = / −  and  as the charge generated by 20 kV over a 
typical electrospinning distance of  = 0-300 mm). The effect was visualised by 
converting the numerical data to line plots (Matlab). Expanding from this analysis, 
electric field investigations were also explored using an electrostatic simulation 
environment called Coulomb3D V9.30 (short-term licence ID: 50869, Integrated 
Engineering Software, Canada). 
 
Figure 2.7: Base electrode and collector model used for 3D simulations. a) CAD models imported into 
Coulomb3D from SolidWorks, b) messed models using triangular elements. The notations C and A 
refer to the centre and the face of the collector respectively. 
Three-dimensional models of the annular base electrodes (  = 1.5 mm and  = 8, 16 
and 32 mm) and a typical collector (as shown in Figure 2.4.a) were created in 
SolidWorks (2015 student version). The models (Figure 2.7) were imported into the 
simulation environment and meshed with 2D triangular elements (5000 plus an extra 
2000 manually applied at base electrode centre). The working fluid (electrospinning 
chamber) was assigned as air at 20C, 101 kPa. The material properties listed in Table 
2.5 were assigned to the collector and base electrodes as specified. Simulations were 
executed for variable voltages (12-20 kV) applied to each of the base electrodes (outside 
diameters of 16, 32 and 64 mm) at variable distances (10-30 cm) from the negatively 
charged collector (-1 kV). Finally, the numerical data from all simulations were 
exported as text files from which 3D plots were generated, using Matlab, of voltage 
a) b) 
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V( ) and electric field intensity, Em( ). 
Table 2.5: Material properties of parts used for electric field simulations. 
Property Collector Base electrode 
Steel type 316L 3CR12 
Electrical conductivity (S/m) 1 474 900 1 351 351 
Thermal conductivity at 500C (W/mK) 40 21 
Elastic modulus (GPa) 200 193 
2.18 Electrospraying parametric studies 
The parameters investigated for the control and optimisation of electrospayed water-
soluble, PEG microparticles included: solution properties (dielectric constant, molecular 
weight and concentration), collecting distance and needle diameter. Moreover, the 
possibility of particle production upscaling was also investigated. The electrospraying 
station described in Figure 2.5 were used for all the studies listed in Table 2.6.  
Table 2.6: Parametric investigations for developing electrosprayed porogens. 
Parameter Range Analysis 
Solution properties 
Dielectric constants: 4.8, 17.8 or 
32.0. Molecular weight: 10 or 20 
kDa. Concentrations: 20-50%. 
Particle diameter (n = 2) 
Collecting distance 10-24cm (increments of 2 cm) 
Particle aspect ratio, circularity 
and area (n = 3) 
Needle diameter 
Di  = 0.26-1.37 mm (G25, 23, 22, 
21, 20, 18 and 15) 
Particle diameter (n = 3) 
Multiple needles 
Single, double and triple 
configurations 
Collecting distribution (n = 1) 
   
The flow rate was held constant at 1 ml/h (based on initial studies not shown). The 
collecting distance, needle and solvent selection were set at 200 mm, G22 (Di = 0.72 
mm) and CHCl3, unless specified otherwise. The exposed surface area of the Taylor 
cone produced from needles with different diameters were calculated by = √ + , where  = Di/2 and  is the length of the Taylor cone as measured using 
ImageJ software (NIH Image, USA) from photographs taken during these experiments 
using. Distribution of particles collected from multiple needles were visualised by the 
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contrast created from pre-sprayed solutions dyed with either Toluidine blue or 
Rhodamine. After electrospraying, the particle colours were revealed (blue/pink) by 
slowly rotating the collector through steam generated from a flask of boiling water. The 
resulting particle distribution was photographed after 1min of steaming.  
2.19 Electrospinning parametric studies 
Collecting speed and flow rate were the parameters investigated for optimising the 
electrospinning conditions of Pel at 16wt% in 50:50wt% THF:DMF. During both 
studies, a blunt hypodermic needle (G15), which protruded 20 mm from a charged base 
electrode (60x60 mm aluminium plate at 12-16 kV), was used to feed the Pel solution 
at a distance of 250 mm between the needle tip and the face of a negatively charged (-
1 kV) collector (Figure 2.4.a). The flow rate was held constant at 2 ml/h in the case of 
the collecting speed study (1000-5000 rpm) while the speed was held at 1000 rpm during 
the flow rate study (1-4 ml/h). The influence on fibre diameter, fibre orientation and 
mechanical properties were analysed during these developmental studies (Table 2.7). 
The fibre orientation index obtained at different rotational speeds (rpm) was also 
express as a function of tangential velocity ( , m/s) for comparison and scalability 
purposes. 
Table 2.7: Parametric investigations for developing biostable scaffolds 
Parameter Range Analysis 
Collecting speed 1000, 2000 or 5000 rpm 
Fibre orientation (n = 4) and 
mechanical properties (n = 3) 
Flow rate 1, 1.5, 2, 2.5 or 4 ml/h Fibre diameter (n = 4) 
   
The processing parameters explored for optimising DP electrospinning were collecting 
speed, solution properties (solvent system variations and concentrations), base 
electrode size, collecting temperature and the addition of a drug incorporated at 
different concentrations. While each of these parameters were varied, all others were 
kept constant. A flow rate of 2 ml/h and a G15 needle were used, unless stated 
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otherwise. The collecting distribution (surface area of collected fibres, mm2) was 
calculated by multiplying the known collector circumference with the measured 
longitudinal length of collected material. The different base electrode surface areas were 
created by exposed holes (circles with diameters of 10 and 25 mm) cut from electrical 
insulation covers (5 mm thick) which shielded the rest of the charged 60x60 mm 
aluminium plate. The covers were fitted so that the needle would protrude from the 
centre of the hole at a same length that it would without the cover, 2 mm. LTE was 
performed by filling the hollow collectors with dry ice. Drugs were incorporated by 
simple add-mixture. The amount of drug was calculated to the weight of the polymer 
(1, 2 or 5wt%) and simply added to the spinning solvent system (50:50% CHCl3:HFIP) 
before dissolving the polymer at RT. The ice chamber was re-filled every 30 min in the 
case of using the large collector. The effect(s) that processing adjustments had on 
electrospun scaffolds were analysed as indicated in Table 2.8. 
Table 2.8: Parametric investigations for developing degradable scaffolds. 
Parameter Range Analysis 
Collecting speed 500, 1000 or 3000 rpm Fibre orientation (n = 4) 
Solution properties 
Co-solvent ratios of 0-100% (for 
HFIP to CHCl3) and polymer 
concentration of 20, 25 or 30wt% 
Collecting distribution (n = 
1), fibre diameter (n = 6) and 
pore size (n = 6) 
Base electrode size 3600, 490 or 80 mm2 
Collecting distribution (n = 
1), fibre diameter (n = 2) and 
pore size (n = 2) 
Collecting 
temperature 
RTE (~295 K) compared to LTE 
(~203 K) at low or high 
concentrations (20 or 24wt%) 
collected on small or large 
collector (25 or 75 mm) 
Morphological observations 
and collecting time (n = 2) 
Drug incorporation 
1 or 2wt% for both Dex and 
HepTBA500 
Release and kinetics (n = 3) 
and in vitro degradation (n = 
3) 
   
2.20 Porosity enhancement by electrospinning and spraying 
Composite structures of electrospun fibres (~2 µm) and removable porogens (~30 µm) 
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produced by a single/triple electrospraying source were investigated as an approach to 
scaffold porosity enhancement. Briefly, an experimental setup for simultaneous 
electrospinning and electrospraying was used as depicted in Figure 2.3. A solution of 
16wt% Pel (in 50:50% THF:DMF) was electrospun (2 ml/h, G15 needle) using the 
primary positive power supply (14 kV) at a distance of 250 mm from a negatively 
charged collector (25mm in diameter at -1 kV and roto-translating at 1000 rpm and 
1.4 mm/s). On the opposite side (200 mm away), 48wt% PEG10kDa (in CHCl3) was 
electrosprayed from a single or triple needle (G22) configuration as shown in Figure 
2.5. The spraying flow rate was 1 ml/h per needle throughout the process (90 min each 
time). Control samples were produced by electrospinning Pel (90 min) without 
simultaneous electrospraying. The collected sheet of material was removed and cut into 
10x10mm samples using a steel ruler and a sharp blade (n = 3 or n = 40 per group for 
the pilot or the implants for in vivo assessments). After recording their individual 
masses (  ), the samples were vigorously shaken in a 1 L glass bottle (24 
hours on a platform shaker) containing 600 ml of DI water/ethanol (90:10, v/v) that 
was replaced after 12 hours. Next, the washed scaffolds were transferred to test tubes 
containing 3 ml of DI water and freeze-dried for 48 hours. Mass of the dried scaffolds 
( ) were determined using the five-decimal balance while the dimensions 
(thickness: ; surface area: , Figure 2.8) were measured (n = 5 locations per image, 
ImageJ) from scaled photographs taken with a stereo microscope (Nikon, SM2800). 
 
Figure 2.8: An illustration of scaffold volume determination. a) Diagram of scaffold volume, examples 
for measuring scaffold b) surface area (scale bar 5 mm) and c) thickness (scale bar 1 mm). 
Finally, scaffold porosity was calculated by equation (2-6): 
a) c) b) 
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= −  (2-6) 
Where = ,  is 1.12 g/cm3 or 1.15 g/cm3 for Pel or DP and = . 
Gravimetrical determination of electrospun scaffold porosity, equation (2-6), has been 
described and used by many others [153, 178, 198, 208, 269, 343, 344]. The mass 
percentage of beads of the composite material before the washing process was defined 
by equation (2-7): 
 �  % =   −  (2-7) 
2.21 Mechanical characterisation 
All polymer samples selected for mechanical characterisation were prepared as 
rectangular strips (30x5 mm, gauge length of 10 mm) and tested using universal tensile 
tester (Instron 5544 equipped with a 500N load cell, Norwood, USA) and custom made 
stainless steel claws with rubber inserts to minimise slippage. The experimental setup 
is shown in Figure 2.9.a-b. 
 
Figure 2.9: Tensile testing of polymer specimens. a) Custom-made grips used for testing all samples. 
Typical examples of b) a specimen being pulled and the output of a results report indicating c) 
maximum elongation, ultimate tensile strength and d) the elastic modulus. 
Dry specimens of known thicknesses (measured as shown in Figure 2.8.c) underwent 
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tensile testing until failure at 66 mm/min (a strain rate of 11%/s, based on the 
compliance of a healthy blood vessel and a heart rate of 72 bpm [345, 346]). Next, the 
raw data captured by the Intron system was imported into Matlab and processed as 
stress-strain plots (an example of the output of a mechanical report can be found in 
Appendix A4). The maximum recorded stress and its corresponding strain value were 
defined as the ultimate tensile strength (UTS) and maximum elongation (� ) 
respectively. Young s modulus ( ) was determined by the slope of the line fitted 
between the 10-20% strain region (see Figure 2.9.c-d). A summary of all mechanical 
experiments is shown Table 2.9. 
Table 2.9: Summary of specimens tested for mechanical properties. Testing directions for electrospun 
scaffolds, with respect to the collector, were either circumferential (C) or longitudinal (L). 
Study description 
Material  
(number of groups) 
Testing 
direction 
Sample size in each 
direction per group 
Heat pressed films Pel, DP0 and DP30 N/a n = 6 
Different fibre orientations Pel (3) C and L n = 3  
Scaffolds for implantation Pel (3) and DP30 (3) C and L n = 6 
2.22 Scaffold architectural characterisation 
Semi-automated macros were compiled with ImageJ (NIH Image, USA) to process 
images of electrosprayed or electrospun structures for architectural characterisation.  
2.22.1 Electrosprayed microparticles 
Bright field microscopy (20X objective at 2.00X digital zoom, Nikon Eclipse 90i, Japan) 
was used to photograph PEG particles collected on microscope slides. Photos were 
taken to create adequate contrast with respect to the background (converting Figure 
2.10.a to b by adjusting the fine focus) at three different locations per slide (middle, 
left and right). The acquired images were processed with a self-constructed processing 
sequence to obtain information on individual particles. Briefly, photos were scaled 
(µm/pixel), converted to an 8-bit image and underwent an automated median threshold 
filter to obtain a binary frame of white background and black particles (as shown in 
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Figure 2.10.c). Next, the built-in particle analyser was used to measure the area 
( ), aspect ratio ( ) and circularity ( ) of individual particles. Finally, the 
averages and standard deviations were calculated for the total particles measured per 
group. The conversion of particle area to a circular diameter was =/ . 
 
Figure 2.10: Image processing of electrosprayed microparticles. Examples of the a) original bright field, 
b) adjusted for higher contrast and b) binary images used for processing. 
2.22.2 Electrospun fibres 
Images were captured (using SEM as described in section 2.6) of the lumenal, ablumenal 
and cross-sectional surfaces from three snippets per electrospun sheet. Cross sectional 
images were kept for illustrative purposes while photos of the lumenal (n = 2) and 
ablumenal (n = 2) surfaces were used for 2D image processing (selected magnifications 
were X500 or X200 for Pel (~2 µm) or DP (~5 µm) electrospun fibres). From these 
images (n = 12 per group, 4 per sample times 3 for the number of electrospun sheets), 
the average fibre diameter, orientation index and equivalent pore size were determined.  
2.22.2.1  Fibre diameter measurement 
The average fibre diameter was calculated by manual measurements as described in 
literature [178, 262, 268]. First, a diagonal line was overlayed from the lower left to the 
upper right corner of the scaled image (µm/pixel, as defined by its scale bar) as 
demonstrated in Figure 2.11. 
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Figure 2.11: Manual measurements of fibre diameters from SEM images. 
The width of each fibre that was intersected by the diagonal line was measured 
perpendicular to its length. The average fibre diameter and standard deviation were 
determined from all thickness measurements collected per scaffold group 
(approximately 40 fibres/image).  
2.22.2.2  Fibre orientation quantification and visualisation 
The entire SEM image (excluding the bottom scale bar) was used as the region of 
interest for quantifying and visualising fibre orientation of electrospun scaffolds. The 
degree of fibre alignment of each scaffold was quantified by its orientation index ( �, 
0≤ �  ≤1). The � was measured as the image s overall pixel coherency using the 
OrientationJ plug-in (developed by [347–349] and previously used to evaluate alignment 
of electrospun fibres [153]).  
 
Figure 2.12: A demonstration of fibre orientation characterisation. a) semi-circle of defined angles and 
ten animated fibres representing either b) aligned or c) random orientated scaffolds with their 
respective orientation indices (OI). 
a) b) c) 
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An � of unity represented perfect alignment while a value approaching zero indicated 
more randomly orientated fibres. This numerical representation of orientation was 
further complimented by colour mapping the direction of individual fibres. The colour 
survey was also generated by the OrientationJ plug-in (custom inputs: hue = 
orientation, saturation = x-gradient and brightness = y-gradient). Finally, � averages 
and standard deviations were determined for all images representing each group, and 
the output images from the colour surveys were saved for illustrative purposes. The 
above described methodology is demonstrated in Figure 2.12 where ten theoretical 
fibres were processed that following either a uniform direction (b) or random paths (c). 
2.22.2.3  Pore size determination 
The methodology of an automated image processing sequence for measuring the two-
dimensional pore sizes of electrospun scaffolds is summarised (frame-by-frame) in 
Figure 2.13. 
  
Step 1 Step 2 Step 3 Step 4 
    
Step 5 Step 6 Step 7 Step 8 
    
Figure 2.13: Image processing of electrospun scaffolds for pore size determination. a) the original and 
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Briefly, the original SEM image was imported, scaled (µm/pixel), cropped to remove 
the scale bar and underwent contrast enhancement (0.3% pixel saturation, steps 1 to 
2). A statistical region merging algorithm (developed by [350]) was applied (Q = 25) 
to merge the colour intensities of the same layered fibres (steps 2 to 3). Next, the images 
were made binary by applying an auto threshold filter (step 4) followed by a median 
filter (a radius of 3.5 pixles, step 5) to smooth out excess noise. The pore boundaries 
were defined by applying the built-in function find edges  (step 6) and filled with black 
pixels by using the fill holes  function (step 7). Finally, the pore areas (excluding the 
ones touching the image borders) were measured by the built-in particle analyser (step 
9). The average pore area and standard deviation were determined from all pores 
measured per scaffold group (approximately 400 pores/image). Pore size was expressed 
as an equivalent circular diameter by converting area to diameter: = / . 
2.23 Healing evaluation of electrospun scaffolds 
The healing performance of TE scaffolds developed during this project was investigated 
using a rat subcutaneous implantation model (as previously used by the UCT-
Cardiovascular Research Unit [55, 153, 292, 302, 338, 351], and others specific for 
electrospun scaffold evaluations [130, 148, 153, 233, 237, 340, 352–359]). All procedures 
were in accordance with the Animal Protection Act (Act 71 of 1962), the Veterinary 
and Paraveterinary Professions Act (Act 19 of 1982) and the South African National 
Standard for the Care and Use of Animals for Scientific Purpose (SANS 10386:2008). 
This study (protocol 015-047) was also approved by the Departmental Research 
Committee and the Animal Ethics Committee of UCT. Moreover, individuals involved 
in the handling of animals were all trained and registered as veterinarians or para-
veterinarians with the South African Veterinary Council (SAVC). Registration number 
for the author of this thesis: AL16/15395. 
The sections to follow provide i) an overview of the study, ii) the processing parameters 
used for implant manufacturing, iii) the procedures used for implant and explantation 
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of samples, iv) the selective immunohistochemistry and v) histological image processing 
techniques for data collection. 
2.23.1 Implant manufacturing and study overview  
The selection of TE scaffolds for healing evaluations in a six-implantation-site model 
were divided into two main material groups (Pel and DP), each having three products 
(as listed in Table 2.10).  
Table 2.10: Scaffold groups selected for subcutaneous implantation 




Low-porosity scaffold produced by conventional 
electrospinning 
HP 
High-porosity scaffold produced by combined 
electrospinning and elecrospraying 
HP+Hep High-porosity scaffold with surface modified heparin 
DegraPol® 
(DP30) 
LTE Low temperature electrospun scaffolds 
LTE+Dex 
Low temperature electrospun scaffolds containing 
5wt% dexamethasone 
LTE+Hep 
Low temperature electrospun scaffolds containing 
5wt% HepTBA500 
   
The biostable (non-degradable Pel) implant groups included a porosity-enhanced 
scaffold (HP) produced by the combined electrospinning/spraying technique (section 
2.20) and one produced by conventional electrospinning (LP) for comparison. 
Furthermore, the high-porosity groups were coated with heparin (HP+Hep, as 
described in section 2.8) to analyse its potential to influence the overall scaffold healing 
response. All bio-degradable scaffolds (DP) were produced by low temperature 
collecting (section 2.19). Two of these groups were incorporated with either 5wt% Dex 
(LTE+Dex) or 5wt% HepTBA500 (LTE+Hep) to analyse each drug s effect(s) against 
the healing performance of scaffolds without localised drug delivery (LTE). The 
parameters used to produce these products are summarised in Table 2.11. Enough 
scaffolds were produced for porosity measurements (n = 40 of 10x10 mm samples per 
group, equation (2-6)) from which subcutaneous implants were randomly selected (n = 
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24 per group) and sterilised using ethylene oxide gas. The remaining samples were used 
for representative characterisation in terms of architecture (pore size, fibre diameter 
and alignment, section 2.22), mechanical properties (strips of 5x30 mm were prepared, 
section 2.21) and drug surface concentration (section 2.10) or release kinetics (section 
2.14). 
Table 2.11: Electrospinning parameters used for implant production. DP, Pel and PEG are the 
polymers used for producing degradable, biostable electrospun scaffolds and water-soluble 
electrosprayed porogens respectively. *The collecting time for producing LP (without electrospraying). 
Parameter DP (LTE) Pel (LP and HP) PEG (porogens) 
Solution concentration (wt%) 24 16 48 
Solvent(s) CHCl3:HFIP DMF:THF CHCl3 
Co-solvent ratio 50:50% 50:50% N/a 
Flow rate (ml/h) 2.0 2.0 1.0 x 3 
Needle size G15 G15 G22 x 3 
Collector size (mm) 75 25 25 
Base electrode size (mm2) 3600 3600 3600 
Distance from collector (mm) 210 250 200 
Collecting speed (rpm) 400 1000 1000 
Translating speed (mm/s) 1.4 1.4 1.4 
Applied voltage (+kV) 9 14 20 
Collecting voltage (-kV) 1 1 1 
Collecting time (hours) 3.5 3.0* and 1.5 1.5 
    
The sample size for the in vivo evaluation, n = 6, for each group was calculated using 
GPower (V3.0.1, Universität Kiel, Germany) for the detection of an expected 20% 
difference of the mean healing performance (comparing the quantified results of tissue 
ingrowth, collagen, cellular, macrophage or vascular densities between scaffold groups) 
based on a standard deviation of 10%, a statistical power of 90% and a two-tailed 
student-t test with a 5% probability of making a type I error (as suggested by [360, 
361]).  
The time-line for the study was designed to evaluate the scaffolds over an implantation 
period of three months with sample retrieval dates at 7, 14, 28 and 84 days (as shown 
in Figure 2.14.a). Therefore, 24 animals (Wistar male rats, six per cage) were acquired 
one week in advance (-7 days) to allow for acclimatisation, and to establish a pre-
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surgery base-line with respect to their behaviour and body mass (310.5±16.8 g on day 
0). Rats were hydrated and fed ad libitum. Subcutaneous implantation surgeries were 
performed on day 0. Each of the products listed in Table 2.10 were randomly assigned 
(using the random generator in MS Excel) to a corresponding implantation site 
numbered 1-6 (Figure 2.14.b) of a randomly picked rat from each cage. Next, the 
implantation sites were rotated clockwise while keeping the same sample allocation 
sequence for the other five rats. Thus, each product (n = 6) was implanted in a different 
anatomical position (n = 6) in each of the six rats per group, thereby, eliminating 
location specific healing responses. 
Figure 2.14: An overview of the in vivo assessment of electrospun scaffolds. Experimental time-line and 
the rat subcutaneous implantation model. 
2.23.2 Subcutaneous implant and explant procedures 
Following the seven days of acclimatisation, animals were medicated with 
buprenorphine (0.05 mg/kg) by subcutaneous injection (G25 needle) at 45-60 min 
preoperatively. All procedures took place in a room that was separate to the animal 
housing room. Rats were anaesthetised in an inhalation chamber at 5% isoflurane with 
an oxygen flow rate of 2 l/min (1bar and 21°C) for approximately 3 min (or until the 
animal has lost consciousness and normal breathing patterns were observed). 
Anaesthesia was maintained by delivering 1.5% isoflurane with an oxygen flow rate of 
1.5 l/min through a custom-made nose cone. The surgical area (dorsal skin) was clipped 
to remove the hair and prepared using betadine iodine and F10 Skin Prep solutions. 
Ocular lubrication was applied to the eyes for the prevention of corneal desiccation. A 
heated plate (37C) was used to maintain the animal s body temperature throughout 
a) b) 
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the surgical procedures (which lasted 35 min/rat on average). To limit contamination, 
all surgical procedures were performed under sterile conditions using sterile drapes, 
instruments (autoclaved) by a scrubbed surgeon following aseptic and Halstead s 
surgical principles. Six evenly spaced incisions of 10 mm in length were made using a 
scalpel blade parallel and on either side (3 per side) of the dorsal midline. Subcutaneous 
pockets of 20x20 mm in length and width were made at each longitudinal incision by 
lateral blunt dissection using surgical scissors (without interconnecting adjacent 
pockets). Next, sterile implants were pre-wetted by submersion in sterile PBS for 1 
min, and were carefully placed within their pre-assigned pockets (one per pocket). The 
incisions were closed with 5/0 nylon sutures and a 16mm curved reverse cutting needle 
(Ethicon, Johnson & Johnson, RSA) using an intradermal cross matrass suture with a 
buried knot. Postoperatively, rats were moved to a separate recovery room where they 
were monitored under a heat lamp until fully conscious and ambulatory before they 
were reunited with their original group (6 per cage) in the housing room. All animal 
received another buprenorphine injection 8hours post operatively. The rats were 
continuously monitored for 8hours following their surgeries, and weighed every day for 
the next three days. Thereafter, rats were monitored daily and weighed weekly. As 
anticipated, all animals survived the surgical procedures and none were euthanised 
before their pre-determined dates. On explantation dates, animals were euthanised by 
an overdose inhalation of halothane (5%) in an enclosure for 15 min followed by a lethal 
intracardiac injection (1ml saturated KCl). Death confirmed animals were dissected in 
prone position. The dorsal skin was laterally reflected to reveal the subcutaneous 
samples in a mirrored order. Each sample with its accompanied tissue were carefully 
removed using surgical scissors and forceps. Next, scaffolds were cross sectioned in 
halves using a sharp microtome blade. The explanted halves were stored in 5 ml test 
tubes containing either 2 ml of zinc (IHC Zinc fixative, BD Pharmingen, USA) or 10% 
formalin fixation solutions. The zinc solutions were replaced after 48 hours. Finally, all 
fixation fluids were drained after 4 days and the samples were transferred to labelled 
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cassettes for histological processing. Figure 2.15 summarises the implant/explant 
procedures and lists the histological stains associated to each of the fixation fluids. 
 
Figure 2.15: Summary of subcutaneous implant and explantation procedures. The first row represents 
the implantation procedure while the bottom row displays the explant process (e.g. 28 days). 
2.23.3 Histology of explants 
Histological preparations were performed at the Histology group of the Cardiovascular 
Research Unit. Briefly, fixed samples were dehydrated by immersion in ascending 
grades of alcohol, embedded in wax, cut into 5 µm sections, mounted onto slides and 
de-waxed using 2,2,4-trimethylpentane (3 times for 20 min each). After hydration in 
descending grades of alcohol, sections of formalin fixated implants were stained with 
Hematoxylin and Eosin (H&E, Merck, Germany and BDH, England), Picroserius Red 
(PSR) and anti-ED1 (Serotec Ltd, Oxford, UK) (Cy3 secondary antibody) counter 
stained with 4',6-diamidino-2-phenylindole (DAPI). Zinc fixated samples were stained 
with anti-CD31 (Fitzgerald International, North Acton, MA) and H&E. Photographs 
were captured using a stereo microscope (Eclipse 90i with a fluorescence unit, Nikon, 
Japan) equipped with a digital camera (DS-Ri1, Nikon, Japan). H&E stains were 
photographed using the 2X objective (digital zoom 1.0X, calibration 3.22 µm/pixel and 
University of Cape Town  WJ van den Bergh 
 
 Chapter: Materials and Methods 73 
analog gain 1.0X) while PSR images were recorded at 4X objective (digital zoom 1.0X, 
calibration 1.61 µm/pixel and analog gain 1.0X). Both CD31 and DAPI/ED1 
(fluorescence) prepared slides were taken at a higher magnification (10X objective, 
digital zoom 0.8X, calibration 1.61 µm/pixel and analog gain 4.0X). The photographs 
were stitched together at an overlap of 10% using NIS-Elements software (Nikon, 
Japan).  
2.23.4 Image processing for scaffold healing evaluation 
2.23.4.1 Tissue ingrowth 
Tissue ingrowth of scaffolds explanted on 7, 14, 28 and 84 days was quantified by batch 
image processing (ImageJ) of both formalin and zinc fixated H&E stained micrographs 
(288 images, n = 6 per group per time point times two fixation media). The processing 
sequence included the following steps, the scaled cross-sectional image of an explant 
was manually cropped alongside its scaffold boundary (  ) and 
pasted on a blank image (white background), as shown in the Figure 2.16. 
 
Figure 2.16: Image processing for quantification of scaffold tissue ingrowth. 
Next, the image was run through an RGB filter (Red, Green, Blue) that was trained 
to isolate H&E positive pixel intensities (100:255, 0:200, 20:225) from the rest of the 
image. A Gaussian blur algorithm with a decay radius of 5 pixels was used to merge 
neighbouring cells together. The resulting image was made binary, black to represent 
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the area that was infiltrated by cells ( ) and white for acellular areas 
( ). Finally, tissue ingrowth was expressed as the percentage of the scaffold 
that was colonised by cells, equation (2-8): 
�  � ℎ % =     (2-8) 
2.23.4.2  Collagen density 
The deposition of collagen inside scaffolds that were explanted on 7, 14, 28 and 84 days 
was quantified by image processing of PSR micrographs (144 images, n = 6 per group 
per time point). Briefly, the scaled cross-sectional image of an investigated specimen 
was manually cropped alongside its scaffold boundary (  ) and 
pasted on a blank image. A custom RGB filter (202:255, 13:180, 68:210) was 
subsequently applied to isolate the positively stained collagen (pixels representing PSR) 
from the rest of the image. The filtered micrograph was converted to a binary image 
(black =  and white = ), as depicted in Figure 2.17. 
 
Figure 2.17: Image processing for quantification of scaffold collagen deposition. 
The effective tissue area inside of an ingrown scaffold (infiltration area minus the 
scaffold material) was calculated as a function of each scaffold s cross-sectional area 
(ROI), tissue ingrowth percentage (from the processed H&E results) and porosity (as 
University of Cape Town  WJ van den Bergh 
 
 Chapter: Materials and Methods 75 
measured before implantation), equation (2-9): 
=   · �  � ℎ% ·  � % (2-9) 
Finally, collagen density was expressed by equation (2-10): 
 �  µm /µm =  (2-10) 
2.23.4.3  Cellularisation and macrophage density 
Cellular and macrophage densities were both quantified from the DAPI/ED1+ images 
taken of explants from 28 and 84 days (72 images, n = 6 per group per time point). 
Images were processed by cropping the scaffold area (  ) from the 
rest of the scaled image and pasting it on a blank image. Next, trained RGB filters 
were used to split the current ROI into separate images containing only the pixels 
intensities that represented DAPI (0:90, 20:200, 60:255) and ED1+ (25:230, 5:85, 0:70) 
areas respectively (as demonstrated in Figure 2.18).  
 
Figure 2.18: Image processing for quantification of cellular densities 
Each of the filtered micrographs were converted to binary images, one that represented 
nuclei (black =  and white = ) and the other contained the macrophages 
(black =  and white = ). The area density of nuclei and macrophages 
per ingrown tissue area were determined from equations (2-11) and (2-12) respectively, 
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where   was determined according to equation (2-9). 
 �  µm /µm =  (2-11) 
� ℎ  �  µm /µm =  (2-12) 
Furthermore, the densities were also expressed in their numbers per mm2 of ingrown 
tissue, as described by equations (2-13) and (2-14). The number of nuclei ( ) and 
macrophages ( ) from the binary images were counted by the built-in particle 
analyser after noise reduction, despeckle , and fill holes  functions were applied. 
 �  nuclei/mm =  (2-13) 
� ℎ  �  macrophages/mm =  (2-14) 
2.23.4.4  Vascularisation 
Scaffolds explanted on 28 and 84 days were also analysed for vascularisation by image 
processing of CD31 micrographs (72 images, n = 6 per group per data point). The 
processing sequence included the following steps, the scaled cross-sectional image of an 
explant was manually cropped alongside its scaffold boundary (  ) 
and pasted on a blank image as shown in Figure 2.19.  
 
Figure 2.19: Image processing for quantification of scaffold vascularisation. 
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An RGB filter, specifically trained for each batch, was applied to isolate the endothelial 
cells (CD31 positive pixels) from the rest of the image. The resulting micrograph was 
converted to a binary image followed by applying dilate , erode , outline  and fill 
holes  built-in functions (black =  and white = ). In similar fashion 
to scaffold cellularisation, vascular densities (as area or number as counted by the 
particle analyser) were calculated by equations (2-15) and (2-16), where  is 
determined from tissue ingrowth from zinc fixated H&E and equation (2-9). 
 �  µm /µm =  (2-15) 
 �  vessels/mm =  (2-16) 
All image processing data were imported into Matlab from which graphs, averages and 
standard deviations were produced. 
2.24 Statistical analysis 
Graph error bars and in-line references of results were expressed as meanstandard 
deviation (unless stated otherwise). The statistical models used for the analysis of 
variance and significance (P value) between data sets depended on the nature of its 
distribution (parametric or non-parametric). Firstly, the distribution of data sets were 
investigated by the Shapiro-Wilk normality test (a Matlab script was compiled based 
on theory from the original author [362]) followed by a Q-Q plot. Analysis of variance 
were based on one-way ANOVA and the student-t test models if data sets were found 
to be normally distributed. Otherwise, non-parametric models Kruskal–Wallis one-way 
analysis of variance and the Wilcoxon sign-rank test were used to determine the P-
values between data sets. A value of P<0.05 was assumed to be significant. A typical 
statistical report for a sample size of n = 6 can be seen in Appendix A5. In the case of 
linear regression, the correlation between the model and data set was optimised for 
least mean squares (unless stated otherwise). Computations and the plotting of graphs 
were performed using either Matlab (R2013a) or Microsoft Office Excel (2016). 
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3 RESULTS AND DISCUSSION 
This chapter summarises the results and discussion for the development of biostable, 
Pellethane® (Pel), and degradable, DegraPol® (DP), TE scaffolds. The subsections 
include studies on bulk material properties, parametric control of the electrospinning 
and electrospraying processes, combined electrospinning and spraying for porosity 
enhancement, drug incorporation and elution, implant manufacturing and finally 
subcutaneous in vivo assessments. 
3.1 Material studies of polymer films 
This section explores Pel and DP (DP0 and DP30) films in terms of their mechanical 
properties and accelerated degradation. The follow-up sections, 3.2 and 3.3, describe 
the development of fibrous structures from the selected biomaterials.  
3.1.1 Mechanical properties 
The tensile test results for heat pressed films made from Pel, DP0 or DP30 are 
illustrated in Figure 3.1. Mechanical properties were characterised in terms of ultimate 
tensile strength (UTS), maximum elongation (� ) and modulus of elasticity ( ). 
   
Figure 3.1: Mechanical properties of polymer films. a) Ultimate tensile strength (UTS), b) maximum 
elongation (� ) and c) elastic modulus (E). ***P<0.001/**P<0.01/*P<0.05. [n = 6].  
Pel films had a UTS (25.11±4.32 MPa) and  �  (1213±84%) approximately five 
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(8.13±0.82 MPa) was similar to that of DP30 (7.96±0.64 MPa, P>0.5) but significantly 
higher than that of DP0 (6.92±0.39 MPa, P<0.05). Within the DP groups, DP30 was 
slightly weaker (3.50±0.25 compared to 4.27±0.48 MPa, P<0.01), had similar �  
(216±29 to 216±38%, P>0.9) but a higher stiffness (P<0.05) when compared to the 
properties of DP0. 
The tensile testing results for Pel films are similar to those of previous studies (UTS 
35-40 MPa with maximum elongations well over 700%) [254]. Likewise, mechanical 
results for DP correlate with previous work [272]. Mechanical properties for DP can be 
altered by varying the hard to soft segment ratio (a hard segment dominating DP is 
stronger) [258, 363]. In this case, that ratio is constant between DP0 and DP30 (40:60% 
hard to soft segment). Although the inventors of DP intended to control degradation 
(glycolate fraction on the soft segment side) independently of mechanical properties, in 
this case, the slight mechanical differences between the tested DP groups can be 
attributed to the glycolate content (0 compared to 30 mol-% for DP0 and DP30 
respectively) [259, 260]. In comparison, hydrolytically resorbable polyesterurethanes 
(such as DP) have a different mechanical behaviour (different molecular chain mobility) 
when compared to biostable polyurethanes (such as Pel) due to the weaker ester bonds 
that exist in the poly(α-hydroxy ester) co-polymers found in the hard/soft segment 
chemistry (PCL and PHB-diols in this case) of DP [252]. 
3.1.2 Degradation in aqueous solutions 
The percentage mass loss for the selected polymers incubated under physiological (pH 
= 7.4, a), acidic (pH = 0.8, b) or basic (pH = 13.0, c) conditions can be seen in Figure 
3.2. Pel films had no significant mass loss after 20 days (P>0.1) while DP30 showed a 
faster degradation rate when compared to DP0 regardless of the media (P<0.05). Both 
DP groups degraded at a faster rate in a base medium (8% and complete disintegration 
for DP0 and DP30 respectively by day 5) when compared to mass loss measured at pH 
levels of 7.4 or 0.8 (0 and 1% for DP0 and DP30).  
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Figure 3.2: Accelerated degradation of polymer films in different media. a) PBS (physiological), b) 1.0 
M HCl (acidic) and c) 1.0 M NaOH (basic). [n = 3]  
Although previous studies have reported that Pel products would crack and degrade 
under harsh environmental conditions (e.g. in vitro oxidation with hydrogen peroxide 
[364], silver nitrate [365] or long-term in vivo implantation [366]), Pel did not show 
significant mass loss due to the short selected time frame and milder conditions. The 
observation of a faster DP degradation rate in a basic compared to an acidic medium 
agrees with a previous study on the rate of hydrolysis of aliphatic polyesters (PCL and 
PLA) in similar conditions. Hydrolytic cleavage of the polyester backbone is enhanced 
in the strong basic (pH ≥ 13) compared to strong acid (pH ≤ 1) conditions due to the 
stronger nucleophile (OH-) that is available in the base environment when compared to 
that found in the acidic solution (H+) [367]. DP30 showed significant degradation while 
DP0 did not show any mass loss because of the higher glycolate fraction on the soft 
segment side (0 compared to 30 mol-%). Similar observations were also reported in a 
previous study of DP films with various glycolate content fractions (DP33 showed 
earlier signs of degradation compared to DP0 after 100 days in vitro 37C, pH = 7 
buffered aqueous solutions) [260]. With the aim of developing biostable, non-degradable 
and degradable TE scaffolds, Pel and DP30 were the chosen biomaterials for the 
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3.2 Biostable scaffold development 
3.2.1 Electrospinning of biostable fibres 
This section summarises the influence of controllable electrospinning parameters on the 
morphological outcome when processing Pel. Parametric studies were essential, due to 
the complexity of the spinning process, to understand and select optimal/acceptable 
conditions for implant ready scaffold production. The explored parameters included 
collecting speed and volumetric feed rate of Pel solutions. 
3.2.1.1 Colleting speed 
The influence of collecting speed on fibre orientation was quantified and visualised 
(pixel coherency) for Pel electrospun scaffolds (Figure 3.3). Furthermore, the 





















Figure 3.3: Fibre orientation for Pel scaffolds at different collecting speeds. a) orientation index as a 
function of collecting speed (velocity conversions are based on a 25 mm diameter collector); b) 
representative SEM images, white arrow indication circumferential direction. Scale bars are 10 µm. 
***P<0.001/**P<0.01/*P<0.05. [n = 4]  
The orientation indices increased from 0.26±0.05, 0.34±0.04 to 0.53±0.07 when Pel 
fibres were collected at 1000, 2000 and 5000 rpm respectively. The relationship between 
orientation index and collecting velocity was best described as � = . + .  (r2 
= 0.99), velocity in m/s (Figure 3.3.a). Colour encoded SEM images in Figure 3.3.b 
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illustrates the higher degree of orientation obtained at higher collecting speeds 
(observably fewer blue/green/yellow diagonal fibres and more red/pink/purple fibres 
in line with the collecting direction).  
   
Figure 3.4: The influence of fibre orientation on mechanical properties. a) Ultimate tensile strength 
(UTS), b) maximum elongation (� ) and c) elastic modulus (E). [n = 3].  
Mechanically, Pel scaffolds collected at 5000 rpm had a circumferential UTS nearly 
twice as strong as the UTS obtained at 2000 or 1000 rpm (6.90±0.19 and 3.39±1.10 or 
3.78±0.28 MPa, P<0.005). Although the UTS for the 5000 rpm was on average lower 
in the longitudinal direction, there were no significant mechanical strength differences 
between the speed groups (P>0.08). Maximum elongation increased in the longitudinal 
(493.6±103 to 873.8±145%, P<0.05) and decreased in the circumferential direction 
(539.0±84 to 347.0±18%, P<0.05) for collecting speeds 1000 to 5000 rpm. An elastic 
modulus of approximately 1.5 MPa was obtained in the circumferential direction 
regardless of the collecting speed (P>0.3) and was 3-7 times greater when compared to 
E (0.21±0.04 to 0.49±0.05 MPa) in the longitudinal direction (P<0.01). 
In accordance with expectation, circumferential uptake velocity directly influences fibre 
orientation (upregulating collecting speed encourages fibre alignment). This parametric 
relationship (using rotating collectors) was also shown in previous investigations [178, 
180–183]. Scaffold strength was expected to be enhanced and maximum elongation 
reduced in the circumferential direction when collected at higher speeds [178, 181, 182]. 
This is due to more fibres being bundled in the same direction (reducing inter-fibre 
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orientation, and therefore mechanical properties, are of importance to design scaffolds 
to maintain a certain compliance or burst pressure (e.g. vascular grafts application) 
that matches that of the native tissue [368]. Although this project has not yet produced 
vascular grafts, the data gathered from the current experiments may be useful to 
optimise the mechanical properties of Pel scaffolds when translated to a small diameter 
collector.  
3.2.1.2 Flow rate 
The fibre diameter of Pel collected scaffolds at different flow rates can be seen in Figure 
3.5. Overall, a faster feed rate ( ) produced larger fibres at the expense of a broader 
distribution (1.0, 1.5, 2.0, 2.5 and 4.0 ml/h produced fibres of 1.41±0.3, 1.65±0.4, 
2.14±0.5, 2.11±0.9 and 3.08±0.9 µm). The relationship between flow rate and fibre 
diameter was estimated to be  = 0.55  + 0.87 µm (r² = 0.97). The Taylor cone 
at 4.0 ml/h was constantly interrupted by excess solution dripping form the needle tip. 
Conversely, the cone at 1.0 ml/h became periodically unstable due to insufficient 
solution at the tip. Flow rates between 1.5-2.5 ml/h had stable Taylor cones and 
allowed uninterrupted spinning. 
Although small changes in flow rate may not have a significant influence on fibre 
diameter (as previously stated for electrospinning PCL at 0.6-1.5 ml/h [176]), several 
authors have confirm the existence of a positive relationship (thicker fibres are produced 
at higher flow rates) [132, 177, 178]. This is mainly due to a larger initial jet diameter 
caused by an increase of solution volume at the tip of the needle which leads to thicker 
fibre formation [169]. Secondly, the formation of fibres with larger diameters at higher 
feed rates may also be due to a lower degree of jet whipping (and consequently less 
fibre stretching) caused by a decrease in charge density as a result of a greater fluid 
volume [84].  
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Figure 3.5: The influence of flow rate on electrospun Pel fibre diameter. a) Box and whiskers 
representation, b) linear trend between fibre diameter and flow rate. [n = 4, >20 fibres per image] 
It is known that a unique flow rate exists, specific to each spinning solution, where fibre 
uniformity is optimised [177]. In the current case study, a flow rate of 2 ml/h was not 
only able to maintain a stable Taylor cone for >3 hours but also produced fibres with 
a narrower diameter distribution (uniformity) at a greater average (larger fibres have 
the inherent advantage of creating larger pores - [210]). Taking the results and 
observations into consideration, the optimal flow rate for Pel was selected at 2 ml/h. 
3.2.2 Electrospraying of soluble microparticles 
Parametric studies were essential to understand and control microparticle production. 
The explored parameters and their influence on electrosprayed polyethylene glycol 
(PEG) particle morphology included solution properties, collecting distance, needle 
diameter and production scalability. The flow rate for all studies were held constant at 
1 ml/h (based on initial trails, data not shown). 
3.2.2.1 Solution properties 
The influence of solvent properties on electrosprayed particle diameter was investigated 
for three different solvents, MeOH, HFIP and CHCl3, at a concentration of 20% (w/v) 
PEG20kDa. A gauge 15 needle (G15) and a collecting distance of 20 cm were used. The 
particles produced from the selected solvents were distinguishable in terms of their sizes 
as observed at the same magnification SEM images presented in Figure 3.6. 
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Figure 3.6: Electrosprayed PEG particles from different solvents. Scale bars are 20 and 5 µm for top 
and bottom SEM images respectively. 
Particles sprayed from a low dielectric solvent (CHCl3, � = 4.8,  = 5.00±0.7 
µm) were larger when compared to the particles processed from solvents with higher 
dielectric constants (�  = 17.8 and 32.0,   = 1.46±0.4 and 2.94±0.9 µm for 
MeOH and HFIP). A convincing inverse correlation was found, Figure 3.7.a, for particle 
diameter as a function of dielectric constant (   = -0.13 � + 5.5 µm, r2 = 0.98) 
while other solvent properties did not follow a clear trend (as seen in the table from 
Figure 3.7.b).  
 
 
 MeOH HFIP CHCl3  
 64 58 61 [C] � 32.0 17.8 4.8  - � 22 16 27 [dyn/cm] 
 0.79 1.60 1.49 [g/ml] 
 
1.46 2.94 5.00 
[µm] 
±0.4 ±0.9 ±0.7 
Figure 3.7: The influence of dielectric constant on electrosprayed particles. a) relationship of particle 
diameter and dielectric constant; b) table of results for average particle diameter (D) for each solvent 
with different boiling points (TBP), dielectric constant (ε), surface tension (γ) and density (ρ). [n = 2, 
>30 particles/image] 
An organic solvent with a lower dielectric constant gives rise to a less conductive 
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increased electrostatic attraction between ion pairs as the dielectric constant decreases 
(qualitatively known as the Nernst-Thomson rule). Moreover, the observation of larger 
particles can be expected when the solution conductivity is decreased. Droplet charge 
density is what drives this occurrence. A higher charge density will result in a greater 
degree of Coulombic fission (CF) before complete solvent evaporation occurs (CF, an 
event when electrostatic forces overcome droplet surface tension, and explode into 
smaller satellite particles, due to a decline in solution volume while electrostatic charge 
remain constant) [72, 369]. This parametric relationship is in accordance with the 
scaling laws of atomisation where particle diameter has the following relationship with 
solution conductivity ∝ �  . Therefore, the larger particles produced from a lower 
dielectric solvent system (chloroform in this case) were in agreement with 
electrohydrodynamic theory, as well as previous observations [370, 371]. In the face of 
universal atomisation applications, i.e. drug delivery devices where particles are made 
at nanoscale [184, 372–375], CHCl3 was a useful solvent selection for optimising 
microparticle size (towards the aim of producing >30 µm spheres to act as temporary 
space holders within a fibrous network). 
3.2.2.2 Collecting distance 
Theoretically, larger particles can be obtained by increasing the molecular weight (� ) 
and/or the volume fraction (�) of the polymer solution (scaling laws section 1.2.3). 
This is true only until a point is reached where fibre (instead of particle) formation will 
take place. At such a point (the Rayleigh limit), macromolecular entanglement (chain 
overlap) is sufficient to resist the forces that governs jet breakup and result in 
continuous fibre formation post to the Taylor cone region (the forces to resist are 
solution surface tension and the successive CF s). For simplistic control, the molecular 
weight for all subsequent studies on electrospraying of PEG/CHCl3 was therefore fixed 
(10 kDa instead of 20 kDa) and the concentration was varied to continue particle 
optimisation (preferably >30 µm). Furthermore, the influence of collecting distance (a 
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parameter that is often overlooked) on particle area ( ), aspect ratio ( ) and 
circularity ( ) were investigated for 40wt% PEG10kDa /CHCl3 sprayed from a G15 
needle. The results are presented by bright field microscope images (Figure 3.8) and 
the data are summarised in Figure 3.9. 
10cm 12cm 14cm 16cm 
    
18cm 20cm 22cm 24cm 
    
Figure 3.8: Particle morphology of electrosprayed PEG particles over a distance. Scale bars are 50 µm. 
An abundance of short strand fibres (40.8±29 µm and 8.1±2 µm of length and 
diameter) or microspheres (13.0±2 µm) were observed at collecting distances ≤12 cm 
or ≥18 cm respectively. The variation of particle geometry, as a function of the distance 
between the needle and collector, was supported with the image analysis results where 
particles at 10-12 cm had a high  (4.1±2.9), low (0.5±0.2) and high 
, (363±248 µm2) when compared to particles measured at 18-24 cm which had 
a low  (1.2±0.4), high (0.9±0.1) and a low  (133±74 µm2). In 
summary, a particle underwent the following geometrical changes as it was collected at 
distances away from the nozzle (illustrated by Figure 3.9.d): short strand fibre (10-12 
cm), elongated ellipse (12-14 cm), mid-pinched ellipse (14-18) and finally spherical 
microparticles with associated satellite particles (18-24 cm). Furthermore, 20 cm was 
found to be a suitable collecting distance to allow simultaneous electro-spinning and -
spraying due to minimal electric field interference with the opposite base electrode (not 
too close to repel the incoming electrospun fibres away from the collector) and at a 
position that would permit maximising particle (spherical) diameter while having 
University of Cape Town  WJ van den Bergh 
 
 Chapter: Results and Discussion 88 
acceptable polydispersity.  
   
 
                      10-12                     12-14                  14-18               18-24 
Distance from the collector [cm] 
 
Figure 3.9: The influence of collecting distance on electrosprayed particles, d) visualisation of particle 
formation towards the collector 
Collecting distance is a parameter that can be optimised to a point where particles 
have the least polydispersity and the best spherical geometry for a set of experimental 
conditions [375]. Another study reported that particle reproducibility (morphologically) 
was limited at a distance that is too close to the collector (15 cm in their experiments) 
while particles collected at a distance further away (20-25 cm) had a narrower size 
distribution [376]. It is also known that the electric field between the needle and 
collector is stronger at shorter distances [377]. Therefore, electrosprayed particles are 
expected to be smaller at distances closer to the collector compared to particles collected 
at distances further away. The latter assumption was experimentally confirmed by 
others [190]. In contrast to this, particle area from the current experiments decreased 
as collecting distance increased (Figure 3.9.c). This observation can be explained 
because the initial particles, collected at closer distances, were short strand fibres and 
not yet particles - an elaboration on this statement will follow. Elongated particles and 
short strand fibres have been identified before [189]. The authors described this 
phenomenon as an interplay between chain entanglement and CF. Elongated or 
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remain frozen, since the energy required to break molecular entanglement is far greater 
than that present during CF [378]. Complementing this tentative explanation, the 
current study is an elegant step-by-step display of how particles are formed during 
flight towards the collector. At closer distances to the Taylor cone (referring to Figure 
3.9.d), short strand fibres/elongated particles are extruded from the straight jet due to 
sufficient chain overlapping which initially resist sphere formation (surface tension). 
Further away from the base electrode, a decline in electric field strength causes 
elongated particles to relax and allow for surface tension to compete against the prior 
dominating electric stresses. Eventually, spherical particles are formed even further 
down the path due to dominating surface tension and successive CF. Each step was 
frozen in its current geometrical state because the charges were neutralised as soon as 
the particle landed on the grounded collector and/or the solvent evaporation process 
was fast enough to preserve the particle s shape. 
3.2.2.3 The influence of needle diameter at optimal concentration 
An increase in polymer concentration of 40 to 48wt% resulted in particles that measured 
more than twice the diameter (13.0±2 to 30.3±14 µm, P<0.001). Moreover, it was 
found that the needle size had little to no influence (P>0.5) on particle diameter when 
electrospraying with 48wt% PEG10kDa/CHCl3 (G25 to G15, with inside diameters of 
0.26-1.37 mm, produced particles within the range of 31.5±15 µm). The diameter of 
particles produced from seven different needles are shown in Figure 3.10. 
  
Figure 3.10: The influence of needle diameter on electrosprayed particle size. a) Taylor cones of needle 
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A concentration of 48wt% was found to be the upper bound to electrospray 
PEG10kDa/CHCl3 from a clear solution at RT. Solutions ≥50wt%, although initially 
transparent, precipitated during the cooling process and lead to solution build-up or 
needle clogging  which ultimately prevented continuous electrospraying at RT. 
Although 48wt% was a uniform solution prior to processing, solution build-up was also 
observed when a large diameter needle was used (such as G15, which was also used in 
the previous experiments). The time of uninterrupted electrospaying at the optimal 
concentration of 48wt% was observed to have a dependency on the surface area of the 
exposed Taylor cone which in turn was controllable by needle gauge selection. A needle 
size of G15 (id = 1.77 mm), G18 (id = 1.23 mm) and G22 (id = 0.72 mm) produced 
Taylor cones surface areas of 3.95, 2.45 and 0.90 mm2 while all other parameters were 
kept constant. Uninterrupted spraying time was increased from <5 min to >2 hours 
when the inside diameter of the needle decreased by 1 mm (simply swopping the G15 
with a G22 needle). In summary, continuous production of water-soluble microparticles 
with diameters >30 µm (as presented by Figure 3.11) was achievable with a solution 
of 48wt% PEG10kDa/CHCl3 (at RT) that was electrosprayed at a flow rate of 1 ml/h 
from a G22 needle (connected to a positively charged base electrode of 60x60 mm) and 
collected at 20 cm. 
Figure 3.11: Electrosprayed polyethylene glycol microparticles. Scale bars are 200 and 20 µm for low 
and high magnifications for both optical and SEM photographs. 
It is generally assumed that larger particles will be produced when electrospraying with 
larger sized needles (those with lower gauge numbers). This statement roughly relies 
on the obvious dependency that the diameter of the needle determines the base of the 
Taylor cone and consequently the size of the particle. Although this parametric 
relationship has previously been observed while electrospraying with two different 
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needle gauges (G26 or G24, id = 0.26 or 0.31 mm [31]), conflicting results have also 
been reported [32]. In a previous study, 10%(w/v) PCL50kDa was dissolved in pure 
chloroform and electrosprayed from either a G26 or a G21 needle (id = 0.26 or 0.51 
mm) [33]. The authors found that needle diameter had no significant influence on the 
measurable size of the collected particles. Another study also reported that particle size 
had no dependency on capillary diameter (the tested range was id = 0.12-0.58 mm) 
[34] 
3.2.2.4 Multiple needles 
Multiple needles were investigated as an attempt to upscale particle production rates. 
Initially, a double needle configuration was tested (side by side needles at 12 mm apart). 
It was found that the two jets repelled each other in such a fashion that caused an 
uneven distribution of material on the surface of the collector (more accumulated on 
the sides than in the middle). A linear array of 3 needles, at a pitch of 12 mm, provided 
a smooth distribution of particles which uniformly covered the entire length of the 
collector (as observed in Figure 3.12).  
  
Figure 3.12: Particle distribution of a triple needle electrospray configuration  
Previous research also showed successful upscaling of the electrospraying process. In 
their particular configuration, PLGA was electrosprayed from parallel needles (id = 
0.06 mm) at a pitch of 0.7 mm [189]. The configuration under current investigation 
(triple G22 needles at a pitch of 12 mm) was adopted for a higher particle production 
rate. 
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3.2.3 Combined electrospinning and spraying 
The composite materials produced by simultaneous electrospinning and electrospaying 
(using a single or triple needle configuration) of Pel fibres and water-soluble PEG 
microparticles are compared to the scaffolds produced by conventional electrospinning 
in Figure 3.13. The SEM images represent scaffold cross sections followed by low and 
higher magnification photographs of the top view (abluminal side). Embedded 
microparticles can be observed in the images where electrospraying were introduced.  
Conventional Single spray Triple spray 
   
   
   
   
Figure 3.13: Composite materials created by combined electrospinning and spraying. Scale bars are 100 
µm (cross sectional and low magnification top view images) and 20 µm (higher magnification images). 
The porosity of conventional electrospun scaffolds increased from 78.6±0.5 to 
88.9±0.5% (P<0.001) or 92.9±0.4% (P<0.001) after bead removal from the composite 
materials created by either a single (bead fraction of 64%) or a triple (bead fraction of 
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73%) needle spraying configuration system respectively. The enhancement of 3D 
interconnectivity and slightly larger pores are visually observed in the cross sectional 
and top view images of Figure 3.14. 
Conventional Single spray Triple spray 
   
   
Figure 3.14: Porosity-enhanced scaffolds after sacrificial bead removal. All scale bars are 20 µm. 
Simultaneous electrospraying PEG microparticles opposite to electrospinning Pel fibres 
(a close-up view of the composite material can be seen in Figure 3.15.a) had no 
significant influence on the resulting fibre diameters (1.9±0.5 µm) regardless of the 
number of needles used (P>0.5). The scaffold thickness of conventional electrospinning 
(228±9 µm) was increased to 495±33 µm or 976±60 µm (after bead removal) when a 
single or triple array of needles were used to include the microparticles. The particles, 
which acted as temporary space holders, slightly increased the two-dimensional pore 
size of conventional scaffolds from 9.7±3 µm to 10.3±4 µm (P>0.1) or 10.7±5 µm 
(P<0.05) for a single or triple needle configuration respectively. The results are 
summarised in Figure 3.15.b. 
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Figure 3.15: Combined electrospinning and spraying results. a) Pel fibres and PEG porogens close-up 
SEM image [20 µm scale bar]; b) scaffold porosity, fibre diameter and pore size results.  
The porosity after porogen incorporation and removal was greater than that of the 
conventional scaffolds because of the volume expansion caused by the inclusion of 
temporary microbeads while the structural mass (fibres) remained constant (porosity 
equation 2-6). A triple needle configuration had a greater influence on porosity due to 
a higher particle production rate which resulted in a higher bead to fibre fraction when 
compared to a single production source. The apparent inadequacy to enlarge scaffold 
pore size can be explained by a closer inspection to the SEM images presented in Figure 
3.16. Even though a two-dimensional quantification of pore size (via image processing) 
might produce the same results in both Figure 3.16.a and Figure 3.16.b, there are 
notably more 3D space created in Figure 3.16.b (where the 30 µm microbead use to be, 
indicated by the red circle) compared to the densely packed fibres from Figure 3.16.a.  
Previous studies have also investigated combined electrospinning and spraying and 
obtained results similar to that of the current study - porosity enhancement of natural 
(84-95%, [148]) and synthetic (87-94%, [233]) electrospun scaffolds. Although these 
authors also showed enhanced cellular infiltration in vitro and in vivo (in a 
subcutaneous model), there were no mention and/or quantification of scaffold 
inflammation nor vascularisation (angiogenesis being one of most important challenges 
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term in vivo performance). Moreover, larger porogens (~50 µm) were sprayed from a 
single source compared to the current developed technique which included smaller 
particles (~30 µm) produced from multiple electrospraying sources. A large sum of 
smaller particles has the potential to uniformly influence the architecture of the scaffold 
by shaping individual fibres. On the other hand, a lower quantity of widespread large 
particles only has a local effect on the fibres that were in contact with the removed 
particle and effectively creating scattered concentrations of high and low fibrous 
densities. Nevertheless, the current study showed that shaping individual fibres has the 
additive advantage of creating wavy fibres which could be useful to mimic the curled 
collagen/elastin fibres found in the ECM of an aortic wall or valve shown in Figure 1.3 
(introduction chapter). The following section was therefore proposed to investigate the 
in vivo performance of scaffolds produced with this newly revised approach to 







Figure 3.16: Architectural comparison of conventional and high-porosity scaffolds. SEM images of a) 
conventionally produced and b) porosity-enhanced electrospun structures. The red circle represents a 
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3.2.4 Biostable implant production 
The Pel scaffolds produced specifically for subcutaneous implantation included a 
conventional low-porosity (LP) and porosity-enhanced structure (HP) without and with 
surface immobilised heparin (HP+Hep). Figure 3.17 presents each implant group with 
a cross section, a top view and a close-up of the fibre s surfaces.  













Figure 3.17: Biostable scaffold selection for subcutaneous implantation. Scale bars for the cross-
sectional SEM images are 100 µm, ablumenal images are 20 and 2 µm for the low and high 
magnifications respectively.  
Conventional electrospinning of Pel (solution viscosity of 3150±8 cPoise) produced 
fibres with an average diameter of 2.14±1.4 µm (LP) and a scaffold thickness of 
1021±141 µm. The combined electrospinning and spraying technique did not influence 
the resulting (HP) fibre diameter when compared to LP (P>0.3, Figure 3.19.a). This 
result, also consistent with the previous section (Figure 3.15.b), suggests that sufficient 
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solvent evaporation occurred before collector impact for both Pel fibres and PEG 
microparticles. The heparinisation of HP fibres increased the average diameter from 
2.02±0.6 to 2.59±0.5 µm (P<0.001), a previous study also confirmed an increase in 
fibre thickness (1.8 to 3.6 µm) as a result of covalent heparin attachment to electrospun 
Pel surfaces [153]. The surfaces of the un-heparinised fibres (LP and HP from images 
in Figure 3.17) appeared smooth compared to a more rippled surface roughness on the 
heparinised groups (also seen by [153]). A close-up of the heparin layer (dehydrated) of 
HP+Hep surfaces can be seen in Figure 3.18. Furthermore, heparinised fibres appeared 
to be welded  at their contact interfaces (as indicated by the red arrow in Figure 3.18). 
It is likely that the respective heparin gel layers of the fibres in contact with each other 
merged during the dehydration process (freeze drying) and/or grafted together by 
gel/amines during the heparinisation process. 
  
Figure 3.18: Fibre morphology of heparinised Pellethane® fibres. Scale bars are 20 and 2 µm for the 
low and high magnification SEM images respectively. 
Combined electrospinning and spraying of Pel fibres and PEG microparticles (average 
diameter of 30±14 µm and bead-fibre composite fraction of 68.6±3%) produced 
scaffolds with a porosity 11% higher than that of the conventional spun scaffolds (LP 
to HP was 79.7±2 to 91.1±1%, P<0.001). These porosity measurements were in line 
with the results obtained from the scaffolds produced in the previous developmental 
section (Figure 3.15.b). Heparinisation only slightly decreased the average porosity by 
0.4% (P<0.05, Figure 3.19.b). The porosity of heparinised scaffolds were expected to 
slightly decline due to the added mass of heparin (a result also seen by other coated 
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electrospun fibres [380]). All biostable implant groups (LP, HP and HP+Hep) had 
similar fibre orientation indices (0.177±0.1, 0.194±0.1 and 0.187±0.1, P>0.5, Figure 
3.19.c) and 2D pore sizes (6.07±4, 6.51±5 and 6.49±5 µm, P>0.2, Figure 3.19.d). A 
total frequency of 18% of the pores measured for any of the high-porosity groups (HP 
or HP+Hep) were measured to be between 15 and 25µm while 14% of the pores were 
in that range for the lower porosity groups (Figure 3.19.e).  
   
   
Figure 3.19: Characteristics of biostable implant groups. a) scaffold porosity [n = 40]; b) fibre 
orientation index [n = 12]; c) fibre diameter [n = 12, >40/image]; d) scaffold pore size [n = 12, 
>250/image]; e) frequency of total pores between 10-25 µm [>3000 pores/group]; f) surface 
immobilised heparin load [n = 5] and confirmation stains [n = 1].  
A higher number of enlarged pores were found for the high-porosity groups due to the 
voids created by the sacrificial extracted PEG particles. Although, the inadequacy of 
2D image quantification to display the impact of removable microparticles on creating 
additional 3D spaces is again highlighted here (as explained in the previous section, 
Figure 3.16). The presence of surface immobilised heparin on the high-porosity groups 
was confirmed with a positive (dark) Toluidine blue stain and was quantified at 5.1±0.6 
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heparin is in a similar range to previous studies (7.5±1.6 mg/g for Pel electrospun 
scaffolds with 76-90% porosities and 1.8±0.1 µm fibres [153] and 6.6±2.0 mg/g for PU 
disks with 82% porosity [286]). 
   
Figure 3.20: Mechanical properties of biostable implant groups. a) Ultimate tensile strength (UTS), b) 
maximum elongation (� ) and c) elastic modulus (E). [n = 6] 
Mechanically, conventional electrospun scaffolds had a UTS 50% greater (P<0.001) in 
the longitudinal (4.53±0.7 MPa) compared to the circumferential direction (3.05±0.1 
MPa) and was approximately 3 times stronger than any of the high-porosity groups 
regardless of measuring direction (P<0.001, Figure 3.20.a). The heparin surface 
modification did not significantly influence mechanical strength in the C direction 
(1.06±0.1 and 0.97±0.2 MPa for HP and HP+Hep, P>0.5) but did produce a scaffold 
that was slightly weaker in the L direction when compared to its non-heparinised 
counterpart (1.61±0.7 and 0.95±0.2 MPa for HP and HP+Hep, P<0.05). The 
maximum elongation of LP (638±42%) was lower than that of HP (758±56%, P<0.05) 
but higher than HP+Hep (478±83%, P<0.01) in the circumferential direction (Figure 
3.20.b). Both LP (533±38%) and HP (650±49%) had a lower ɛmax in the L direction 
compared to C (P<0.01) while HP+Hep experienced a similar strain in both directions 
(P>0.9). The Young s modulus of LP (0.88±0.3 and 0.79±0.1 MPa, for C and L) was 
4 times higher (P<0.001) than that of HP (0.21±0.1 and 0.28±0.1 MPa) or HP+Hep 
(0.22±0.0 and 0.42±0.1 MPa) in the C direction and nearly twice as stiff in the L 
testing direction (P<0.001, Figure 3.20.c). Effectively, heparinisation slightly increased 
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elastic modulus for LP was similar in both testing directions (P>0.4) while HP 
(P<0.05) and HP+Hep (P<0.001) was less stiff in the C compared to the L direction. 
Porosity-enhanced electrospun scaffolds are known to have a weaker mechanical 
strength and rigidity (modulus) due to the loss in bulk material, but has the potential 
to be more compliant towards native tissue, when compared to their normally produced 
counter parts [153, 178, 230, 232]. Mechanical properties were shown in previous studies 
to be controllable by controlling the sacrificial fibre fraction (by flow rate) of removable 
fibres during dual electrospinning [153, 178]. A similar approach could be adopted here 
to control the bead fraction (using a set number of needles instead of flow rate) to 
control the mechanical compliance to match that of the targeted tissue. Furthermore, 
the heparinisation of Pel fibres have also been shown to have an effect on the bulk 
mechanical properties [153]. Similar to the results obtained in the current study, the 
authors observed an increase in Young s modulus and a lower maximum elongation 
when compared to un-heparinised scaffolds. These effects could be related to the added 
material (the mass of a heparin layer made the scaffolds stiffer) and the chemical 
processing (weakened the scaffold s structural integrity). An additional effect that could 
also have resulted in a more rigid matrix, could have been due to fibres welded  at 
their contact interfaces (HP+Hep) compared to lose fibres (HP), as it was observed in 
Figure 3.17 and Figure 3.18. 
3.2.5 Healing assessment of biostable implants 
This section is a summary of the 12week, in vivo assessment (rat subcutaneous model) 
for the biostable scaffolds. The in vivo performance of each implant was analysed and 
quantified in terms of tissue ingrowth followed by collagen, cellular, macrophage and 
vascular density. 
3.2.5.1 Scaffold tissue ingrowth 
Representative H&E (the dark pink areas shown positively stained tissue) micrographs 
for the biostable implant groups are shown in Figure 3.21 for 7, 14, 28 and 84 days 
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respectively. 















    
Figure 3.21: Representative H&E micrographs of biostable implant groups. Scale bars are 500 µm. 
Cellular infiltration occurred from all surfaces (there appeared to be no preferred side) 
and observably increased over time for all biostable scaffolds, as illustrated by the 
representative H&E micrographs. Tissue ingrowth of conventional electrospun scaffolds 
(LP) followed a linear trend of 0.48Tdays + 2% (r2 = 0.99), and was limited to 42% at 
84 days (Figure 3.22). Conversely, the enhanced porosity groups showed a much higher 
ingrowth rate and were almost fully ingrown after 28 days. The ingrowth profiles of 
HP and HP+Hep were indistinguishable up to the first two time-points. On day 28, 
HP was 30% more ingrown than HP+Hep (89.8±12% and 58.5±17, P<0.05), after 
which both obtained full ingrowth at the final time point (99.5±0 and 99.1±0%, 
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P>0.2). Similar ingrowth profiles for all Pel groups were observed with the quantified 
result from the zinc fixated H&E micrographs (Appendix A6). 
 
Figure 3.22: Tissue ingrowth of biostable implant groups.Graph insert: scaled x-y plot of tissue 
ingrowth for each group. 
A relatively slow cellular migration rate and limited infiltration depth (only the 
peripheral areas) of scaffolds produced by standard electrospinning, as seen in this 
study, have also been reported by many others [153, 233, 237, 352, 354, 381]. The pore 
sizes, and their level of interconnectivity, of LP scaffolds were insufficient to 
accommodate cells and their associated oxygen/nutrient supply to penetrate and 
survive beyond a depth of 200-300 µm, even after 3 months of implantation. The cells 
that have indeed survived within the LP scaffolds, were probably kept alive by supplies 
from the surrounding tissue (due to the oxygen diffusion limit being in the range of 
100-200 µm [297]). The faster migration rate and full tissue ingrowth of a ~1 mm thick 
porosity-enhanced scaffold (by adding and removing sacrificial components to yield 90-
95% porosities) has also been observed by others [148, 153, 352]. This result can be 
explained, not only by the known correlation between tissue ingrowth rate and scaffold 
porosity, but also, by the presence of sufficient interconnected three-dimensional pores 
(created by the 30 µm porogens) that accommodated cellular migration along with the 
required support networks (nutrients, oxygen and waste) which allowed long-term 
survival. Retrospectively, heparinisation of high-porosity groups had a minimal 
influence on tissue ingrowth, when compared to the controls, after 3 months of 
implantation. The initial retardation (7-28 days) may have been due to the slightly 
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lowered porosity, thicker and slightly fused fibres as a result of the heparinisation 
process that hindered early stage cellular infiltration. 
3.2.5.2 Collagen density 
Representative PSR (the red areas are positively stained collagen) micrographs for the 
biostable implant groups are shown in Figure 3.23 for 7, 14, 28 and 84 days respectively. 















    
Figure 3.23: Representative PSR micrographs of biostable implant groups. Scale bars at 500 µm. 
There were no significant differences of collagen density between the groups at any of 
the measured time points between 7-28 days (P>0.1, Figure 3.24). Nevertheless, the 
measured collagen deposition between 28 and 84 days doubled inside both high-porosity 
scaffolds (0.15±0.1 to 0.29±0.1 µm2/µm2, P<0.05) while collagen in the lower porosity 
scaffolds was at a constant (P>0.3) yet in a lower (P<0.05) range of 0.23±0.1 µm2/µm2. 
Collectively, the percentage of collagen area per tissue area for all groups increased at 
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a rate of approximately 6%/week between 7 and 28 days (1-19%) and nearly plateaued 
to 0.6%/week between 28 and 84 days (19-25%) - as shown by the inserted plot in 
Figure 3.24. 
 
Figure 3.24: Collagen deposition of biostable implant groups.Graph insert: x-y plot representing the 
combined collagen density of all groups. 
Collagen deposition is associated with the tissue remodelling process (cells secreting 
new ECM [343]) and also plays a crucial role in strengthening tissues that are under 
high biomechanical stresses, e.g. blood vessels/heart valves. Following injury, collagen 
fibres found in blood vessel walls (or vascular grafts) are known to increase 
circumferentially and longitudinally in order to re-establish homeostatis in response to 
mechanical cues [382, 383]. In another study, the collagen and elastin content inside 
electrospun heart valves increased over time and eventually matched that of the native 
tissue after 12 months of implantation (in vivo sheep model) [63]. The authors also 
made a positive remark towards the formation of an increasingly organised and more 
matured collagen/elastin fibrous matrix found in the leaflets of the heart valves as a 
function of time. Furthermore, other studies have also confirmed positive relationships 
between collagen density and scaffold architecture (porosity[352] and pore sizes[384]). 
The measured collagen density was higher inside porosity-enhanced electrospun 
scaffolds (1mm thick PCL implants that had a 60% PEO sacrificial fibre fraction before 
removal) compared to conventional (lower porosity) groups after 12 weeks (obtained 
full tissue ingrowth at this point) of implantation in a subcutaneous model [352]. Cells 
seeded in gelatin scaffolds with larger pores had a higher collagen (type I, II and X) 
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deposition rate when compared to smaller pores (pores sizes were tested from 50-500 
µm) [384]. High collagen densities could, however, also be associated with scar tissue 
formation. Previous researchers classified scar tissue, histologically, as highly packed 
clusters of collagen. In contrast, scar-less/regenerative healing was classified as 
organised and evenly distributed collagen fibres, similarly to the native tissue [385]. 
Therefore, the increasing collagen densities over time followed by elevated contents for 
the porosity-enhanced groups (which was due to larger 3D pores and higher porosities) 
after 12 weeks of implantation agree with current literature. Moreover, the organised 
and matured  nature of the collagen fibres observed in the high-porosity groups had 
more regenerative characteristics compared to the concentrated ridges (scar tissue 
formation characteristics) found along the tissue inner boundaries of the low-porosity 
groups. 
3.2.5.3 Cellular density 
Representative micrographs for the degradable implant groups are shown in Figure 3.25 
for 28 and 84 days respectively. The blue areas, DAPI, are positively stained nuclei and 
the red areas, ED1, are positively stained macrophages. 
Time (d) LP HP HP + Hep 
28 
   
84 
   
Figure 3.25: Representative ED1 micrographs of biostable implant groups. Scale bars are 100µm 
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The ratio of DAPI area per tissue area (ADAPI/Atissue) inside the conventional electrospun 
scaffolds (0.47±0.1 µm2/µm2) was twice as high as that of the high-porosity (0.20±0.1 
µm2/µm2) or heparinised high-porosity groups (0.23±0.1 µm2/µm2, P<0.05) at 28 days 
(Figure 3.26). At 84 days, LP (0.12±0.1 µm2/µm2) had a similar cellular density when 
compared to either of the porosity-enhanced groups (P>0.4) while the density found in 
HP was double than that of the HP+Hep groups (0.20±0.1 µm2/µm2 or 0.10±0.1 
µm2/µm2, P<0.05). Over time (28 compared to 84 days), ADAPI/Atissue inside LP and 
HP+Hep scaffolds decreased (P<0.01 and P<0.05) while HP remained similar (P>0.8).  
The number of nuclei counted per tissue area for LP (4355±1486/mm2) was nearly 
1500/mm2 nuclei more than the number counted for HP (2460±641/mm2) or HP+Hep 
(2825±362/mm2, P<0.05) after 28 days. There was no significant difference (P>0.3) 
between the number of nuclei counter per tissue area for HP and HP+Hep at day 28. 
In agreement with the measured ADAPI/Atissue over time, the number of nuclei inside LP 
(2254±446/mm2) and HP+Hep (1968±492/mm2) scaffolds decreased from 28 to 84 days 
(P<0.05 and P<0.05) while HP (2603±296/mm2) remained similar (P>0.6). 
 
Figure 3.26: Cellular density of biostable implant groups. Cellular density in a) area and in b) number.  
Many suggested that complete regeneration of implantable TE scaffolds would be 
encouraged by rapid cellularisation and maintaining a healthy density [210, 338, 352, 
386]. Scaffolds with ideal cellularities have been associated with superior ECM secretion 
and vascularisation (mainly due to an abundance of M2-macrophages, i.e. the 
proangiogenic and remodelling phenotype) when compared to those with lower cellular 
a) b) 
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counts [210]. Furthermore, maintaining a healthy cellular density over a prolonged 
period could also result in a faster enzymatic degradation rate of the scaffold material 
[238]. Several researchers have quantified in vivo cellularity for TE scaffolds. Porous 
polyurethane disks (82% porosity, 160µm pores) had a cellularity of 1500/mm2 after 10 
days of implantation in a rat subcutaneous model [338]. Porosity-enhanced electrospun 
scaffolds (a PCL construct which contained 60% PEO prior to removal) obtained a 
cellular density of 1200/mm2 after 12 weeks (subcutaneously) while the low-porosity 
groups (0% PEO) had a 600/mm2 at the same time point [352]. Additionally, 
electrospun PCL scaffolds (83% porosity, 30 µm pores) maintained a cellular density of 
2000-3000/mm2 between 28-100 days as vascular grafts in a rat circulatory model [210]. 
More of the same results were found for porosity-enhanced PCL scaffolds (93% porosity, 
26 µm pores), which had a density of 2500-4500/mm2 while conventional electrospun 
scaffolds (87% porosity, 4 µm pores) obtained a cellularity of 1000-3000/mm2 between 
1 to 3 months as a vascular grafts in a rabbit carotid circulatory model [238]. It is 
evident, from these studies, that cellular density positively correlated with porosity 
(and to some extend pore size). Also, a density of 3000/mm2 (give or take a thousand 
cells) can be expected from scaffolds with high porosities (>90%). The cellularities 
measured for the current high-porosity groups were, as suggested by literature, in a 
healthy range. Despite a superior cellularity expected for the porosity-enhanced groups, 
the abnormally high density measured after 28 days for the low-porosity groups could 
be explained by the clustering of frustrated cells at the peripheral areas of the LP 
scaffolds (i.e. a high cellular count normalised to a small tissue ingrowth area will 
naturally result in a high density). The main reason for these frustrated cells would be 
due to the pores being too compact and small for the cells to penetrate the scaffold. 
3.2.5.4 Macrophage density 
The macrophage densities presented in Figure 3.27 are the quantified results of the 
positively stained macrophages (ED1 - red areas), as can be seen from the samples in 
Figure 3.25. 
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Figure 3.27: Macrophages per tissue area of biostable implant groups. Macrophage density in a) area 
and in b) number. 
There were no significant differences in macrophage area density (AED1+/Atissue) or 
macrophages counted per tissue area between the Pel groups at any of the measured 
time points (P>0.1). Collectively, the ED1+ area and macrophage count was 
approximately 0.05 µm²/µm² and 500 macrophages/mm². Despite the apparent 
decrease in macrophage densities over time (28 compared to 84 days), only LP had a 
lower AED1+/Atissue (P<0.05) and macrophage count (P<0.05) while HP and HP+Hep 
remained unchanged (P>0.08). 
Macrophages are known to play an intricate role in effective healing of implantable 
medical devices [387, 388]. Following injury, macrophages are activated in response to 
the signals received at the implantation site (damaged tissue). Polarised macrophages 
can conveniently be subdivided in to two opposing phenotypes (M1/M2) [204]. M1 cells 
are the classically activated  pro-inflammatory macrophages while the M2 type (anti-
inflammatory) promotes tissue remodelling and vascularisation (known to be a supplier 
of proangiogenic molecules such as VEGF [389]). Among other signals, scaffold micro-
architecture is also known to stimulate macrophage polarisation. Authors have shown, 
in vitro [201] and in vivo [210], that electrospun scaffolds with thicker fibres and their 
inherently larger pores tended to activate more M2 macrophages rather than M1 which 
were found to be in larger numbers when in contact with thinner fibres and smaller 
pores. The macrophages labelled in the current study (ED1+) included both M1 and 
M2 phenotypes. Despite not being able to distinguish between the phenotypes found in 
a) b) 
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the different groups, the apparent decrease of macrophage densities over time may be 
attributed to a less aggressive foreign body reaction towards the implants at the end of 
the study. 
3.2.5.5 Vascular density 
Representative CD31 micrographs (the dark areas are positively stained endothelial 
cells) for the degradable implant groups are shown in Figure 3.28 for 28 and 84 days 
respectively. The dashed lines in the LP groups represent the tissue area (the red line 
is at the base of the scaffold while the black line indicates the tissue ingrowth boundary 
in the direction towards the middle of the scaffold). 
Time (d) LP HP HP + Hep 
28 
   
84 
   
Figure 3.28: Representative CD31 micrographs for no-degradable implant groups. Scale bar: 100 µm. 
Blood vessel area per tissue area (Avessels/Atissue) inside the LP scaffolds (0.036±0.030 
µm²/µm²) was not significantly different (P>0.1) when compared to that of HP 
(0.026±0.003 µm²/µm²) or HP+Hep (0.008±0.007 µm²/µm²) at 28 days of implantation 
(Figure 3.29). Although, Avessels/Atissue for HP scaffolds was 3 times larger than that of 
HP+Hep at 28 days (P<0.01). At the last time point, Avessels/Atissue for HP+Hep 
(0.010±0.003 µm²/µm²) was lower than both HP (0.021±0.004 µm²/µm², P<0.01) and 
LP (0.030±0.020µm²/µm², P<0.05) scaffolds. 
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There were no differences in the number of vessels counted per tissue area between any 
of the groups at 28 days. At 84 days, the number of vessels per Atissue for LP 
(278±191/mm2) and HP (148±21/mm2) were similar (P>0.1) while HP+Hep had fewer 
vessels (111±19/mm2, P<0.05). Vascular density did not significantly change (neither 
vessel area nor vessel count per tissue area) for any of the groups over time (P>0.5), 
i.e. between 28 and 84 days.  
 
Figure 3.29: Blood vessels per tissue area of biostable implant groups. Vascular density in a) area and 
in b) number.  
Although the low-porosity groups appeared to have had a greater vascular density, 
compared to the high-porosity groups, it is important to remember that these regions 
(only found in peripheral areas) contained frustrated cells due to the limited ingrowth 
spaces (with reference to sections 3.2.5.1 and 3.2.5.3). Moreover, the centre of the LP 
scaffolds was consistently acellular even after 3 months of implantation. These are not 
desirable healing indications and therefore not recommended for long-term 
implantation [379]. On the contrary, the ingrowth spaces created by the dissolved PEG 
porogens (porosity-enhanced groups) accommodated endothelial cells to migrate deep 
into the scaffolds and encouraged the remodelling of a healthy vasculature throughout 
the entire scaffold. Enhanced in vivo vascularisation have been associated with greater 
porosity and larger pore sizes of TE scaffolds in previous studies [55, 153, 202, 210]. 
The vascular densities measured for the high-porosity groups in the current study were 
comparable to that of other high-porosity electrospun scaffolds reported in literature 
(100-300/mm2 [238]). Despite previous success on improved in vivo vascularisation of 
a) b) 
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porous polyurethane disks with surface modified heparin (6.6±2.0 mg/g [286]), 
heparinised electrospun scaffolds have also been reported (with a similar surface load  
of 7.5±1.6 mg/g [153]) to have no influence on vascular densities after 28 days of 
implantation. While the dependency on heparin surface concentration might be ruled 
out by such opposing results, a possible explanation could be hidden in the scaffold 
architecture (i.e. foams with well defended pores compared to fibrous structures). 
Adding a heparin layer to well defined, rigid structures did not influence the effective 
pore sizes of the scaffolds [290, 292]. In contrast, the heparinised fibres in the current 
study were welded  together at their touching interfaces and resulted in a more rigid 
structure (supported by Figure 3.18 and mechanical results from Figure 3.20). These 
architectural changes reduced the effective pore size by inhibiting cells from moving 
individual fibres (HP+Hep) compared to the loose, freely movable fibres of the control 
(HP) samples. Effectively, the vascularisation process of HP+Hep was delayed as a 
result of a slower ingrowth rate (as shown in section 3.2.5.1). 
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3.3 Biodegradable scaffold development 
3.3.1 Solvent evaporation rates 
Among the solvents capable of dissolving DP at room temperature, CHCl3 and HFIP 
were selected (only chlorinated and fluorinated solvents dissolved DP out of 21 tested 
compounds, see Appendix A7 for the complete list). CHCl3 and HFIP, as pure solvents, 
achieved complete evaporation by the 2 hour time point (651.5±11 mg to 1.2±2 mg, 
99.8±0.3%) as shown in Figure 3.30. Dissolving DP at a concentration of 18wt% in 
either of the solvents reduced the 2hour evaporation rate by approximately 12% and 
40% for DP/CHCl3 (87.9±1.2%) and DP/HFIP (61.6±0.9%) respectively. Furthermore, 
the evaporation rate of HFIP from HFIP/DP was delayed, 20% on average, when 
compared to CHCl3/DP between 2 to 4 hours and only managed to evaporate more 
than 90% after 24 hours. 
  
Figure 3.30: DP solvent evaporation rate comparison. a) Solvent evaporation profiles for CHCl3 and 
HFIP over 24 hours; b) evaporation profiles between 2-5 hours. [n = 3]. 
A hydrogen bonding may form between a carbonyl (C=O) and an alcohol (OH) 
functional group. This affinity could be enhanced by the presence of fluorine atoms 
found in fluorinated alcohols (six in the case of HFIP) [390]. The results from the 
current study showed that pure CHCl3 and HFIP had approximately the same 
evaporation rates due to similar properties at RT (boiling point, vapor pressure and 
density, as shown in Appendix A1). The delayed evaporation rate that was found for 
HFIP from DP/HFIP compared to CHCl3 from DP/CHCl3 may therefore be explained 
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of CHCl3) and the pairs of carbonyls found in each of the hard, soft and junction 
repeating units of DP (see chemical structures in Figure 3.31). 
Figure 3.31: Chemical structures used for degradable scaffolds development. a) structure of DegraPol® 
where the blue dots indicate carbonyl groups identified in the repeating unit; b) solvents used for 
electrospinning. 
3.3.2 Scaffold drug incorporation 
3.3.2.1 Heparin modification 
The chemical modification (ion exchange) of heparin sodium (HepNa+) to HepTBA was 
confirmed with NMR. Representative 1H NMR spectra before and after the resulting 
ion exchange process are illustrated in Figure 3.32. The solvent reference peaks (D2O) 
are indicated with an arrow between 4.7-4.8 ppm while the internal reference peaks, 
heparin s acetyl group (Ac), can be found at 4.2-4.3 ppm. TBA proton peaks, indicated 
by numbers (1-4), are shown between (3.4-3.6), (1.9-2.1), (1.6-1.8) and (1.2-1.4 ppm) 
respectively.  
Increasing the reacted TBA/MeOH concentration of 4.2, 8.0, 12.2, 16.4 or 80.0 mg/ml 
to form heparin variations that are labelled HepTBA25, 50, 75, 100 and HepTBA500 
(Figure 3.33.a) resulted in a linear increase (24.1±0.2, 47.1±0.7, 68.4±1.1 and 79.6±0.6 
for HepTBA25-100) of the ratio of the average integrated TBA proton peaks to that of 
the Ac peaks (Figure 3.33.b). This ratio plateaued when heparin acid (HepH+) was 
reacted with excess TBA (HepTBA500 had a maximum integral ratio of 83.9±1.2). An 
1H NMR spectrum of TBA alone plus the protonated version of heparin (HepH+), prior 
a) 
b) 
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to its reaction with TBA/MeOH, can be found in Appendix A8. 
 
Figure 3.32: The ion-exchange of heparin sodium to heparin-tributylammonium. a) 1H NMR spectra of 
heparin sodium and b) heparin-tributylammonium. 
Sodium salt of heparin is known for being insoluble in typical, less polar than water, 
organic electrospinning solvents [243, 310, 391]. A chemical modification, replacing the 
sodium ions with tributylamine, was previously proposed to expand heparin s solvent 
solubility array and therefore its biomaterial incorporated applications [310]. These 
authors successfully produced an amphiphilic salt of heparin that was not just soluble 
in water but also in HFIP. Here, reported for the first time, are data captured for a 
finer control over this modification (i.e. controlling the amount of H+ replaced with 
TBA+ after all Na+ were removed). Adjusting the TBA content of this heparin 
conjugate has potential influences on its solubility and bioactivity which will be 
showcased in the sections to follow. Nevertheless, the positive relationship found in the 
current study between TBA-to-Ac proton signals and the concentration of TBA ions 
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backbone of heparin were replaced with TBA molecules due to its higher availability 
at higher concentrations in the reaction solution. This trend, of course, was also 
expected to reach a maximum (which can be seen in Figure 3.33.b) when all available 
H+ ions where replaced with TBA+ ions despite them being in excess. 
Figure 3.33: 1H NMR spectra of heparin-tributylammonium variations.  
3.3.2.2 Drug solubility in organic solvent systems 
The solubility of heparin, in the form of HepTBA500, was positively altered for a wide 
range of organic solvents when compared to the solubility of HepNa+. HepTBA500 was 
found to be soluble, tested at 5% (w/v), in the selected DP solvents (HFIP and CHCl3, 
previous authors also confirmed solubility in HFIP [310]) and a selection of other 
common electrospinning solvents (ethanol, isopropanol, THF and DMF) while HepNa+ 
was soluble in only water (the lower bound testing concentration was 0.1%). Successful 
solubility of HepTBA variations (transparent solutions at RT) was found to favour 
higher TBA content products. This could be attributed to TBA s inherent hydrophobic 
side chains which, at increasing concentrations, increased HepTBA s hydrophobicity 
and therefore solubility in less polar solvents. Solubility tests with DP solvents showed 
that HepTBA25 and HepTBA50 was soluble in HFIP but not CHCl3 while higher TBA 
content products (HepTBA75, 100 and 500) dissolved in both solvents. Both 
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of the TBA content) favoured dissolution in HFIP compared to CHCl3. Moreover, both 
drugs precipitated out of solution when DP was added to drug/CHCl3 solutions. In 
contrast, drug/HFIP or high HFIP content of drug/HFIP:CHCl3 solutions remained 
homogeneous when DP was dissolved (concentrations 18-24wt% were tested). A solvent 
system of HFIP/CHCl3 at 50:50% was therefore selected to allow incorporation of both 
drugs into identical (transparent) DP electrospinning solutions. A summary of 
drug/solvent solubility at a concentration of 5(w/v)% is shown in Table 3.1. 








HepNa+ I I I 
HepH+ I I I 
HepTBA25 I S S 
HepTBA50 I S S 
HepTBA75 S S S 
HepTBA100 S S S 
HepTBA500 S S S 
Dexamethasone I S S 
    
3.3.2.3 In vitro elution of heparin or dexamethasone 
Drug release profiles for DP scaffolds electrospun at RT containing 0, 1 or 2wt% of 
either heparin (HepTBA500) or Dex over a period of 45 days are shown in Figure 3.34.a 
and Figure 3.34.b respectively (SEM micrographs were taken of the 2wt% loaded 
samples). Furthermore, the mass loss for each group was also determined after 90 days 
(Figure 3.35). HepTBA500 incorporated at 1wt% released 25, 56 and 109% of the total 
dosage on 1, 6 and 44 days. The release for 2wt% were 27, 38, 57% of the total dosage 
on 1, 6, and 44 days. Dex incorporated at 1wt% released 21, 75 and 87% of the total 
dosage on 1, 6 and 44 days. The release for 2wt% were 20, 86, 97% of the total dosage 
on 1, 6, and 44 days. 
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Figure 3.34: Drug elution study from RT electrospun scaffolds. a) Heparin-TBA500 and b) 
Dexamethasone at 2wt% concentrations with their respective release profiles (1 and 2wt%). SEM 
image scale bars are 20 µm. 
Besides the architecture and material selection of the delivery device (mean diffusion 
distance and polymer degradation rate [198]), the drug type and its polymorphic form, 
crystallinity, molecular size, the total load in the polymer matrix and the drug s 
solubility in the release medium are known factors that influences the release kinetics 
of a drug from the same polymer matrix [327, 328]. Thus, Dex could have had a faster 
delivery rate compared to HepTBA500, at the same concentrations, due to the large 
difference in molecular size (300Da vs 12kDa). Smaller particles (Dex in this case) were 
expected to have a faster diffusion rate compared to larger particles when both were 
imbedded in the same polymer matrices and eluted from the same incubation fluid 
(both drugs were highly soluble in PBS). Faster delivery rates were expected for drugs 
at higher dosages due to a greater concentration gradient inside the polymer matrix 
[198]. This dependency was also seen by previous drug elution studies with variable 
concentrations similar to that of the current study for both a modified heparin-TBA 
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Figure 3.35: Mass loss of DP electrospun scaffolds in vitro. a) DP scaffold mass loss profile over time; 
b) mass loss for drug containing samples at 90 days. [n = 3].  
DP scaffolds followed an in vitro mass loss of approximately 0.12%/day over the first 
90 days of incubation (Figure 3.35.a). Neither the drug type nor its concentration, 
HepTBA500/Dex at 1/2wt%, had a significant influence on the mass loss percentages 
when compared to the drug-free DP scaffolds (with the lowest single comparison being 
P>0.1, Figure 3.35.b). Collectively, all DP scaffold groups (initial mass of 14.9±4 mg) 
lost between 8-18% (or 11.8±3% on average) of its original mass after a period of 3 
months.  
The in vitro degradation of DP electrospun scaffolds, high glycolide content DP30 in 
particular - also used in the current study, have been investigated before. The molecular 
weight (Mw) of DP decreased from 78 kDa (day 0), 41 kDa (14 days) to 26 kDa (day 
28) while sustaining a mere 0.2-2% mass loss over the period of a month [21, 273]. 
Although the current study was extended to 3 months, a mass loss of 1% at day 33 is 
in line with the previous studies. Therefore, a similar molecular weight decrease (54% 
after 28 days) was also expected [273]. These characteristics, high molecular weight 
decrease with minimal mass loss, classifies DP s degradation mechanism as bulk 
degradation (and not surface erosion). Briefly, ester chains of typical poly(α-hydroxy 
esters) were cleaved by water molecules that diffused deep into the polymer matrices 
inside the electrospun fibres which resulted in an overall reduction in molecular weight 
of the bulk material. Significant mass loss only occurred at a later stage. If DP degraded 
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and PGS [392]), the scaffolds would have experienced a linear mass loss throughout the 
study while retaining the internal structure s molecular weight (explained based on 
theories proposed in [393]). 
3.3.2.4 Anti-thrombogenic properties of heparin variations 
The time to initiate a clot within a sample of human blood (reaction time, RTEG) treated 
with heparin sodium (HepNa+, 0.01 mg/ml) was delayed by more than 6 times when 
compared to samples where heparin was not present (RTEG values of 49.0±4.0 and 
7.6±0.8 min respectively, P<0.01). Conversely, heparin sodium stripped from all Na+ 
ions (heparin in acid form, HepH+) had a reaction time similar to the control samples 
(7.2 min). 
Figure 3.36: Reaction times of human blood treated with heparin variations. a) RTEG values for heparin 
variations [n = 1 for HepH+, n = 2 for all other]; b) linear correlation between TEG reaction time and 
TBA content (as determined by NMR). 
All variations of heparin-TBA (at 0.01 mg/ml) were found to be anti-thrombotic to 
some extent, RTEG_HepTBA > RTEG_control >8 min (11.8±5.7, 17.2±8.1, 28.6±2.5, 29.6±6.3 
and 40.3±1.1 min for HepTBA25, 50, 75, 100 and HepTBA500, Figure 3.36.a). The 
time to initiate a blood clot was slower when blood was treated with higher TBA 
content compounds (i.e. when more H+ were replaced with TBA) compared to the lower 
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0.91) was fitted for the reaction time as a function of the integral ratio (as defined by 
equation (2-3)) of TBA to Ac from 1H NMR results (Figure 3.36.b). Not only did 
HepTBA500 have the longest reaction time among the heparin-TBA variations, it was 
9 minutes faster than the time of HepNa+ at the same (w/v) concentration (P<0.05). 
Figure 3.37: Anti-thrombotic properties of heparin before and after electrospinning. a) reaction time 
values; b) representative TEG graph. ** P<0.01. [n = 3]. 
The RTEG for HepTBA500 (16.4±2.9 min) was within the same range than that of 
HepNa+ (18.21±1.7 min, P>0.4) when they were tested at concentrations of 0.018 and 
0.01 mg/ml respectively (molar equalised concentrations according to models proposed 
by [302]). Additionally, HepTBA500 retained its anti-thrombotic properties prior to 
processing and as a scaffold eluted product (the reaction times before and after 
electrospinning were 16.4±2.9 and 19.9±2.6 min respectively, P>0.2, Figure 3.37.a). 
Typical TEG profiles were overlayed for a blood control sample (which started to clot 
4 times earlier than any version of heparin, P<0.05) and two barely distinguishable 
blood+heparin curves in Figure 3.37.b. HepTBA500 started to clot at the same time 
point (20 min), had a slightly sharper clotting angle (25 compared to 30) and a similar 
maximum amplitude (50 mm) when compared to HepNa+. Additional TEG results 
(clotting angle, maximum amplitude and K value) can be found in Appendix A3. 
The blood clotting cascade can be prevented/interrupted by effective inhibition of 
activated factors Xa and IIa (thrombin). Antithrombin (AT-III), when activated by 
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respectively [394]. Interactions between heparin and neighbouring proteins are usually 
ionic in nature (heparin behave, like DNA, as a polyelectrolyte). When the ionic 
compounds HepNa+ or HepTBA+ binds to AT-III, the positively charged amino acids 
of AT-III (a serpin - serine protease inhibitor) form ion pairs with the negatively 
charged sulfo (SO3¯ with high affinity) and carboxyl groups (COO¯ with less affinity) 
– on the pentasaccharide sequence GlcNS6S3S of heparin [395, 396] (individual 
saccharides can be seen in Figure 1.16 of the introduction chapter) – by releasing the 
cations, Na+ and TBA+ respectively. Thus, it can be concluded that the lack of 
antithrombotic properties of HepH+ is due to AT-III being unable to bind to the non-
ionic COOH or SO3H groups of HepH+. Furthermore, HepTBA compounds with higher 
TBA contents had an increasing anti-thrombotic performance (i.e. longer reaction 
times) due to more activation sites for AT-III as more H+ were replaced with TBA+.  
One of the major challenges associated with scaffold drug incorporation via blend 
electrospinning, is preventing sensitive agents/proteins from losing their bioactivity 
during or after processing [198]. The previous work on HepTBA showed that this 
heparin derivative had antithrombotic properties comparable to its commercial form 
(HepNa+) [310]. Nevertheless, that study did not elaborate on whether the samples 
were tested before or after the electrospinning process. Here, the in vitro anti-
thrombotic performance of HepTBA and its newly expanded derivatives are shown for 
the first time. Moreover, HepTBA500 was tested before and after electrospun fibre 
incorporation. These new results show that HepTBA is indeed able to retain its 
bioactivity despite the harsh conditions associated with electrospinning (i.e. strong 
solvents and high electric fields). 
3.3.2.5 Cytotoxicity of heparin variations 
The smooth muscle cells used for the viability assay (XTT) before (0 hr) and after (72 
hr) heparin treatments, at the ultimate scaffold concentration of 0.5 mg/ml, are 
represented in Figure 3.38. After 3 days, the seeded cells were confluent (successful 
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proliferation occurred) and their morphology appeared to be unchanged (no signs of 
infection) when compared to the cells at inception.  
 PBS control HepNa⁺ HepTBA500 
0 hr 
72 hr 
Figure 3.38: Rat SMC prior to and after heparin treatments. Scale bars are 50 µm  
The absorbance measurements for all tested variations of heparin were similar (a 
collective absorbance of 1.12±0.05, P>0.07,) and slightly lower than that of the control 
samples (1.25±0.05, P<0.05, Figure 3.39a) but well above the background readings 
(0.26±0.02, P<0.001). After background removal (Figure 3.39b), the relative cell 
viability for HepNa+ and HepTBA500 were 85.9±9 and 91.5±3% (no significant 
difference, P>0.1) while the control samples were 100.0±5% (higher than any version 
of heparin, P<0.05).  
  
 Figure 3.39: Rat SMC viability assay of heparin variations. a) Absorbance measurements taken as the 
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background subtraction. *P<0.05; [n = 4]  
Heparin is known to inhibit proliferation of smooth muscle cells (SMC) [288, 289]. Lee 
at al. showed that heparin, independently of dosage (tested at 0.05-0.1 mg/ml, which 
is lower than the current study), reduced human SMC growth by 30% when compared 
to untreated cells after 3 days of incubation (an MTS assay was used to quantify 
bioactivity of the hSMCs) [285]. Although the origin of the cells, concentration and 
type of assay were slightly different, these results agree with the findings from the 
current study, i.e. a 14% reduction of SMC growth also after 3 days of incubation. 
Importantly, replacing Na+ ions with TBA+ had no influence on heparin s cytotoxicity 
(or its ability to inhibit SMC proliferation), at a tested concentration of 0.5 mg/ml, 
regardless of the TBA ratio. 
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3.3.3 Electrospinning of degradable fibres 
This section summarises the influence of controllable electrospinning parameters on the 
morphological outcome when processing DP. Parametric studies were essential, due to 
the complexity of the spinning process, to understand and select optimal/acceptable 
conditions for implant ready scaffold production. The parameters explored in this 
section were collecting speed, solution properties, base electrode configuration and 
collecting temperature.  
3.3.3.1 Collecting speed 
The influence of collecting speed on fibre orientation was quantified and visualised 






















Figure 3.40: Fibre orientation for DP scaffolds at different collecting speeds. a) orientation index as a 
function of collecting speed (velocity conversions are based on a 25 mm diameter collector); b) 
representative SEM images, white arrow indication circumferential direction. Scale bars are 50 µm. 
***P<0.001/**P<0.01/*P<0.05. [n =4]  
The orientation indices increased from 0.30±0.02, 0.36±0.06 to 0.75±0.06 when DP 
fibres were collected at 500, 1000 and 3000 rpm respectively. The relationship between 
orientation index and collecting velocity ( , m/s) was best described as � =. + .  (r2 = 0.99). Colour encoded SEM images in Figure 3.40.b illustrates the 
higher degree of orientation obtained at higher collecting speeds (less blue/green/yellow 
diagonal fibres and more red/pink/purple fibres in line with the collecting direction can 
be observed). 
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A higher degree of electrospun fibre alignment as a result of a faster tangential velocity 
of a rotating collector is a well-known parametric relationship [178, 180–183]. As 
mentioned before, section 3.2.1.1, alignment of electrospun fibres could be a useful tool 
for tailoring the mechanical properties of TE scaffolds to match that of the targeted 
tissue. Additionally, fibre alignment is also known to guide cellular growth in 
predetermined directions [397, 398]. Here, data are presented for specific control over 
fibre alignment of DP scaffolds spun from a solvent system with a low dielectric 
constant (i.e. pure CHCl3, � = 4.8). Interestingly, fibres from DP scaffolds were easier 
to align (obtained higher coherencies at lower speeds, e.g. 0.26 and 0.36 for Pel and DP 
at 1000 rpm) than Pel. This could be explained by the different solvent systems used 
for processing these two polymers. Greater electrostatic repulsions governed more 
whipping of Pel fibres, radial momentum, due to a more conductive spinning solution 
(solvents THF and DMF with � = 7.6 and 36.7 respectively) when compared to a lower 
conducting solution, DP/chloroform, which resulted in less side to side movements 
during the instability phase. Collecting incoming fibres that are predominantly in a 
straight line, of course, are easier to align (at lower speeds) than fibres that are flying 
in multiple directions. One of the advantages of controlling fibre alignment by adjusting 
solution conductivity would be to avoid mechanical limitations (such as heat, vibrations 
or fatigue) associated with extreme rotational speeds required to obtain a certain degree 
of orientation on smaller diameter collectors. A probable application for this research 
project, depending on its success, would be to produce small diameter (4 mm) vascular 
grafts. Then, the translation of an � of ~0.3 from a 25 mm to a 4 mm diameter 
collector, as an example, would require increasing the collecting speed of 2000 to 12500 
rpm and 500 to 3125 rpm for Pel and DP respectively (based on predictive equations 
from Figure 3.3 and Figure 3.40). Such predictions are realistic when compared to 
previous attempts for producing 4 mm diameter grafts, speeds were on average 4000 
rpm with outliers being 250 or 35000 rpm [138]. 
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3.3.3.2 Solution properties 
Morphological changes of electrospun DP scaffolds from different CHCl3/HFIP solvent 
systems are represented by SEM images in Figure 3.41. Fibres spun from a pure CHCl3 
solvent system appeared to be smooth and cylindrical. The inclusion of HFIP to the 
spinning solution caused wet landing  (insufficient solvent evaporation) and consequent 
fibre fusion  (fibres merging with neighbouring fibres). Increasing the HFIP content 
lead to finer and more fused fibres (25-50% HFIP). Fibres obtained by further addition 
of HFIP (50-100%) was observed to have a flat (2D) ribbon  like appearance and made 
sample removal from the collector s surface more challenging (difficult to separate it 
from the collector s surface without tearing it in the circumferential direction).  
100% CHCl3 75:25% 50:50% 25:75% 100% HFIP 
Figure 3.41: Fibre fusion at different solvent systems of DP scaffolds. Solutions were all at DP 20wt%. 
SEM images were taken of the ablumenal surfaces; scale bars are 50 µm.  
Morphological changes of scaffolds produced at different DP concentrations spun from 
pure HFIP are represented by SEM images in Figure 3.42. An increase in concentration 
(20-30wt%) improved scaffold morphology to some extent, transforming flat ribbons 
(also seen at 100%HFIP in Figure 3.41) to more cylindrical fibres. However, the wet 
landing  and the resulting fusion  of fibres were not resolved by simply increasing the 
polymer concentration. A higher solution concentration (20 to 30wt%) also resulted in 
a smaller fibre distribution area/whipping radius (Figure 3.42), a longer straight jet 
segment (35 to 110 mm, Figure 3.43a), larger fibres (3.2±1.1 to 7.2±2.4 µm, P>0.001) 
and associated pores (5.0±5.6 to 19.6±18.8 µm, P>0.001). The average pore size 
appeared to have a linear dependency on the average fibre diameter of =. − .  (r2 = 0.94, Figure 3.43b). 
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Figure 3.42: Scaffold morphology and distribution observed DP concentrations. SEM images were 
taken of lumenal and ablumenal surfaces. Scale bar are 50 µm. Red lines indicate start/end of collected 
area. 
Although fused, an increase in concentration was expected to produce thicker fibres 
[107] and larger pores [210]. Reduced fibre diameters were also expected to be formed 
from solvents with higher dielectric constants [84]. You et al. also compared 
electrospinning chloroform with HFIP (polymers used were PLA, PLGA or PGA) [143]. 
This investigation showed that thinner fibres are obtainable when spinning with HFIP 
compared to chloroform, which is in line with the current study. Successful 
electrospinning (smooth, bead-free and cylindrical fibres) strongly relies on solvent 
properties and therefore the solvent selection [94]. Known for being the most often used 
electrospinning solvent [93, 94, 138, 139], HFIP has been the solvent of choice for 
processing many synthetic/natural polymers (see section 1.2.2.1 and Figure 1.8 for the 
advantages of electrospinning with HFIP). It is therefore curious that the majority of 
DP researchers chose chloroform as their gold standard solvent for electrospinning [21, 
178, 208, 261, 263–265, 267, 269, 270, 272, 273] while only a few introduced a mixture 
University of Cape Town  WJ van den Bergh 
 
 Chapter: Results and Discussion 128 
of CHCl3 and HFIP [262, 268, 271] (with a 25% HFIP being the maximum fraction 
[268]). The fact that HFIP showed good solubility of DP at RT adds to the mystery 
(see DP solvents in Appendix A7). Perhaps the fusion phenomenon of fibres, as 
observed in the current study, is the main reason for HFIP not being selected to 
electrospin DP. Although the authors provided no explanations, only a single study 
mentioned fusion of DP fibres when HFIP was included in a co-solvent system (80:20% 
CHCl3:HFIP) [262]. It seemed that the simplest approach to avoid fusion of DP fibres 
was to stay clear from using HFIP as a solvent. However, the current project aimed at 
incorporating both Dex and Hep into the same DP spinning solution - both drugs have 
poor solubility in CHCl3 and considering DP s limited RT solvents, using HFIP as a 
solvent/co-solvent was appealing. Therefore, the sections to follow will include an 
attempt to explain this unspoken  phenomenon of DP fibre fusion, followed by 
proposed solutions to overcome this issue. 
Firstly, the fusion of electrospun fibres have been seen before [134, 135, 142]. In these 
cases, fibres fused because of insufficient evaporation due to the inclusion of a co-solvent 
with a higher boiling point (DMF as co-solvent with THF for a segmented 
polyurethane) or an elevated flow rate or collecting speed. Despite them being valid 
explanations for their studies, they are not applicable to the current study due to HFIP 
having a lower boiling point than CHCl3 and because both DP/CHCl3 (smooth and 
separate) and DP/HFIP (fused) were electrospun at the same parameters (constant 
flow rate, concentration, distance from collector and collecting speed). An alternative 
explanation could be, and would also be consistent with the bulk experimental results 
from section 3.3.1, a delayed evaporation rate of HFIP from DP/HFIP compared to 
CHCl3 from DP/CHCl3 solutions due to the high affinity (hydrogen bonding) that exist 
between HFIP and DP. Briefly, a thin skin of DP would form around the unevaporated 
solution while fibres are traveling through the air and get dissolved again by its own 
core upon contact with the collector. Fibres above and adjacent to neighbouring fibres 
would merge and fused together to form structures seen in Figure 3.42. 
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Figure 3.43: Scaffold architectural changes due to shifts in DP concentration. a) Electrospinning 
straight segment, resulting fibre diameters and pore sizes; b) linear trend between fibre diameter and 
pore size. [n = 2x3, >20 fibres per image & >100 pores per image].  
3.3.3.3 Base electrode configuration 
Focusing, steering or aligning fibre deposition with auxiliary electrodes have been 
shown to be an effective external parameter to control electrospun scaffold morphology 
[101, 399–404]. Here, the potential of adjustable base electrode surface area is 
investigated as a novel electrospinning parameter. Furthermore, base electrode size is 
also considered as a tool to decrease the degree of fibre fusion of DP spinning solutions. 
  
Figure 3.44: Electric field curves of annular disc shaped base electrodes. a) 2D plot for solving equation 
(2-5) for 16, 32 and 64 mm diameter discs; b) Coulomb3D results for applied voltages V1 = 12-20 kV.  
Numerical simulations of the electric field (Em, V/m), as a function of one dimensional 
distance (x, mm) from the base electrode (with diameter of 16, 32 or 64 mm) in the 
direction towards the collector, were calculated using equation (2-5) and Coulomb3D 




































































































University of Cape Town  WJ van den Bergh 
 
 Chapter: Results and Discussion 130 
data captured by solving for equation (2-5) and the results obtained from Coulomb3D 
simulations were both consistent with observing the maximum electric field peaks 
(Emmax) at x<5 mm and that the peak values were strongly dependant on the disc s 
size (a smaller surface area produced a larger Emmax). A small disc (16 mm) produced 
a 440% higher Emmax than the large disc (7.32, 2.90 and 1.67x105 V/m for 16, 32 and 
64 mm, Coulomb3D eg. at V1 = 12 kV). Observations from 3D vector field 
visualisations (Figure 3.45) confirmed the high field intensity that was found near the 
surface of the base electrode and rapidly declines into a more uniform field towards the 
collector. 
Figure 3.45: Electric field visualisations of a simple base electrode configuration. Produced using 
Coulomb3D from Integrated Engineering Software. 
Per equation (2-5), electric fields were expected to peak at distances close to the base 
electrode regardless of the electrode size (as described by the roots of equation (2-5), 
see Appendix A9 for supporting graphs). Moreover, the highest field created by the 
smallest diameter annular base electrode was also expected due to a constant potential 
energy being distributed over a smaller surface area (i.e. a higher charge density is 
created by smaller base electrode).  
The concept of using base electrode surface area as a controllable electrospinning 
parameter to alter scaffold morphology was tested for a low dielectric solvent system 
(20wt% DP/CHCl3) using a large (3600 mm2, LBe), medium (490 mm2, MBe) and small 
(80 mm2, SBe) base electrode. Reducing the size of the base electrode from LBe to SBe 
increased the fibre deposition area (36 to 90 cm2), decreased the average fibre diameter 
(7.1±1.5 to 6.1±1.0 µm, P<0.01), increased scaffold pore size (15.1±6.0 to 17,7±7.7 
µm, P<0.001) and showed observably less fibre fusion (Figure 3.46 and Figure 3.47). 
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Figure 3.46: The influence of base electrode size on DP scaffold morphology.Scale bars are 100 and 20 
µm. Red line indicates start/end of collecting area.  
The concentrated charge from the SBe, as expected from the simulations, transferred 
more energy to the spinning solution compared to a larger electrode and induced a 
greater whipping radius with a subsequent wider distribution area. This outcome is 
consistent with a previous study for using a cylindrical focusing base electrode of 
multiple needles [401]. More whipping also caused further stretching of the solution 
filament (resulting in thinner fibres) and allowed for more solvent to evaporate which 
decreased the degree of fibre fusion before collection. 
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Figure 3.47: Influence of base electrode size on fibre diameter and pore size. 
**P<0.001/**P<0.01/*P<0.05. [n>30 fibres, n>150 pores].  
Although the SBe reduced the degree of fusion of DP/CHCl3 spun scaffolds (due to an 
enhanced electric field that caused a greater whipping radius), it failed to have the 
same effect when electrospinning with DP/HFIP (Figure 3.48). A charge concentrated 
base electrode that promotes additional solvent evaporation was still insufficient to 
break the affinity between HFIP and DP (the hydrogen bonding mentioned in the 
previous sections). Nevertheless, a base electrode with adjustable surface area could be 
a useful tool for additional control over the electrospinning process. 
DP/HFIP DP/CHCl3 
  
Figure 3.48: Morphology of DP spun scaffolds using a small base electrode. a) 20wt% DP spun from 
100% HFIP; b) 20wt% DP spun from 100% CHCl3. Scale bars are 20 µm.  
3.3.3.4 Combined electrospinning and spraying 
Attempts to enhance DP scaffold porosity using the combined electrospinning and 
electrospraying technique (section 2.20) failed. Microscope images taken approximately 
5min post collecting showed how DP fibres would collapse down the sides of the beads 
and thereby, breaking fibre continuity (indicated by the black arrow, Figure 3.49.a-b). 
Not only did the unevaporated solvent dissolve the fibres but also the nearby beads as 
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3.49.c-d). The result was a weak scaffold that collapsed on itself after time. 
Figure 3.49: Combined electrospinning and spraying with DP and PEG. (a-b) microscope images scale 
bars are 100 and 25 µm; (c-d) SEM images scale bars are 200 and 20 µm. 
Combined electrospinning and spraying was successful in producing high-porosity 
scaffolds with enhanced healing for Pel (shown in section 3.2.5) as well as previous 
studies [148, 233, 238]. Failure to apply this technique to DP mainly was due to the 
delayed evaporation rate of HFIP from the fibres after collection (explained in section 
3.3.3.2). The microparticles were heavily affected by the presence of unevaporated 
HFIP from the DP fibres due the fluorinated alcohol also being a PEG solvent. 
3.3.3.5 Collecting temperature 
An alternative approach to successfully prevent the DP/HFIP fibre fusion phenomenon 
was required after manipulation of the previously mentioned parameters were 
insufficient (flow rate, polymer concentration, solvent ratios and base electrode area).  
RTE LTE 
  
Figure 3.50: The influence of collecting temperature on DP electrospun fibres. A concentration of 
20wt% (50:50% CHCl3/HFIP) and the small (25 mm) collector were used. a) RT (22C); b) low 
temperatures (approx. -70C). Scale bars are 20 µm.  
The new approach involved the use of dry ice (-78.5C) to cool the collector to 
temperatures below the solvent freezing points (-60.3 and -3.3C for CHCl3 and HFIP) 
a) b) c) d) 
a) b) 
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so that fibres would snap freeze  into their volumetric positions upon contact with the 
collector s surface. This way, additional time would be provided for solvent to 
evaporation and/or sublimation before returning to a liquid phase. The influence of 
LTE on scaffold morphology was explored and optimised for a low or high DP 
concentration (20 or 24wt%) collected on a small or large collector (25 or 75 mm).  
The 25 mm collector, filled with dry ice, successfully lowered the degree of fusion for 
20wt% DP spun fibres. The transformation of fibres merging with neighbouring fibres 
in the case of room temperature electrospinning (RTE) to cylindrical and observably 
less fused fibres when collected on a cold collector (LTE) can be seen in Figure 3.50. 
The maximum collection time was <10 min before the collector started to heat up 
(noted when a clear metallic surface was exposed instead of white icicles) and had to 
be refilled with dry ice. 
100% CHCl3 (RTE) 100% HFIP (RTE) 50:50% (RTE) 50:50% (LTE) 
    
Figure 3.51: Electrospun fibre fusion correction by low temperature collecting. A concentration of 
24wt% and the large collector (75 mm) was used. The percentages refer to the solvent content by 
weight. Scale bars are 50 µm. 
The LTE process was optimised to further reduce fibre fusion (by increasing polymer 
concentration to minimise fibre solvent content) and to extend the collection time (by 
using a larger 75 mm collector). Spinning at a concentration of 24wt% resulted in 
(Figure 3.51): smooth individual fibres (approximately 10µm) when RTE from pure 
chloroform, heavily fused fibres when RTE from pure HFIP, less fused fibres when RTE 
from a 50:50% mixture and finally smooth individual fibres (approximately 5 µm) when 
LTE of the mixed solvent system. The 75 mm collector loaded with dry ice provided 
at least 1hour of continuous LTE.  
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3.5 hours of collected LTE 48 hours of drying 
  
Figure 3.52: LTE with a dry ice and the large collector. a) 3.5 hours of 24wt% DP LTE; b) 48 hours 
post drying process. 
Collecting LTE for 3.5 hours (and refilling the ice chamber every 30 min) resulted in 
an icy-fibrous composite layer (of ~10 mm thick) around the circumferential surface of 
the large collector (Figure 3.52). After 48 hours of drying, LTE scaffolds had an average 
porosity that was 40% higher than those obtained by RTE (83±3 to 43±11%, 
P<0.001). Interestingly, micro indentations (4.7±2.2µm) appeared on abluminal fibre 
surfaces at >3.5 hours of LTE (fibres collected at 10mm away from the collector s 
surface, Figure 3.53). This limitation, 3.5 hours of collecting time, was a trade-off 
between accompanied micro indentations and maximising scaffold thickness (as an 
attempt to reach 1 mm) for implant ready production. 
Lumenal Ablumenal 
  
Figure 3.53: SEM images of LTE fibre morphology. a) luminal smooth fibres and b) micro indentations 
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The fusion of DP fibres electrospun from solvents that contained HFIP was resolved 
by LTE. A possible explanation could be that the HFIP inside the fibres reached a 
solid phase once captured by the cooled collector and evaporated during the drying 
process without dissolving the skin of the DP fibres. Furthermore, the structural 
porosity of DP scaffolds was increased by LTE when compared to RTE due to two 
possible reasons. Firstly, LTE has been known [205, 208, 236, 237] to be an effective 
porosity enhancement technique by including inter-fibre ice crystals that are formed 
from local air moisture to act as temporary space holders (much like the PEG 
microparticles from section 3.2.3). Secondly, LTE also increased scaffold porosity by 
preventing fibre fusion. This allowed fibres to form three dimensional stacks instead of 
merging into the same plane as in the case of RTE. The indentations observed on the 
ablumenal fibre surfaces (Figure 3.53) were made by the ice crystals due to the core 
fluid (DP/HFIP) not being completely frozen at roughly 10mm away from the 
collector s surface. It is proposed/assumed that the prolonged collection of material had 
an isolation effect that was significant enough to prevent the entrapped fluid inside the 
last layer of collected fibres to reach its solid phase. Thus, the unevaporated HFIP was 
still able to dissolve or swell the fibre s skin to such an extent that allowed the inter-
fibre ice crystals to leave imprints. Dimpled fibres could be useful for applications where 
additional fibre surface area is required. 
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3.3.4 Biodegradable implant production 
The degradable implants produced for the subcutaneous assesment included a low 
temperature collected DP control scaffold (LTE), a 5wt% dexamethasone incorporated 
DP scaffold (LTE+Dex) and one containing 5wt% of the modified heparin, 
HepTBA500, (LTE+Hep). Figure 3.54 presents each implant group with a top view 
and close-ups of both lumenal and ablumebal topographies. 



















Figure 3.54: Degradable scaffold selection for subcutaneous implantation. Scale bars for the low 
(lumenal) and high (lumenal and ablumenal) magnification SEM images are 100 and 10 µm 
respectively.  
LTE of DP (solution viscosity at RT was 6850±8 cPoise) produced fibres with an 
average diameter of 5.19±1.2 µm and a scaffold thickness of 636±96 µm (Figure 3.55.a). 
Drug incorporated fibres had comparable diameters (P>0.09) which were collectively 
smaller than that of the drug free scaffolds (P<0.001), 4.24±1.1 µm and 3.74±1.5 µm 
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for dexamethasone and heparin blended fibres respectively. Adding salts to an 
electrospinning solution is known to increase its conductivity (proportional to 
concentration [405]), which result in further fibre stretching and therefore, reduced fibre 
diameters [406]. Thus, adding drugs to DP solutions (especially ionic products) were 
also expected to produce thinner fibres. Supporting this assumption and the results 
from the current study, reduced fibre diameters have been reported as a result of 
heparin [243] and dexamethasone [244, 323] blend electrospinning. The porosity of LTE 
scaffolds was reduced (as shown in Figure 3.55.b) from 83.0±3% to 78.3±8% or 
73.3±4% for scaffolds containing dexamethasone or heparin respectively (P<0.01), 
LTE+Dex scaffolds were more porous than LTE+Hep (P<0.05). 
   
  
 
            LTE | LTE+Hep 
 iv) 
Figure 3.55: Characteristics of degradable implant groups. a) fibre diameter [>40 fibres/image]; b) 
scaffold porosity [n = 40]; c) fibre orientation index [n = 8]; d) scaffold pore size [>300 pores/image]; 
e) frequency of total pores between 10-25 µm [>2400 pores/group]; f) heparin confirmation stains 
(Toluidine blue). 
All degradable implant groups had similar orientation indices (P>0.6), LTE (0.17±0.1), 
LTE+Dex (0.18±0.1) and LTE+Hep (0.16±0.1, Figure 3.55.c). Drug incorporation 
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from 16.39±11 µm (44% of the total pores were within the range of 15< <25 µm) 
to 11.56±9 µm (40% were 15< <25 µm) and 10.85±10 µm (30% were 
15< <25 µm) for dexamethasone and heparin respectively (P<0.001). The average 
scaffold pore sizes between the drug incorporated groups were not significantly different 
(P>0.3). The smaller pore sizes of LTE+Hep/Dex scaffolds may be attributed to the 
decrease of fibre diameters and lower porosities associated with the inclusion of drugs 
(lower porosities and smaller fibres are theoretically expected to produce smaller pore 
sizes, =  −  , [211, 407]). The presence of heparin in LTE+Hep groups was 
confirmed with positive (purple) Toluidine blue stains i) immediately post processing 
and after ii) 1 min, iii) 48 hours and iv) 45 days of in vitro incubation (Figure 3.55.i-
iv).  
Drug-free DP scaffolds were slightly stronger in the longitudinal direction (0.56±0.1 
MPa) than in the circumferential direction (0.32±0.2 MPa, P<0.01), as shown in Figure 
3.56.a. Conversely, heparin incorporated scaffolds were stronger in the circumferential 
direction (0.41±0.1 MPa) than that of UTS in the longitudinal direction (0.21±0.1 
MPa) while LTE+Dex was approximately 0.46 MPa in both directions (P>0.4). 
Although all three groups had similar orientation indices, fibres were more 
circumferentially aligned when a drug was added to the spinning solution (higher 
conductivity) when compared to the control fibres. Effectively, drug incorporation 
decreased mechanical strength in the L direction (more extreme in the case of Hep) 
and increased C strength (more extreme in the case of Dex). The maximum elongation, 
presented in Figure 3.56.b, was similar for each group in both circumferential and 
longitudinal directions (P>0.1). Collectively, drug incorporated scaffolds reduced the 
maximum elongation of LTE (123±14%) by 57% (66±15%, P<0.001) and 81% 
(42±13%, P<0.001) for LTE+Dex and LTE+Hep respectively. The elastic modulus 
(Figure 3.56.c) of LTE was more than double in the longitudinal direction (1.91±0.4 
MPa) when compared to the modulus in the C direction (0.79±0.2 MPa, P<0.001). 
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Inversely, heparin incorporated scaffolds were half as stiff in the longitudinal direction 
(0.90±0.2 MPa) compared to the stiffness in the direction circumferential (1.91±0.4 
MPa, P<0.001) while dexamethasone incorporated scaffolds had an E of approximately 
1.7 MPa for both testing directions (P>0.7). On average, DP scaffolds had a Young s 
modulus in the region of 1.50±0.5 MPa regardless of drug incorporation or testing 
direction. The addition of biological agents influenced the electrohydrodynamics of the 
fibre formation process and resulted in significant morphological alterations (fibre 
diameter, porosity and pore sizes were affected). It is therefore no surprise that the 
drug incorporated scaffolds had slightly different mechanical properties compared to 
the drug-free samples. Electrospinning of Dex blended fibres was formely reported to 
produce scaffolds that were mechanically weaker (lower E, UTS and maximum 
elongation) than their drug-free controls [323]. Likewise, heparin incorporated scaffolds 
were also previously mentioned to have poor mechanical properties [313]. 
   
Figure 3.56: Mechanical properties of degradable implant groups. a) Ultimate tensile strength (UTS), 
b) maximum elongation (� ) and c) elastic modulus (E). [n = 6]  
The in vitro release of HepTBA from LTE+Hep scaffolds over a period of three months 
is presented in Figure 3.57. A cumulative dosage of 40, 47 and 48% of the total load 
(indicated by the red line) was delivered on 1, 7 and 90 days respectively. Effectively, 
the first half of the incorporated HepTBA was released within the first week and the 
other half (at 25 mg/g) remained embedded within the fibres for the rest of the 3 month 
study (i.e. no measurable elution took place past 7 days). The assumption that the 
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confirmation of the presence of heparin at 45 days (a positive purple stain as previously 
demonstrated in Figure 3.55.f.iv).  
   
Figure 3.57: HepTBA in vitro release profiles from degradable implants. a) cumulative and b) 
instantaneous release profiles; c) fitted Korsmeyer-Peppas model for 90 days in vitro [n = 3]. 
The release of dexamethasone from LTE+Dex scaffolds over a period of three months 
is presented in Figure 3.58. The cumulative release of dexamethasone was 9, 36 and 
78% of the total the dosage on 1, 7 and 90 days respectively. In contrast to the HepTBA 
elution profile, dexamethasone followed a near constant instantaneous release rate (3-
5 mg/g per day) for the first week and depleted approximately 80% of its initial dosage 
(50 mg/g) by the end of the study. Table 3.2 are the results for fitting theoretical 
release models to the actual in vitro data obtained from measuring the release 
concentrations of both HepTBA and Dex loaded scaffolds. 
   
Figure 3.58: Dexamethasone in vitro release profiles from degradable implants. a) cumulative and b) 
instantaneous release profiles; c) fitted Korsmeyer-Peppas model for 90 days in vitro [n = 3].  
























































































































































k = 0.13� = 0.49
r2 = 0.99
c)
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kinetics of both 5wt% incorporated HepTBA and Dex from LTE scaffolds. This model 
was fitted (r2 = 0.86) for the entire length of the HepTBA release study (due to the 
validation of less than 60% release, i.e. U90days/Uꝏ<0.6 [329]) which resulted in a rate 
constant ( ) of 0.46 and a release exponent (�) of 0.02.  
A comparison between the model and actual measurements are shown Figure 3.57.c. 
The release of dexamethasone followed a near perfect Korsmeyer-Peppas fit (r2 = 0.99) 
with a  value of 0.13 and a release exponent of 0.49 (Fickian diffusion, � = 0.5). The 
model was applied to only the first month of data, due to U90days/Uꝏ>0.6 and 
U30days/Uꝏ<0.6, and can be seen in Figure 3.58.c. 
Table 3.2: Theoretical models for LTE release kinetics of HepTBA and Dex 
Model/ Zero-order First-order Higuchi Korsmeyer-Peppas 
Drug k r2 k r2 k r2 k � r2 
HepTBA 2.96E-04 0.11 3.09E-04 0.09 1.66E-03 0.70 4.60E-01 0.02 0.86 
Dex 6.78E-03 0.65 1.95E-03 0.44 1.06E-01 0.77 1.32E-01 0.49 0.99 
          
Diffusion is considered to be the main mechanism behind the release kinetics of 
bioactive molecules from electropsun scaffolds [241–244, 324–326]. Many factors may 
influence their diffusion profiles, such as fibre/scaffold architecture, polymer 
degradation, solubility of both drug and polymer or the physiological conditions. 
Although there were slight architectural differences (fibre diameter, pore size and 
porosity), it is likely that the primary reason for the distinguishable release profiles for 
HepTBA and Dex was because of their vast difference in molecular size. Dex, being the 
smaller molecule, had a faster delivery rate when compared to that of HepTBA due to 
it being able to diffuse faster through the polymeric matrices [329], as demonstrated in 
section 3.3.2.3. Dex has been incorporated into electrospun scaffolds [239, 244, 322, 
323]. In one study, PEOT/PBT electrospun scaffolds containing Dex at 0.5-2wt% [323] 
showed delivery characteristics comparable to that of the current study with 20 and 
60% released on day 2 and 28 respectively (� = 0.33). This was similar to that of the 
release for LTE+Dex (16 and 67% for day 2 and 30, � = 0.49). These corresponding 
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results are confirmation that dexamethasone, blended into electrospun scaffolds, 
released via Fickian diffusion. On the other hand, the initial burst release and 
subsequent plateaued profile for HepTBA from LTE+Hep scaffolds was consistent with 
a previous incorporation and release of 1,5 and 10wt% HepTBA from PLCL electrospun 
scaffolds [310]. The authors showed that the cumulative release of HepTBA did not 
exceed 36/53% for the incorporated loads of 5/10wt% even after 4 weeks in vitro, which 
agrees with the current study (5wt% HepTBA from LTE+Hep did not exceed the 50% 
load even after 12 weeks). Although the original authors of HepTBA [310] did not 
analyse its release kinetics, others have shown that heparin sodium eluted from PCL 
electrospun scaffolds, at a concentration of 0.5wt%, followed a diffusion model with an 
exponent of �  = 0.1 [243] (HepTBA from the current study was �  = 0.02). 
Furthermore, profiles resembling the release of HepTBA, Figure 3.57, was also observed 
for the release of DNA (both heparin and DNA are considered to behave as 
polyelectrolytes, as mentioned in section 3.3.2.4) from PLGA/PLA-PEG electrospun 
scaffolds [241], as well as heparin sodium from PU films [408]. The evidence provided 
in literature, the in vitro release results from the current study together with the 
positive stains for heparin after 45 days of incubation (Figure 3.55.f.iv), supports a 
consensual description. That is, the release of HepTBA from DP electrospun scaffolds 
provided an initial burst release of heparin molecules followed by a second stage that 
may be regarded as surface modification rather than a sustained diffusive elution. 
Fortunately, such a heparin profile might be beneficial for medical devices such as 
vascular grafts. In this application, the initial, post implantation stages are crucial to 
prevent SMC proliferation and avoid intimal hyperplasia which usually causes graft 
failure [243]. Therefore, a LTE+HepTBA scaffold would not only inhibit initial SMC 
proliferation but will also provide an antithrombotic surface and promote tissue 
regeneration, these are known properties of scaffolds with heparinised surfaces [60, 292, 
338, 409]. 
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3.3.5 Healing assessment of biodegradable implants 
This section includes results and discussion for the in vivo assessment (rat subcutaneous 
model) of the specifically selected degradable scaffolds in terms of quantified tissue 
ingrowth followed by collagen, cellular, macrophage and vascular density. 
3.3.5.1 Scaffold tissue ingrowth 
Representative H&E (the dark pink areas are positively stained tissue) micrographs for 
the degradable implant groups are shown in Figure 3.62 for 7, 14, 28 and 84 days 
respectively. 





















    
Figure 3.59: Representative H&E micrographs of degradable implant groups. Scale bars are 500 µm. 
Degradable scaffolds had similar ingrowth percentages after the first week, between 13-
25% (P>0.1). LTE+Dex followed a linear ingrowth rate over the period of 84 days 
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(1.05T+4.4%, r2 = 0.99) while LTE and LTE+Hep both had rapid initial trends 
followed by plateaued curves towards the last time point (all groups ended between 88-
98%, Figure 3.61). The ingrowth for heparin incorporated scaffolds were slightly lower 
than that of the control groups (43.0±14 and 72.0±5% compared to 68.3±12 and 
84.4±8%, P<0.05) but higher than the dexamethasone incorporated scaffolds (17.1±9 
and 40.1±24%, P<0.05) at time points 2 and 4 weeks. Scaffold degradation was 
observable at 84 days as indicated by the red arrows in Figure 3.59 with respect to the 
internal ridges described in Figure 3.60. 
 
Figure 3.60: Internal ridges found in the cross section of LTE scaffolds. The red arrows indicate the 
layers of fibre laminations. Scale bar is 100 µm. 
The ingrowth profiles for heparin and the drug-free LTE scaffolds suggested that the 
presence of HepTBA had little to no influence on the ingrowth rate of cells regardless 
of each scaffold s architectural differences (LTE+Hep had a lower porosity and smaller 
pore sizes when compared to LTE, Figure 3.55.b). On the other hand, the delayed 
tissue ingrowth for the LTE+Dex scaffolds, could be attributed to the architectural 
differences caused by the drug incorporation process and/or the localised delivery of 
dexamethasone. The changes in scaffold porosity/pore sizes seems to be an unlikely 
explanation when considering that the architecture of Dex loaded scaffolds were a closer 
match to that of the drug-free ones compared to the LTE+Hep scaffolds (which had 
nearly un-affected ingrowth rates). A more plausible explanation could be that the 
suppressed tissue ingrowth during the first month of the LTE+Dex scaffolds was caused 
by the sustained delivery of most of the dexamethasone load over that same period (in 
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vitro prediction was ~70% of the total dose within 30 days, Figure 3.58), and that full 
tissue ingrowth was only achievable at the end of the study when the drug was nearly 
depleted.  Such an explanation is also be in line with others who showed that Dex 
incorporated scaffolds limited in vivo cellular infiltration while the drug maintained a 
sustained delivery [239, 314, 316]. The bulk degradation of the scaffold material, 
observed with reference to the internal ridges (Figure 3.59), appeared at a time point 
(>28 days) that was comparable with timelines from literature [21, 273] and in vitro 
results from the current project (Figure 3.35 from section 3.3.2.3). Several studies have 
concluded that the hydrolytic degradation rates for PCL scaffolds were 
indistinguishable between in vitro and in vivo [410, 411] while others suggested that 
degradation occurred faster in vivo due to its unique dynamics and enzymatic 
environment [108]. Nevertheless, a mass and molecular weight loss of ~20% (own data, 
section 3.3.2.3) and >56% (literature [21, 273]) was anticipated for three months of in 
vivo DP scaffold degradation. 
 
Figure 3.61: Tissue ingrowth of degradable implant groups. Graph insert: scaled x-y plot of tissue 
ingrowth. 
3.3.5.2 Collagen density 
Representative Picrosirius Red (PSR) micrographs for the degradable implant groups 
are shown in Figure 3.62 for 7, 14, 28 and 84 days (collagen is represented by the red 
areas). There were no significant differences of collagen density between the degradable 
implant groups at any of the measured time points (P>0.1). Collectively, the 
percentage of collagen area per tissue area increased at rate of approximately 6%/week 
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between 7 and 28 days (3-23%) and slowed down to 1.3%/week between 28 and 84 
days respectively (23-33%, Figure 3.63). 





















    
Figure 3.62: Representative PSR micrographs of degradable implant groups. Scale bars at 500 µm. 
A lower collagen density would have been expected for scaffolds releasing 
dexamethasone due to the anti-inflammatory agent s ability to supress the infiltration 
of host immune cells and thereby, moderate collagen deposition [314]. This would have 
hold true given that inflammatory cells, i.e. activated macrophages, secrete cytokines 
such as monocyte chemoattractant protein-1 (MCP-1) that are known for the 
recruitment of host monocytes and thereby promoting EC, SMC, elastin and collagen 
formation [30, 238, 412, 413]. Although similar outcome was expected for the current 
case study, the collagen densities for the LTE+Dex scaffolds were not significantly 
lower and can therefore not draw the same conclusions. Nevertheless, the overall 
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deposited collagen was observed to be well organised and showed minimal signs of scar 
tissue formation - only near the fused ridges that were formed during the LTE process 
(as shown in Figure 3.62). 
 
Figure 3.63: Collagen deposition of degradable implant groups.Graph insert: x-y plot representing the 
combined collagen density of all groups. 
3.3.5.3 Cellular density 
Representative ED1+ micrographs for the degradable implant groups are shown in 
Figure 3.64 for 28 and 84 days respectively (blue = nuclei, red = macrophages). 
Time (d) LTE LTE + Dex LTE + Hep 
28 
   
84 
   
Figure 3.64: Representative ED1 micrographs of degradable implant groups. Scale bars are 100 µm 
The DAPI area per measured tissue area (ADAPI/Atissue) within the degradable scaffold 
groups were similar at each of the measured time points (P>0.1, Figure 3.65). The 
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cellularity of heparin incorporated scaffolds was twice as high on 28 days (0.35±0.1 
µm²/µm²) compared to that at 84 days (0.17±0.1 µm²/µm², P<0.05), while the density 
for the other groups were relatively constant over time (P>0.3). The nuclei count per 
Atissue was constant (on average 3025±380 nuclei/mm2) for each degradable group over 
both time points (28 and 84 days, P>0.4) and was also comparable within the groups 
(P>0.1). 
 
Figure 3.65: Cellular density of degradable implant groups. Cellular density in a) area and in b) 
number.  
An overal cellularity of 3000 nuceli/mm2 obtained by LTE scaffolds, with or without 
drugs, is comparable to that of the high-porosity Pel groups developed in this project 
as well as other porosity-enhanced scaffolds from literature (as explained in section 
3.2.5.3). Moreover, maintaining a healthy cellular density over a prolonged period of 
three months is not only essential for implant survival but also beneficial towards 
scaffold degradation [238]. 
3.3.5.4 Macrophage density 
The quantified macrophage densities are presented in Figure 3.66 from the positively 
stained ED1 areas (examples are shown in Figure 3.64). There were no differences in 
ED1+ area (AED1+) nor the number of macrophage per tissue area (Atissue) between any 
of the degradable groups at any of the measured time points (P>0.2). Although all 
groups appeared to have a decline in macrophage density over time (28 compared to 
84 days), only dexamethasone incorporated scaffolds had slightly lower densities 
(0.105±0.108 µm²/µm² | 765±678/mm² compared to 0.006±0.011 µm²/µm² | 
a) b) 
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48±64/mm², P<0.05) while LTE and LTE+Hep had no differences between the time 
points (P>0.1). Collectively, macrophage density for all three groups was 0.1 µm²/µm² 
| 590 macrophages/mm² at 28 days and 0.01 µm²/µm² | 113 macrophages/mm² at 84 
days respectively. 
 
Figure 3.66: Macrophages per tissue area of degradable implant groups. Macrophage density in a) area 
and in b) number.  
The density of infiltrated inflammatory cells, macrophages in particular, is an 
acceptable indication of foreign body response towards TE scaffolds [55, 239, 292, 414]. 
A higher density of activated macrophages, in general terms, has been associated with 
a greater immune response. Vacanti et al. have shown that the localised delivery of 
Dex (at a total load of 5.7wt%) from PCL or PLLA electrospun scaffolds were able to 
reduce the foreign body response (a lower macrophage density followed by a thinner 
fibrous capsule) in a rat subcutaneous model [239]. The quantification of macrophages 
for the current Dex releasing scaffolds (LTE+Dex) was unable to produce a similar 
outcome. Sample variation and/or the time frame selected for quantification (inability 
to measure earlier time points, <28 days, due to minimal tissue ingrowth - Figure 3.59) 
were possible limitations for not being able to show a significant in vivo effect of 
localised dexamethasone delivery. Despite its mentioned influence of moderating 
inflammation [288, 289], heparin releasing scaffolds did not affect the foreign body 
response, in terms of macrophage density, in the current case study nor in did it in a 
previous study of heparinised PU foams [292]. 
a) b) 
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3.3.5.5 Vascular density 
Representative CD31+ (the dark areas are endothelial cells) micrographs for the 
degradable implant groups are shown in Figure 3.67 for 28 and 84 days respectively. 
The red line indicates the base of the scaffold for LTE+Dex at 28 days when tissue 
ingrowth was limited to the scaffold boundaries. 
Time (d) LTE LTE + Dex LTE + Hep 
28 
   
84 
   
Figure 3.67: Representative CD31 micrographs of degradable implant groups. Scale bars are 100 µm. 
The red line indicates the scaffold boundary. 
The vessel area (Avessels/Atissue) of LTE, LTE+Dex and LTE+Hep scaffolds were not 
significantly different at 28 days of implantation (P>0.1, Figure 3.68). At the end-point 
(84 days), the vessel area for the heparin incorporated scaffolds (0.053±0.01 µm²/µm²) 
was nearly twice as high as that of the control groups (0.028±0.01 µm²/µm², P<0.01) 
and 4 times higher than the dexamethasone incorporated scaffolds (0.013±0.01 
µm²/µm², P<0.01). LTE+Dex was significantly lower than LTE (P<0.01). LTE+Hep 
was the only group that obtained a significantly higher vessel area over time (from 28 
to 84 days, P<0.01). 
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Figure 3.68: Blood vessels per tissue area of degradable implant groups. Vascular density in a) area 
and in b) number.  
Heparin is known for enhancing the vascularisation process [290–293]. The presence of 
heparin inside LTE+Hep scaffolds did eventually highlight this effect, although not 
significant at 28 days, by producing enhanced vascular densities at the final time point. 
This was most likely due to heparin s ability to bind to proangiogenic growth factors 
(such as bFGF and VEGF) which in turn, were able to form more endothelial cells 
inside the scaffolds. Besides being a potent anti-inflammatory agent, dexamethasone 
releasing scaffolds have been recognised to also exhibit anti-angiogenic effects [415, 416]. 
Although the results from the previous section (3.3.5.4) did not show the anti-
inflammatory effects of Dex, a secondary in vivo effect was confirmed by the reduced 
vascularisation of LTE+Dex scaffolds at the final time point. Nevertheless, this 
outcome was anticipated due to a theoretical decline in available proangiogenic growth 
factors as a result of less infiltrating inflammatory cells (i.e. macrophages). 
  
a) b) 
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4 CONCLUSION 
In this chapter, conclusions are formulated for the investigations that led to the 
development of biostable and biodegradable TE scaffolds respectively: 
Development of biostable electrospun scaffolds: 
 Optimal conditions to successfully electrospin fibres (biostable, Pel) and 
electrospray particles (water-soluble, PEG) were established. As expected, 
electrospinning at a higher flow rate produced thicker fibres while speeding up the 
collector improved fibre alignment (and the mechanical strength in the 
circumferential direction). Selecting a solvent with a low dielectric constant and 
increasing the solution concentration resulted in the desired increase in diameter 
of electrosprayed particles. Increasing molecular weight on the other hand, had a 
limited effect on particle size as short strand fibres would be produced beyond a 
certain level. Interestingly, electrospraying at close distances (using conditions 
presented in this project) also altered the morphology of particles from 
microspheres to short strand fibres. Such geometries may be useful for future drug 
delivery and further TE developments. 
 A combined electrospinning and electrospraying technique was used to increase 
the porosity of conventional electrospun scaffolds (<80%, LP). Selective removal 
of 30 µm porogens (electrosprayed from a triple array of spinnerets) from its 
original composite material of 2 µm fibres (produced by simultaneous 
electrospinning from a single source) was found to be an effective strategy to 
produce highly porous scaffolds (>90%, HP). 
 Furthermore, heparin (Hep) was successfully immobilised by hydrogel grafting 
and covalent attachment to fibre surfaces of the high-porosity scaffolds 
(HP+Hep). 
 Porosity-enhanced scaffolds were found to be mechanically weaker and less stiff 
University of Cape Town  WJ van den Bergh 
 
 Chapter: Conclusion 154 
in both testing directions than the LP groups, but preserved sufficient structural 
integrity. The heparinisation process slightly reduced scaffold porosity, increased 
the average fibre diameter and result in a more rigid scaffold (fibres also appeared 
to be bonded at fibre-fibre interfaces) compared to an un-heparinised counterpart. 
Although both LP and HP groups had similar orientation indices and 2D pore 
sizes, fibres of HP scaffolds were observed to be individually 3D shaped wave like  
(a similarity to actual ECM) due to the inclusion and removal of 30 µm spheres, 
rather than straight (as were the case for LP groups). 
 The healing response towards biostable scaffolds presented in this project (LP, 
HP and HP+Hep) were evaluated in a rat subcutaneous implantation model for 
7, 14, 28 and 84 days. Cellular infiltration into the HP groups was significantly 
improved with respect to the limited tissue ingrowth observed for LP scaffolds 
even after three months of implantation. This outcome is believed to be due to 
the additional pores created by the removal of 30µm porogens that was not only 
responsible for i) the architecture that facilitated cells to penetrate the entirety of 
the scaffold, but also ii) providing enough inter-fibre spaces for effective diffusion 
of nutrients and cellular waste that ensured long-term cellular survival. With 
regards to HP+Hep, the observed retardation of early tissue ingrowth, and the 
consequent delayed vascularisation, may have been the result of fibre-fibre bonds 
that impaired initial cellular infiltration. Heparinising high-porosity scaffolds did 
not further improve healing (especially in terms of vascularisation), but such TE 
scaffolds may be useful for applications such as vascular grafts or heart valves 
where anti-thrombotic surfaces are desirable. Nevertheless, the combined 
electrospinning and electrospraying technique presented in this project has much 
potential to produce TE scaffolds with improved healing capabilities. 
Development of biodegradable electrospun scaffolds: 
 In establishing electrospinning conditions for biodegradable fibres (DP), collecting 
at a higher velocity increased fibre orientation (as with Pel). Moreover, fibre 
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diameter correlated directly with solution concentration and indirectly with 
solvent conductivity. 
 Decreasing the size of the base electrode (e.g. 80 mm2 instead of 3600 mm2) was 
observed to reduce fibre diameter, increase pore sizes and fibre collection area due 
to a greater induced electric field (as predicted by mathematical modelling and 
visualised in 3D field simulations). A size adjustable base electrode may provide 
tissue engineers with additional control over the electrospinning process for future 
TE scaffold developments. 
 The addition of HFIP (required as a co-solvent to solubilise heparin in the 
spinning solution), caused fibres to fuse to adjacent ones. This phenomenon is 
believed to be a result of delayed HFIP evaporation due to carbonyl-alcohol 
(polymer-solvent) hydrogen bonding. Low temperature electrospinning (LTE) was 
used to successfully reduce fibre fusion and increase scaffold porosity and pore 
sizes.  
 Dexamethasone (Dex) was successfully incorporated into biodegradable scaffolds 
by dissolving the drug in the processing solution prior to low temperature 
electrospinning (LTE+Dex). 
 Hep was modified to its amphiphilic salt of heparin-tributylammonium (HepTBA) 
to render it soluble in the organic solvent system. This modified Hep retained its 
(in vitro) bioactivity before and after successful inclusion and elution into/from 
biodegradable scaffolds (LTE+Hep). 
 Compared to heparin sodium, HepTBA has shown to have i) no adverse cytotoxic 
effects during a three-day viability study using rat smooth muscle cells and have 
ii) similar anti-thrombotic properties at equimolar concentrations using whole 
human blood.  
 The in vitro release of incorporated Dex from LTE+Dex followed a near perfect 
Fickian diffusion model that delivered almost its entire dosage after three months. 
Release of HepTBA, from LTE+Hep scaffolds, had an initial burst release followed 
University of Cape Town  WJ van den Bergh 
 
 Chapter: Conclusion 156 
by a second stage that could be regarded more of a surface modification rather 
than an elution due to half of its dose still embedded into the scaffolds even after 
three months of incubation. The distinguishable elution profiles for these drugs 
may have been due to their vast difference in molecular weight which resulted in 
different release kinetics (HepTBA, being a much larger molecule than Dex, 
defused at a slower rate). 
 Incorporation of bioactive molecules affects the electrohydrodynamics of the 
electrospinning process which impacts both scaffold architectural and mechanical 
properties. A mechanically weaker, less porous scaffold with thinner fibres and 
consequently, smaller pores can be expected when incorporating either Dex or Hep 
into DP scaffolds. 
 The healing response towards biostable scaffolds (LTE, LTE+Dex and 
LTE+Hep) were also evaluated in a rat subcutaneous implantation model for 7, 
14, 28 and 84 days. Although Dex is an anti-inflammatory agent, the localised 
delivery of this drug from incorporated scaffolds (LTE+Dex) showed some 
reduction in cellular infiltration but, had no effect on scaffold inflammation. On 
the other hand, the localised delivery of Hep from LTE+Hep scaffolds showed a 
similar tissue ingrowth rate and, an enhanced scaffold vascularisation. Such an 
effect was as expected due to Hep s known ability to bind to pro-angiogenic 
growth factors, and thereby, promoting blood vessel formation. This, together 
with its anti-thrombotic properties, could make LTE+Hep scaffolds especially 
useful for applications such as vascular grafts and TE heart valves. 
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5 RECOMMENDATIONS 
Although techniques were developed to produce tissue regenerative scaffolds with some 
success, many unexplored opportunities emerged. Therefore, this chapter provides 
suggestions for the continuation of the current research with regards to specific sub-
topics. The recommendations below are either to improve or expand knowledge towards 
developing TE scaffolds that would promote ideal device-host integration: 
An outlook on electrospraying 
 Empirical formulas with parametric inputs (e.g. concentration, molecular weight 
and solvent properties) could be useful to predict and control PEG porogen 
sizes. Therefore, the creation of models based on the current scaling laws and 
validation with a large set of experimental data is recommended. 
 Establishing optimal parameters (concentration, molecular weight and solvent 
system) for various polymers to controllably produce elongated particles (i.e. 
particles on the verge of electrospinning). 
 Investigation of elongated particles as potential drug delivery devices for injectable 
medicines. Elliptical shaped particles may have the advantage of undergoing 
fewer collisions in a stream-line circulatory system compared to spherical 
geometries. 
 Using knowledge obtained from this thesis to launch an investigation into short 
strand fibres as structural reinforcements for implantable TE devices (e.g. the 
leaflets of heart valves or inside hydrogels). 
An outlook on electrospinning 
 Studying the effect(s) on scaffold morphology (diameter and pore size) by 
adjusting the length of the charged needle that is extended beyond the base 
electrode (expected outcome: a longer needle length should be associated with 
greater whipping radius). If this is a useful parameter, design a mechanism that 
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could adjust the length in real-time. 
 Building on the simulations (using Coulomb3D) and observations of base 
electrodes with different surface areas from the current study, investigate the 
effect(s) of electrode geometry (e.g. squares compared to triangles) and its 
material selection (e.g. aluminium compared to copper). 
 Developing a climate controlled environment (with feedback on temperature and 
relative humidity) that could improve the reproducibility of the electrospun 
scaffolds. 
Combined electrospinning and electrospraying as a porosity enhancement technique 
 Finding the optimal porogen size by the same approach described in this project 
(suggested range to explore 5-50 µm) that would produce scaffolds with the best 
healing performances. Healing could be quantified in terms of macrophage 
(M1/M2) and vascular densities. For example, the optimal porogen size will be 
one used to created scaffolds with the lowest M1 and highest M2 and vascular 
densities. 
Suggestions for novel DegraPol® TE scaffold developments 
 Investigation of a bioactive, composite scaffold of electrospun DP fibres and 
electrosprayed DP microparticles. In this case, the bioactive agent (e.g. Dex or 
HepTBA) is incorporated into the particles instead of the fibres. That way, the 
need for LTE would be eliminated and the scaffold s structural integrity will not 
be compromised due to fibre-drug incorporation. 
 Exploration of DP scaffolds produced by melt electrospinning or melt 
electrospinning writing (MEW). Among other things, such technologies are 
attractive due to their no-solvent approach which may accommodate 
electrospinning of DP fibres. 
 Drug incorporation of bioactive agents into the core of DP fibres by co-axial 
encapsulation. Pilot studies of co-axial electrospinning were explored during this 
project. A complete needle design with initial results can be used as a starting 
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point (see hollow fibres as an example in Appendix A10). 
On scaffold drug incorporation 
 Recommendation of using core-shell DP fibres where HepTBA is incorporated into 
the shell and Dex inside the core. This way, HepTBA could provide an anti-
thrombotic surface and improve healing (as shown in this study) while allowing 
the release of Dex via diffusion through the wall of the material.  
 Investigation of DP or Pel electrospun scaffolds releasing bioactive nitric oxide 
(NO) for promoting angiogenesis. A comparison study of vascular densities 
produced by the in vivo release of NO compared to HepTBA would be useful 
information for future developments of producing vascular grafts. 
 Investigation of localised Dex delivery at different concentrations to show reduced 
scaffold inflammation. The current study was unable to show a lower 
inflammatory response at a load of 5wt%. It is suggested to investigate the 
release of Dex at a broader range of 3-7wt% (as highlighted in section 1.3.4). 
An outlook on the use of HepTBA for TE scaffolds 
 Evaluation of the healing responses (including long-term patency rates) of DP 
electrospun vascular grafts with incorporated HepTBA in a circulatory in vivo 
model using the current load of 5wt%. 
 Expanding on the current in vitro and in vivo success of HepTBA incorporated 
into electrospun DP scaffolds, this compound could also be explored using 
different materials (e.g. PCL, PLA or PGS) and other scaffold architectures (e.g. 
foams/sponges or even hydrogels).  
Notes on translating production techniques to develop vascular grafts 
 Using the current relationships developed between collecting speed and fibre 
orientation to downscale the electrospinning process to a smaller diameter 
collector (2-4 mm). Moreover, the mechanical properties could be optimised to 
match that of native blood vessels. Alternatively, fibre alignment may also be 
controlled by adjusting solvent ratios. For example, a higher degree of 
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anisotropy could be obtained by increasing the co-solvent content of THF or 
CHCl3 in the case of Pel (THF:DMF) or DP(HFIP:CHCl3). 
 Producing vascular grafts by means of LTE. It is proposed to downscale the 
process by circulating a cold fluid (e.g. ethanol at -70C) through a narrow tube 
(<4 mm) instead of using a large, dry ice filled enclosure as the collector. Unlike 
the current LTE collector, such a design would also ensure un-interrupted LTE 
for longer periods. 
 Investigation of an alternative approach to avoid fusion of neighbouring DP fibres 
that were electrospun from HFIP:CHCl3 solvent systems. Scaffolds could be 
collected with a charged fluid bath containing a solvent that is both miscible 
with HFIP and a DP non-solvent (e.g. water, isopropanol or methanol, Appendix 
A7). In this case, the HFIP entrapped in the fibres could have a faster diffusion 
rate towards the collecting fluid than the ambient air (as in conventional 
collecting) and might not have enough time to re-dissolve the polymer. 
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7 APPENDICES 
A1: Properties of organic solvents 















 [⁰C] � - 
Dioxane 2.2 40.0 5.E-15 32.0 16.4 1.30 101 1.03 
Anisole* 4.3 36.2 N/a N/a N/a 1.05 154 0.99 
Chloroform 4.8 27.2 1.E-10 169.0 25.9 0.57 61 1.48 
Chlorobenzene 5.6 33.0 7.E-11 9.5 18.8 0.80 132 1.11 
Ethyl acetate 6.0 24.0 1.E-09 78.0 23.0 0.43 77 0.90 
Tetrahydrofuran (THF) 7.6 28.0 5.E-05 133.0 21.0 0.55 66 0.88 
Trifluoroethanol (TFE)* 8.6 16.5 N/a N/a N/a 0.90 77 1.38 
Dichloromethane (DCM) 9.1 28.1 4.E-11 376.0 30.9 0.44 40 1.33 
Dichloroethane (DCE) 10.5 32.2 4.E-11 71.0 32.7 0.90 84 1.25 
Hexafluoro isopropanol (HFIP)* 17.8 16.1 N/a 120.0 N/a 1.02 58 1.60 
Cyclohexanone 18.2 34.5 5.E-18 3.1 28.0 2.20 156 0.95 
Isopropanol 18.3 21.7 6.E-08 35.1 54.6 2.00 82 0.79 
Acetone 20.6 23.3 5.E-09 194.0 35.5 0.33 56 0.79 
Ethanol 22.4 22.3 1.E-09 45.7 65.4 1.08 78 0.79 
Methyl pyrrolidone (NMP) 32.2 40.7 2.E-08 0.3 36.0 1.80 202 1.03 
Methanol 32.6 22.6 2.E-09 103.0 46.2 0.60 64 0.79 
Dimethylformamide (DMF) 36.7 35.0 6.E-08 3.8 40.4 0.82 153 0.95 
Dimethylacetamide (DMAC) 37.2 34.0 N/a 1.0 40.1 0.92 166 0.95 
Acetonitrile 37.5 29.1 6.E-10 71.0 46.0 0.38 82 0.78 
Trifluoro acetic acid (TFA)* 42.1 22.0 N/a N/a N/a 0.74 72 1.53 
Dimethyl sulfoxide (DMSO) 46.6 43.7 2.E-09 0.7 44.4 2.00 189 1.10 
Water 80.1 72.8 5.E-01 19.0 100.0 0.89 100 1.00 
Formamide 109.5 58.9 N/a 30.0 N/a 3.23 210 1.13 
Dielectric constant at 20⁰C (�), surface tension at 20⁰C (�), electrical conductivity (� ), vapour pressure ( ), polarity ( ), 
dipole ( , boiling point ( ) and specific gravity ( �). References: Handbook of organic solvent properties (Ian Smallwood, 
1996) [137] & *http://depts.washington.edu 
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A2: Additional DegraPol® review summaries 
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ratio; degradation rate can be controlled independent of 













n/a n/a 1.9 
8.4 
46 
n/a Rat sciatic nerve implantation  
 
[mass loss up to 88wt% over 24 weeks: lower b 

















Rat chondrocytes, osteoblasts and macrophages 
 
[Favourable cell adhesion and proliferation on DP surface; 
degradation products failed to induce any cytotoxic effects 
nor did it activate macrophages at low concentrations] 
n/a 
[363] 
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Relevant study/in vitro cell culture 
[conclusion] 










n/a n/a Rat chondrocytes 
 











n/a n/a Rat osteoblasts and human cell line HFO1 
 
[Cells attached and proliferated preferentially on DP 
surfaces] 
Rat subcutaneous implantation 
 
[Most areas within the pores were filled with fibrous 







n/a n/a 50-400 Hydrolytic degradation in buffered solutions 
 
[Degradation rate is determined by quantity and 
distribution of glycolyl-glycolate ester bonds; higher 











n/a n/a Human tracheal chondrocytes 
 
[Cultivated chondrocytes populated DP film and 












n/a n/a Human primary bladder smooth muscle cells 
 
[Cell grown on the DP foam as well as inside the pores; 



















DegraPol 10 n/a 10 Line cells (C2C12 and L6) and primary human satellite 
cells (HSCs); mechanical characterisation 
 
[DP membranes showed promising cellular response and did 
not produce toxic residuals; displayed satisfactory 








n/a 10-25 Fibroblast viability; hydrolytic degradation investigation 
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Relevant study/in vitro cell culture 
[conclusion] 















DegraPol n/a n/a n/a Myoblast culture 
 
[Improved myogenesis can be obtained and directed within 









n/a n/a Chondrocytes (static & dynamic) 
 
[DP fibrous scaffold successfully supported cell phenotype] 
 Rabbits for 8 weeks 
 
[DP provided a good substrate for fibrous tissue 
deposition with an excellent degree of neo-
angiogenesis (increasing number of positive CD31 






DegraPol n/a n/a n/a Fibroblasts & endothelial cells 
 
[Cells behaved differently on DP structures; fibroblast 
adhesion and proliferation was superior compared to 
endothelial cells. Furthermore, hemocompatibility was 



















[Cell proliferation was similar between PLGA and DP; 
cellular infiltration increased with increasing porosity] 
n/a 
[178] 







n/a n/a Whole human blood 
 
[No differences between PLGA and DP. Decreased fibre 
diameter triggered lower coagulation; larger fibres triggered 







DegraPol n/a  75 n/a n/a Rabbit Achilles tendon implantation for 12 weeks 
 
[Observable degradation of 50%; DP scaffolds had 
favourable tissue response and could potentially serve 
as a carrier for GFs] 
[269] 
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Relevant study/in vitro cell culture 
[conclusion] 






DegraPol new n/a 75 n/a n/a Rabbit Achilles tendon implantation for 6 weeks 
 
[Successfully prevented peritendinous adhesion; DP 








DegraPol15 n/a 71 n/a Smooth muscle cells 
 
[Cell proliferation and viability of DP was comparable to 
PLGA] 
Rat cystoplasty model for 8 weeks 
 
[DP revealed higher smooth muscle regeneration and 








n/a 75 45 (f) 
6 (f) 
n/a Rabbit Achilles tendon implantation for 12 weeks 
[No adverse reactions of tendon tissue; no difference 














DegraPol classic/new n/a 60-70 1.5-2.3 Electrospinning parameter study, drug release and rabbit 
tenocyte culture 
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(S)-2,6- diisocyanate methyl 
caproate 
α,ω-dihydroxy-poly(adipic acid-alt-
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~67 (1:1.5 hard-to-soft) 
2,2,4-trimethylhexamethylene 
diisocyanate 
















(ɛ-caprolactone)}-diol ~50 (equal amounts) 
2,2,4-trimethylhexamethylene 
diisocyanate 
















(ε-caprolactone)-diol Mn~2660 40 
2,2,4-trimethylhexamethylene 
diisocyanate 






























































ε co-glycolide 15 [271] 
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ε co-glycolide Mn~1000 15 [262] 
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A3: Supporting thromboelastography results 
Callibration data for individual TEG channels tested against the Level I biological control fluid 
Channel R[min] K [min] Angle [deg] MA [mm] 
A1 1.5 0.8 84 52.5 
A2 1.4 0.8 84.4 53.1 
B1 1.4 0.8 83.2 50.5 
B2 1.4 0.8 84.4 53.1 
C1 1.5 0.8 82.4 56.4 
C2 1.5 0.8 84 53.7 
D1 1.2 0.8 83.9 55.8 
D2 1.3 0.8 84.1 54.5 
Suggested  
Level I ranges 
0.0-3.0 0.0-2.0 77.0-89.0 44.0-61.0 
 
Additional data for TEG performance analysis of HepTBA products 
 
 





























































ɵ (deg) MA (mm) K (min)
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A4: Output of a typical mechanical tensile testing report
 
Specimen example: DegraPol® (DP0) film  
 
A5: Output of a typical statistical report   
 
Example: histological results (vascular density at 84days) of explanted electrospun scaffolds 
(DegraPol®, n = 6). 
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A6: Comparison of tissue ingrowth from different fixation media  
 
Tissue ingrowth of Pellethane® groups over 3 months 
 
 
Tissue ingrowth of DegraPol® groups over 3 months 
 
A7: Solvents tested for DegraPol® solubility at room temperature 
Solvent Score  Solvent Score 
Acetone 3  Ethyl acetate 3 
Acetonitrile 3  Ethylene glycol 4 
Anisole 2  Hexafluoro isopropanol (HFIP) 1 
Chlorobenzene 2  Isopropanol 4 
Chloroform 1  Methanol 4 
Cyclohexanone 2  Methylpyrrolidone (NMP) 2 
Dichloromethane (DCM) 1  Tetrahydrofuran (THF) 2 
Dichloroethane (DCE) 1  Toluene 2 
Dioxane 2  Trifluoro ethanol (TFE) 1 
Dimethylacetamide (DMAC) 2  Trifluoro acedic acid 1 
Dimethylformamide (DMF) 2    
Scores are allocated as: (1) solvent, (2) good swelling agent, (3) poor swelling agent and (4) 
non-solvent. 
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A8: Supporting NMR spectra of heparin ion-exchange process  
 
Heparin sodium (HepNa+) and heparin acid (HepH+) before/after removal of Na+ during 
the ion-exchange process. 
 
 
Tributylamine (TBA) before ion-exchange process 
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A9: Supporting numerical results of electric field simulations 
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Solid PU fibres (cross) Hollow PU fibres (cross) Hollow PU fibres (top) 
   
 
 
